drTarget portfolio target-disease associations for cardiovascular diseases DrTarget’s AI-Powered Indication Expansion for Cardiovascular Diseases

DrTarget’s AI-Driven Insights into Cardiovascular Diseases

DrTarget has identified 342 target proteins from PubChem screens associated with 357 cardiovascular diseases, utilizing data from Open Targets and other public sources. By applying machine learning models and AI-powered analytics, we uncover new therapeutic targets and drug repurposing opportunities for conditions such as heart failure, atherosclerosis, hypertension, and rare cardiovascular disorders.

Our AI-powered approach enables:

✔ Identification of novel drug targets for cardiovascular diseases
✔ Drug repurposing strategies to accelerate treatment discovery
✔ Pathway and biomarker analysis for precision cardiology

By integrating AI-driven virtual screening and multi-source validation, DrTarget supports the discovery of next-gen cardiovascular therapies aimed at improving heart health and vascular function.

Target-disease associations for cardiovascular disorders.

Check best scored target-disease associations in table:

PubChemAssay	program	diseaseName	assayType	testedCompounds	activeCompounds	associationScore	numberOfEvidences
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	congestive heart failure	targetBased	335239	801	0.351769550612851	13
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	congestive heart failure	targetBased	335238	390	0.351769550612851	13
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	congestive heart failure	targetBased	335531	328	0.527581485904718	6
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	congestive heart failure	targetBased	339297	1446	0.651600017001438	50
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	congestive heart failure	targetBased	76168	1231	0.613250657387013	22
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	atrial fibrillation	targetBased	305610	3878	0.541829820157546	315
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	atrial fibrillation	targetBased	305610	1082	0.541829820157546	315
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	atrial fibrillation	targetBased	305610	1552	0.802439563669594	261
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	atrial fibrillation	targetBased	343666	1267	0.802439563669594	261
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	atrial fibrillation	targetBased	342084	3260	0.802439563669594	261
Factor XIa 1536 HTS	F11_modulation	atrial fibrillation	targetBased	218707	302	0.357517588702518	23
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	atrial fibrillation	targetBased	405130	6428	0.420727514448716	59
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	atrial fibrillation	targetBased	373462	23	0.420727514448716	59
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	atrial fibrillation	targetBased	405130	6428	0.420727514448716	59
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	atrial fibrillation	targetBased	305610	2592	0.783777345668684	234
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	atrial fibrillation	targetBased	86095	1114	0.539624047756777	26
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	atrial fibrillation	targetBased	276265	806	0.424659611479414	15
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	atrial fibrillation	targetBased	335531	328	0.670494073297023	97
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	atrial fibrillation	targetBased	339297	1446	0.656155319809075	74
Primary biochemical high-throughput screening assay for inhibitors of Focal Adhesion Kinase (FAK)	PTK2	atrial fibrillation	targetBased	96879	811	0.348342323787707	21
Thrombin 1536 HTS	F2_modulation	atrial fibrillation	targetBased	217233	557	0.673166313522287	170
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	atrial fibrillation	pathwayBased	271402	1048	0.334098389930725	11
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	atrial fibrillation	pathwayBased	267412	5703	0.334098389930725	11
qHTS Assay for Tau Filament Binding	MAPT	atrial fibrillation	targetBased	69668	1391	0.334098389930725	11
HCS assay for microtubule stabilizers	TUBB	atrial fibrillation	targetBased	195821	1625	0.435406862853961	17
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	hypertension	targetBased	86095	1442	0.421637500320573	54
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	hypertension	targetBased	86095	1151	0.421637500320573	54
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	hypertension	targetBased	394050	3624	0.50567174512419	25
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	hypertension	targetBased	306502	3633	0.304005649962294	22
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	hypertension	targetBased	335180	1022	0.304005649962294	22
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hypertension	targetBased	99314	335	0.383046446409166	146
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hypertension	targetBased	196176	782	0.383046446409166	146
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hypertension	targetBased	99314	390	0.383046446409166	146
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hypertension	targetBased	196177	811	0.383046446409166	146
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hypertension	targetBased	196176	670	0.383046446409166	146
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hypertension	targetBased	196177	519	0.383046446409166	146
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	hypertension	targetBased	86095	1114	0.293898359792957	13
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	hypertension	targetBased	335531	328	0.784665512239552	1291
MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1_inhibitors	hypertension	targetBased	335777	499	0.436366272016687	11
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	hypertension	targetBased	339297	1446	0.668853049947844	367
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	hypertension	targetBased	76168	1231	0.565070002375135	27
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	hypertension	targetBased	339674	2841	0.674429375550638	181
Allosteric Modulators of D1 Receptors: Primary Screen	D1	hypertension	targetBased	57705	3413	0.512185146348314	6
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	hypertension	targetBased	361330	3713	0.512185146348314	6
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	hypertension	targetBased	355805	11440	0.512185146348314	6
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	hypertension	targetBased	104728	4230	0.343100200487281	7
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	hypertension	targetBased	316642	617	0.542390725803381	20
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	myocardial infarction	targetBased	305610	1552	0.359248840869334	21
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	myocardial infarction	targetBased	343666	1267	0.359248840869334	21
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	myocardial infarction	targetBased	342084	3260	0.359248840869334	21
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	myocardial infarction	targetBased	319204	3065	0.379088804549568	72
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	myocardial infarction	targetBased	316970	306	0.379088804549568	72
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	myocardial infarction	targetBased	86095	1442	0.339277341652025	118
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	myocardial infarction	targetBased	86095	1151	0.339277341652025	118
qHTS for Inhibitors of TGF-b	TGFB1	myocardial infarction	pathwayBased	403345	4970	0.32105894859906	913
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	myocardial infarction	targetBased	394050	3624	0.376253753005692	31
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	myocardial infarction	targetBased	335239	991	0.578271542280002	11
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	myocardial infarction	targetBased	335239	695	0.578271542280002	11
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	myocardial infarction	targetBased	405130	6428	0.555353879811961	333
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	myocardial infarction	targetBased	373462	23	0.555353879811961	333
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	myocardial infarction	targetBased	405130	6428	0.555353879811961	333
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	myocardial infarction	targetBased	325247	1021	0.418499778482598	30
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	myocardial infarction	targetBased	59788	212	0.408625509213493	11
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	myocardial infarction	targetBased	86095	1114	0.294234899440742	38
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	myocardial infarction	targetBased	359518	300	0.439839067210336	6
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	myocardial infarction	targetBased	335652	1779	0.439839067210336	6
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	myocardial infarction	targetBased	362274	1056	0.439839067210336	6
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	myocardial infarction	targetBased	336308	6862	0.439839067210336	6
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	myocardial infarction	targetBased	357537	806	0.439839067210336	6
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	myocardial infarction	targetBased	339887	1178	0.439839067210336	6
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	myocardial infarction	targetBased	276265	806	0.355475691441654	6
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	myocardial infarction	targetBased	335531	328	0.659633610265158	76
HTS of Smad transcription factor inhibitors	SMAD3	myocardial infarction	targetBased	88033	251	0.430244164060686	118
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	myocardial infarction	targetBased	339297	1446	0.670611093215975	227
Thrombin 1536 HTS	F2_modulation	myocardial infarction	targetBased	217233	557	0.599407497681816	152
HCS assay for microtubule stabilizers	TUBB	myocardial infarction	targetBased	195821	1625	0.581891484264645	13
Primary qHTS for Inhibitors of ATXN expression	ATXN2_repressors	myocardial infarction	targetBased	358434	2554	0.307714483936324	20
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	coronary artery disease	targetBased	319204	3065	0.513875832928574	147
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	coronary artery disease	targetBased	316970	306	0.513875832928574	147
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	coronary artery disease	targetBased	86095	1442	0.470428412517821	183
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	coronary artery disease	targetBased	86095	1151	0.470428412517821	183
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	coronary artery disease	targetBased	363803	2412	0.414572866969997	13
qHTS for Inhibitors of TGF-b	TGFB1	coronary artery disease	pathwayBased	403345	4970	0.376449062041855	224
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	coronary artery disease	targetBased	394050	3624	0.387861128233729	70
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	coronary artery disease	targetBased	335239	991	0.592008485412301	10
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	coronary artery disease	targetBased	335239	695	0.592008485412301	10
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	coronary artery disease	targetBased	405130	6428	0.384469301589397	153
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	coronary artery disease	targetBased	373462	23	0.384469301589397	153
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	coronary artery disease	targetBased	405130	6428	0.384469301589397	153
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	coronary artery disease	targetBased	325247	1021	0.411957572558763	21
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	coronary artery disease	targetBased	369953	3123	0.266582952262131	6
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	coronary artery disease	targetBased	344733	7043	0.277611256410927	45
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	coronary artery disease	targetBased	335239	801	0.452107414048022	599
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	coronary artery disease	targetBased	335238	390	0.452107414048022	599
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	coronary artery disease	targetBased	99314	335	0.538184411305718	204
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	coronary artery disease	targetBased	196176	782	0.538184411305718	204
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	coronary artery disease	targetBased	99314	390	0.538184411305718	204
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	coronary artery disease	targetBased	196177	811	0.538184411305718	204
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	coronary artery disease	targetBased	196176	670	0.538184411305718	204
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	coronary artery disease	targetBased	196177	519	0.538184411305718	204
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	coronary artery disease	targetBased	86095	1114	0.440700143257634	29
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	coronary artery disease	targetBased	276265	806	0.375083156200627	6
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	coronary artery disease	targetBased	335531	328	0.666430352142117	442
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	coronary artery disease	targetBased	343467	1710	0.445363479109043	10
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	coronary artery disease	targetBased	356160	3470	0.39314131155056	20
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	coronary artery disease	targetBased	356160	1703	0.39314131155056	20
HTS of Smad transcription factor inhibitors	SMAD3	coronary artery disease	targetBased	88033	251	0.552484115357613	54
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	coronary artery disease	targetBased	339297	1446	0.614742335189791	48
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	coronary artery disease	targetBased	76168	1231	0.435439202613319	10
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	coronary artery disease	targetBased	305610	3794	0.601498428437273	11
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	coronary artery disease	targetBased	339674	2841	0.601498428437273	11
Thrombin 1536 HTS	F2_modulation	coronary artery disease	targetBased	217233	557	0.649046640119132	118
HCS assay for microtubule stabilizers	TUBB	coronary artery disease	targetBased	195821	1625	0.641765925028877	28
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	coronary artery disease	targetBased	316642	617	0.440994765306032	15
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	coronary artery disease	targetBased	343468	734	0.513031657023707	18
HTS of Smad transcription factor inhibitors	SMAD3	aortic aneurysm	targetBased	88033	251	0.501060091567992	63
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	heart disease	targetBased	305610	3878	0.336382820641752	2001
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	heart disease	targetBased	305610	1082	0.336382820641752	2001
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	heart disease	targetBased	305610	1552	0.5744892428341	1627
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	heart disease	targetBased	343666	1267	0.5744892428341	1627
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	heart disease	targetBased	342084	3260	0.5744892428341	1627
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	heart disease	targetBased	86095	1442	0.491789587663523	249
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	heart disease	targetBased	86095	1151	0.491789587663523	249
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	heart disease	targetBased	335239	991	0.610101705726402	24
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	heart disease	targetBased	335239	695	0.610101705726402	24
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	heart disease	targetBased	305610	2592	0.337779720181742	1164
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	heart disease	targetBased	335239	801	0.388259441397677	2598
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	heart disease	targetBased	335238	390	0.388259441397677	2598
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	heart disease	targetBased	86095	1114	0.482009080109138	883
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	heart disease	targetBased	276265	806	0.420322702524328	19
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	heart disease	targetBased	335531	328	0.593237032510884	412
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	heart disease	targetBased	324747	813	0.400381769027036	16
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	heart disease	targetBased	339297	1446	0.48950855104779	265
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	heart disease	targetBased	76168	1231	0.494409718878496	153
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	heart disease	targetBased	305610	3794	0.494040568817361	17
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	heart disease	targetBased	199169	715	0.329286693560426	3157
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	heart disease	targetBased	302297	1165	0.329286693560426	3157
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	heart disease	targetBased	339674	2841	0.527003319061794	45
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	heart disease	targetBased	369953	760	0.442491548090815	45
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	heart disease	targetBased	369953	498	0.442491548090815	45
Glucocerebrosidase	GBA1	heart disease	targetBased	48118	549	0.295851471883425	192
Thrombin 1536 HTS	F2_modulation	heart disease	targetBased	217233	557	0.439971747608358	209
HCS assay for microtubule stabilizers	TUBB	heart disease	targetBased	195821	1625	0.274582164904876	34
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	heart failure	targetBased	305610	1552	0.547212563446782	10
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	heart failure	targetBased	343666	1267	0.547212563446782	10
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	heart failure	targetBased	342084	3260	0.547212563446782	10
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	heart failure	targetBased	394050	3624	0.537056766771359	15
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	heart failure	targetBased	335239	801	0.64314305161478	117
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	heart failure	targetBased	335238	390	0.64314305161478	117
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	heart failure	targetBased	335531	328	0.645161667574849	44
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	heart failure	targetBased	324747	813	0.582667962238769	9
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	heart failure	targetBased	339297	1446	0.660625331502392	81
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	heart failure	targetBased	76168	1231	0.597582643776577	29
qHTS Assay for Antagonists of the Relaxin Receptor RXFP1	relaxinInhibitors	heart failure	targetBased	350177	2058	0.402671409429789	15
qHTS Assay for Antagonists of the Relaxin Receptor RXFP1Taking the negative queue for PMs	relaxin PMs	heart failure	targetBased	350177	2058	0.402671409429789	15
qHTS Assay for Agonists of the Relaxin Receptor RXFP1	RXFP1	heart failure	targetBased	362198	1084	0.402671409429789	15
HCS assay for microtubule stabilizers	TUBB	heart failure	targetBased	195821	1625	0.366142497875815	6
Factor XIa 1536 HTS	F11_modulation	pulmonary embolism	targetBased	218707	302	0.529837764887743	9
Thrombin 1536 HTS	F2_modulation	pulmonary embolism	targetBased	217233	557	0.630479729710024	26
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	atrial flutter	targetBased	305610	1552	0.561048672319976	20
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	atrial flutter	targetBased	343666	1267	0.561048672319976	20
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	atrial flutter	targetBased	342084	3260	0.561048672319976	20
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	atrial flutter	targetBased	335531	328	0.529463532047883	9
qHTS for Inhibitors of TGF-b	TGFB1	angina pectoris	pathwayBased	403345	4970	0.291232525916009	30
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	angina pectoris	targetBased	335531	328	0.662387380315676	134
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	angina pectoris	targetBased	339297	1446	0.615165132654478	23
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	atherosclerosis	pathwayBased	362051	17187	0.307719686617144	1501
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	atherosclerosis	targetBased	99314	335	0.431128940589068	990
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	atherosclerosis	targetBased	196176	782	0.431128940589068	990
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	atherosclerosis	targetBased	99314	390	0.431128940589068	990
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	atherosclerosis	targetBased	196177	811	0.431128940589068	990
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	atherosclerosis	targetBased	196176	670	0.431128940589068	990
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	atherosclerosis	targetBased	196177	519	0.431128940589068	990
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH)	PLA2G7	atherosclerosis	targetBased	326024	4934	0.344157854845113	518
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	atherosclerosis	targetBased	335531	328	0.388681972644248	6
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	atherosclerosis	targetBased	339297	1446	0.523118463288717	14
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	left ventricular hypertrophy	targetBased	394050	3624	0.28891104408561	29
HCS assay for microtubule stabilizers	TUBB	Coronary Restenosis	targetBased	195821	1625	0.310920784693153	6
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	Coronary Vasospasm	targetBased	335531	328	0.642829168666001	119
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	ventricular fibrillation	targetBased	305610	1552	0.760259527871274	51
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	ventricular fibrillation	targetBased	343666	1267	0.760259527871274	51
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	ventricular fibrillation	targetBased	342084	3260	0.760259527871274	51
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ventricular fibrillation	targetBased	339297	1446	0.411238352018758	12
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	vascular disease	targetBased	86095	1442	0.259756508590195	420
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	vascular disease	targetBased	86095	1151	0.259756508590195	420
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	vascular disease	targetBased	217959	2390	0.259257178462855	247
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	vascular disease	pathwayBased	70898	707	0.26037973565382	72
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	vascular disease	pathwayBased	131324	544	0.26037973565382	72
qHTS assay for re-activators of p53 using a Luc reporter	TP53	vascular disease	pathwayBased	321427	201	0.308282010064809	737
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vascular disease	targetBased	54509	528	0.308282010064809	737
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vascular disease	targetBased	54513	338	0.308282010064809	737
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vascular disease	targetBased	125394	1890	0.308282010064809	737
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vascular disease	targetBased	124022	1156	0.308282010064809	737
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	vascular disease	pathwayBased	193400	1987	0.322472728273551	337
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	vascular disease	pathwayBased	193714	1590	0.322472728273551	337
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	vascular disease	targetBased	404343	257	0.322472728273551	337
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	vascular disease	targetBased	335531	328	0.333129665796641	710
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	vascular disease	targetBased	343467	1710	0.303404291721427	121
HTS of Smad transcription factor inhibitors	SMAD3	vascular disease	targetBased	88033	251	0.31738553424318	944
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	vascular disease	targetBased	193542	587	0.259830615135327	68
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	vascular disease	targetBased	339297	1446	0.256542920788158	346
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	vascular disease	targetBased	339674	2841	0.311051929154863	182
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	vascular disease	targetBased	369953	760	0.25398423452813	69
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	vascular disease	targetBased	369953	498	0.25398423452813	69
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	vascular disease	targetBased	194628	267	0.281944830858339	35
Thrombin 1536 HTS	F2_modulation	vascular disease	targetBased	217233	557	0.278048642860817	660
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	peripheral arterial disease	targetBased	363803	2412	0.541518657430405	12
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	peripheral arterial disease	targetBased	394050	3624	0.507918611603607	9
HCS assay for microtubule stabilizers	TUBB	peripheral arterial disease	targetBased	195821	1625	0.366953918967478	8
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	cardiac arrhythmia	targetBased	305610	3878	0.717418405216669	970
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	cardiac arrhythmia	targetBased	305610	1082	0.717418405216669	970
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	cardiac arrhythmia	targetBased	305610	1552	0.815852504474459	1310
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	cardiac arrhythmia	targetBased	343666	1267	0.815852504474459	1310
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	cardiac arrhythmia	targetBased	342084	3260	0.815852504474459	1310
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	cardiac arrhythmia	targetBased	363803	2412	0.539628835168446	7
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	cardiac arrhythmia	targetBased	305610	2592	0.597082684094759	166
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	cardiac arrhythmia	targetBased	359518	300	0.542720161698728	8
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	cardiac arrhythmia	targetBased	335652	1779	0.542720161698728	8
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	cardiac arrhythmia	targetBased	362274	1056	0.542720161698728	8
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	cardiac arrhythmia	targetBased	336308	6862	0.542720161698728	8
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	cardiac arrhythmia	targetBased	357537	806	0.542720161698728	8
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	cardiac arrhythmia	targetBased	339887	1178	0.542720161698728	8
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	cardiac arrhythmia	targetBased	335531	328	0.604597373994676	52
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	cardiac arrhythmia	targetBased	359207	1189	0.578250225184157	7
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	cardiac arrhythmia	targetBased	63676	1938	0.578250225184157	7
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	cardiac arrhythmia	targetBased	359207	316	0.578250225184157	7
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	cardiac arrhythmia	targetBased	63656	2179	0.578250225184157	7
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	cardiac arrhythmia	targetBased	359207	4555	0.578250225184157	7
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	cardiac arrhythmia	targetBased	363803	502	0.580213188041739	7
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	cardiac arrhythmia	targetBased	363803	2629	0.580213188041739	7
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	cardiac arrhythmia	targetBased	363803	1450	0.580213188041739	7
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	cardiac arrhythmia	targetBased	363803	698	0.577168330395272	6
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	cardiac arrhythmia	targetBased	363803	2133	0.577168330395272	6
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	cardiac arrhythmia	targetBased	363803	1081	0.577168330395272	6
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	cardiac arrhythmia	pathwayBased	271402	1048	0.361351848709784	22
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	cardiac arrhythmia	pathwayBased	267412	5703	0.361351848709784	22
qHTS Assay for Tau Filament Binding	MAPT	cardiac arrhythmia	targetBased	69668	1391	0.361351848709784	22
HCS assay for microtubule stabilizers	TUBB	cardiac arrhythmia	targetBased	195821	1625	0.335410282414491	7
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	blood pressure	targetBased	394050	3624	0.308553519683985	6
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	blood pressure	targetBased	335531	328	0.406928483573352	17
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	blood pressure	targetBased	339674	2841	0.445041065782812	28
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	electrocardiography	targetBased	305610	3878	0.590050079226244	203
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	electrocardiography	targetBased	305610	1082	0.590050079226244	203
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	electrocardiography	targetBased	305610	1552	0.431082166107401	54
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	electrocardiography	targetBased	343666	1267	0.431082166107401	54
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	electrocardiography	targetBased	342084	3260	0.431082166107401	54
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	electrocardiography	targetBased	363840	2624	0.527705179950392	17
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	electrocardiography	targetBased	305610	2592	0.451022018543145	59
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	electrocardiography	targetBased	368927	620	0.445812129516972	35
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	sudden cardiac arrest	targetBased	305610	1552	0.459752810561344	20
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	sudden cardiac arrest	targetBased	343666	1267	0.459752810561344	20
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	sudden cardiac arrest	targetBased	342084	3260	0.459752810561344	20
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	sudden cardiac arrest	targetBased	339297	1446	0.647528186233432	36
HTS of Smad transcription factor inhibitors	SMAD3	thoracic aortic aneurysm	targetBased	88033	251	0.329835797553122	35
Factor XIa 1536 HTS	F11_modulation	venous thromboembolism	targetBased	218707	302	0.660405165989325	101
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	electrocardiography	targetBased	276265	806	0.487395272317986	19
Thrombin 1536 HTS	F2_modulation	venous thromboembolism	targetBased	217233	557	0.704341553035662	518
HCS assay for microtubule stabilizers	TUBB	vascular disease	targetBased	195821	1625	0.272405235445476	36
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	cardiac arrhythmia	targetBased	339297	1446	0.637646823165619	67
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	QT interval	targetBased	305610	3878	0.596223074271587	24
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	QT interval	targetBased	305610	1082	0.596223074271587	24
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	QT interval	targetBased	305610	1552	0.449874560758587	18
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	QT interval	targetBased	343666	1267	0.449874560758587	18
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	QT interval	targetBased	342084	3260	0.449874560758587	18
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	QT interval	targetBased	305610	2592	0.348212042945037	12
HTS of Smad transcription factor inhibitors	SMAD3	intraocular pressure measurement	targetBased	88033	251	0.473819659941471	9
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	cardiac troponin T measurement	targetBased	368927	620	0.429531803958325	6
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	congenital heart disease	targetBased	305610	1552	0.27185250121656	332
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	congenital heart disease	targetBased	343666	1267	0.27185250121656	332
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	congenital heart disease	targetBased	342084	3260	0.27185250121656	332
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	congenital heart disease	targetBased	359207	1432	0.523986132818436	18
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	congenital heart disease	pathwayBased	70898	707	0.532266653827459	10
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	congenital heart disease	pathwayBased	131324	544	0.532266653827459	10
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	congenital heart disease	targetBased	339297	1446	0.355696532380639	8
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	congenital heart disease	targetBased	339674	2841	0.516813251834099	7
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	congenital heart disease	targetBased	369953	2602	0.798914888419431	147
Factor XIa 1536 HTS	F11_modulation	acute coronary syndrome	targetBased	218707	302	0.284450312827731	11
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	pulse pressure measurement	targetBased	86095	1442	0.465211580389372	11
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	pulse pressure measurement	targetBased	86095	1151	0.465211580389372	11
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	pulse pressure measurement	targetBased	639428	9218	0.508571324863295	6
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	acute coronary syndrome	targetBased	405130	6428	0.286544845943286	26
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	acute coronary syndrome	targetBased	373462	23	0.286544845943286	26
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	acute coronary syndrome	targetBased	405130	6428	0.286544845943286	26
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH)	PLA2G7	acute coronary syndrome	targetBased	326024	4934	0.288472534590608	80
CYP2C19 Assay	CYP2C19_inhibitors	acute coronary syndrome	targetBased	95857	20295	0.466037961739569	216
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	acute coronary syndrome	targetBased	339297	1446	0.554062551323282	11
Thrombin 1536 HTS	F2_modulation	acute coronary syndrome	targetBased	217233	557	0.58681113834509	26
HCS assay for microtubule stabilizers	TUBB	acute coronary syndrome	targetBased	195821	1625	0.584323923650328	11
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	pulse pressure measurement	targetBased	339674	2841	0.44919567405545	14
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.	TRHR	pulse pressure measurement	targetBased	361330	651	0.453922410273476	6
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers	TRHR	pulse pressure measurement	targetBased	361330	2424	0.453922410273476	6
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	hypotension	targetBased	335239	991	0.562382434947179	9
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	hypotension	targetBased	335239	695	0.562382434947179	9
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	hypotension	targetBased	339297	1446	0.6612423935077	103
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	orthostatic hypotension	targetBased	339297	1446	0.549035277361439	18
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	ventricular tachycardia	targetBased	305610	1552	0.6948342910003	133
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	ventricular tachycardia	targetBased	343666	1267	0.6948342910003	133
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	ventricular tachycardia	targetBased	342084	3260	0.6948342910003	133
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	ventricular tachycardia	targetBased	363803	2412	0.577574040941104	8
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	ventricular tachycardia	targetBased	359518	300	0.577168330395272	6
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	ventricular tachycardia	targetBased	335652	1779	0.577168330395272	6
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	ventricular tachycardia	targetBased	362274	1056	0.577168330395272	6
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	ventricular tachycardia	targetBased	336308	6862	0.577168330395272	6
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	ventricular tachycardia	targetBased	357537	806	0.577168330395272	6
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	ventricular tachycardia	targetBased	339887	1178	0.577168330395272	6
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ventricular tachycardia	targetBased	339297	1446	0.595189466920042	12
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	diastolic blood pressure	targetBased	86095	1442	0.451433217156287	6
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	diastolic blood pressure	targetBased	86095	1151	0.451433217156287	6
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	diastolic blood pressure	targetBased	363840	2624	0.393552178253481	9
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	diastolic blood pressure	targetBased	335531	328	0.470326091275314	14
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	diastolic blood pressure	targetBased	339674	2841	0.494806026280812	27
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	mean arterial pressure	targetBased	335531	328	0.450938883450173	8
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	mean arterial pressure	targetBased	339674	2841	0.448642022948897	12
Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA)	MSRA	diastolic blood pressure	targetBased	362026	1074	0.425250264145875	23
Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA)	MSRA	diastolic blood pressure	targetBased	362577	2709	0.425250264145875	23
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	diastolic blood pressure	targetBased	331671	10022	0.343307910677457	8
Primary qHTS for Inhibitors of ATXN expression	ATXN2_repressors	diastolic blood pressure	targetBased	358434	2554	0.298344540355862	47
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	pericarditis	pathwayBased	362051	17187	0.549333638497012	69
HCS assay for microtubule stabilizers	TUBB	pericarditis	targetBased	195821	1625	0.52560928186248	6
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	acute myocardial infarction	targetBased	405130	6428	0.365976586519998	53
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	acute myocardial infarction	targetBased	373462	23	0.365976586519998	53
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	acute myocardial infarction	targetBased	405130	6428	0.365976586519998	53
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	acute myocardial infarction	targetBased	99314	335	0.427547631514323	65
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	acute myocardial infarction	targetBased	196176	782	0.427547631514323	65
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	acute myocardial infarction	targetBased	99314	390	0.427547631514323	65
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	acute myocardial infarction	targetBased	196177	811	0.427547631514323	65
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	acute myocardial infarction	targetBased	196176	670	0.427547631514323	65
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	acute myocardial infarction	targetBased	196177	519	0.427547631514323	65
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	acute myocardial infarction	targetBased	339297	1446	0.510726398888352	17
Thrombin 1536 HTS	F2_modulation	acute myocardial infarction	targetBased	217233	557	0.496166108771324	59
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	heart valve disease	targetBased	335239	801	0.443766096667661	13
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	heart valve disease	targetBased	335238	390	0.443766096667661	13
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	ST Elevation Myocardial Infarction	targetBased	335239	801	0.28904568668655	48
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	ST Elevation Myocardial Infarction	targetBased	335238	390	0.28904568668655	48
Thrombin 1536 HTS	F2_modulation	ST Elevation Myocardial Infarction	targetBased	217233	557	0.593802462774375	9
HCS assay for microtubule stabilizers	TUBB	ST Elevation Myocardial Infarction	targetBased	195821	1625	0.539555581875448	6
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	cardiac arrest	targetBased	305610	1552	0.515630405814729	31
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	cardiac arrest	targetBased	343666	1267	0.515630405814729	31
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	cardiac arrest	targetBased	342084	3260	0.515630405814729	31
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	cardiac arrest	targetBased	324747	813	0.529763004236026	10
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	cardiac arrest	targetBased	339297	1446	0.565626365447611	27
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	Agents acting on the renin-angiotensin system use measurement	targetBased	335531	328	0.443260371744578	6
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	Prinzmetal's angina	targetBased	335531	328	0.664977476876164	306
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	atrial heart septal defect	targetBased	344733	7043	0.300714231973763	11
uHTS identification of small molecule modulators of NR3A	GRIN3A	cerebral atherosclerosis	targetBased	339772	8480	0.638992421523723	21
Thrombin 1536 HTS	F2_modulation	intermediate coronary syndrome	targetBased	217233	557	0.543359118242622	6
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Myocardial Ischemia	targetBased	86095	1442	0.440369982475793	47
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Myocardial Ischemia	targetBased	86095	1151	0.440369982475793	47
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	Myocardial Ischemia	targetBased	86095	1114	0.423950615788154	14
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	Myocardial Ischemia	targetBased	335531	328	0.574534968426493	8
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Myocardial Ischemia	targetBased	339297	1446	0.434244558165963	29
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	Myocardial Ischemia	targetBased	319204	3065	0.33411871853546	9
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	Myocardial Ischemia	targetBased	316970	306	0.33411871853546	9
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Wolff-Parkinson-White Syndrome	targetBased	305610	3878	0.385390364097753	8
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Wolff-Parkinson-White Syndrome	targetBased	305610	1082	0.385390364097753	8
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	systolic heart failure	targetBased	335239	801	0.407578504803233	8
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	systolic heart failure	targetBased	335238	390	0.407578504803233	8
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH)	PLA2G7	endothelial dysfunction	targetBased	326024	4934	0.289018312328131	68
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Prolonged QT interval	targetBased	305610	3878	0.734109946020632	2070
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Prolonged QT interval	targetBased	305610	1082	0.734109946020632	2070
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Prolonged QT interval	targetBased	305610	1552	0.734041769977036	3500
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Prolonged QT interval	targetBased	343666	1267	0.734041769977036	3500
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Prolonged QT interval	targetBased	342084	3260	0.734041769977036	3500
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	Bradycardia	targetBased	359207	1189	0.556882803103682	6
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	Bradycardia	targetBased	63676	1938	0.556882803103682	6
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	Bradycardia	targetBased	359207	316	0.556882803103682	6
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	Bradycardia	targetBased	63656	2179	0.556882803103682	6
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	Bradycardia	targetBased	359207	4555	0.556882803103682	6
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Bradycardia	targetBased	339297	1446	0.507645320472039	6
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Ventricular fibrillation	targetBased	305610	1552	0.407152792746921	42
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Ventricular fibrillation	targetBased	343666	1267	0.407152792746921	42
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Ventricular fibrillation	targetBased	342084	3260	0.407152792746921	42
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Abnormality of the cardiovascular system	targetBased	305610	3878	0.675190267140752	1550
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Abnormality of the cardiovascular system	targetBased	305610	1082	0.675190267140752	1550
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Abnormality of the cardiovascular system	targetBased	305610	1552	0.711592736821994	2381
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Abnormality of the cardiovascular system	targetBased	343666	1267	0.711592736821994	2381
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Abnormality of the cardiovascular system	targetBased	342084	3260	0.711592736821994	2381
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	Abnormality of the cardiovascular system	pathwayBased	70898	707	0.481626628052691	19
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	Abnormality of the cardiovascular system	pathwayBased	131324	544	0.481626628052691	19
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	Abnormality of the cardiovascular system	targetBased	305610	2592	0.612683747155337	239
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	Abnormality of the cardiovascular system	targetBased	335239	801	0.630409551474951	502
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	Abnormality of the cardiovascular system	targetBased	335238	390	0.630409551474951	502
HTS of Smad transcription factor inhibitors	SMAD3	Abnormality of the cardiovascular system	targetBased	88033	251	0.406522914717714	73
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	Abnormality of the cardiovascular system	targetBased	199169	715	0.569277510327076	411
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	Abnormality of the cardiovascular system	targetBased	302297	1165	0.569277510327076	411
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	Abnormality of the cardiovascular system	targetBased	194628	267	0.536386687475283	104
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	Abnormal heart morphology	pathwayBased	70898	707	0.53214174757145	9
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	Abnormal heart morphology	pathwayBased	131324	544	0.53214174757145	9
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	Patent ductus arteriosus	targetBased	316642	617	0.567131293854564	20
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	Ischemic stroke	targetBased	335531	328	0.516525873530802	9
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Ischemic stroke	targetBased	339297	1446	0.436685419032319	8
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	Ischemic stroke	targetBased	369953	760	0.312229359586519	12
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	Ischemic stroke	targetBased	369953	498	0.312229359586519	12
Thrombin 1536 HTS	F2_modulation	Ischemic stroke	targetBased	217233	557	0.353397775729454	20
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Ventricular arrhythmia	targetBased	305610	1552	0.683101878753051	162
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Ventricular arrhythmia	targetBased	343666	1267	0.683101878753051	162
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Ventricular arrhythmia	targetBased	342084	3260	0.683101878753051	162
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Ventricular arrhythmia	targetBased	335239	991	0.439916790832495	8
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Ventricular arrhythmia	targetBased	335239	695	0.439916790832495	8
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Ventricular arrhythmia	targetBased	339297	1446	0.641084137971574	32
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	Reduced left ventricular ejection fraction	targetBased	335531	328	0.563971467918354	9
HTS of Smad transcription factor inhibitors	SMAD3	Vascular dilatation	targetBased	88033	251	0.293136199956077	7
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Arrhythmia	targetBased	305610	1552	0.260133066682535	69
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Arrhythmia	targetBased	343666	1267	0.260133066682535	69
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Arrhythmia	targetBased	342084	3260	0.260133066682535	69
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	heart conduction disease	targetBased	305610	2592	0.271846747382295	290
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	short QT syndrome	targetBased	305610	3878	0.568605630843682	215
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	short QT syndrome	targetBased	305610	1082	0.568605630843682	215
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	short QT syndrome	targetBased	305610	1552	0.41039245993415	99
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	short QT syndrome	targetBased	343666	1267	0.41039245993415	99
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	short QT syndrome	targetBased	342084	3260	0.41039245993415	99
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	short QT syndrome	targetBased	305610	2592	0.443689779602828	318
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	essential hypertension	targetBased	335531	328	0.655030426761749	86
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	essential hypertension	targetBased	339297	1446	0.306714129819747	10
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	pericardial effusion	targetBased	330392	1295	0.284879239032575	8
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	arteriosclerosis disorder	targetBased	108286	1415	0.552064990371929	6
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	thrombotic disease	targetBased	86095	1442	0.286083808767426	13
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	thrombotic disease	targetBased	86095	1151	0.286083808767426	13
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	thrombotic disease	targetBased	369953	760	0.514268280638907	18
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	thrombotic disease	targetBased	369953	498	0.514268280638907	18
Thrombin 1536 HTS	F2_modulation	thrombotic disease	targetBased	217233	557	0.629548975281352	445
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	ventricular septal defect	targetBased	344733	7043	0.293378171058506	11
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Jervell and Lange-Nielsen syndrome	targetBased	305610	3878	0.829758025318848	193
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Jervell and Lange-Nielsen syndrome	targetBased	305610	1082	0.829758025318848	193
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	pulmonary hypertension	targetBased	360873	7438	0.295826525946821	9
qHTS of Nrf2 Activators	Nrf2 activators	pulmonary hypertension	pathwayBased	403871	1243	0.295826525946821	9
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	pulmonary hypertension	targetBased	99314	335	0.307468927254904	180
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	pulmonary hypertension	targetBased	196176	782	0.307468927254904	180
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	pulmonary hypertension	targetBased	99314	390	0.307468927254904	180
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	pulmonary hypertension	targetBased	196177	811	0.307468927254904	180
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	pulmonary hypertension	targetBased	196176	670	0.307468927254904	180
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	pulmonary hypertension	targetBased	196177	519	0.307468927254904	180
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	pulmonary hypertension	targetBased	76168	1231	0.514121558566674	17
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	pulmonary hypertension	targetBased	339674	2841	0.293303559901386	183
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	sinoatrial node dysfunction and deafness	targetBased	335531	328	0.798234352836398	89
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Brugada syndrome	targetBased	305610	3878	0.399136095092878	52
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Brugada syndrome	targetBased	305610	1082	0.399136095092878	52
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Brugada syndrome	targetBased	305610	1552	0.478699522092586	53
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Brugada syndrome	targetBased	343666	1267	0.478699522092586	53
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Brugada syndrome	targetBased	342084	3260	0.478699522092586	53
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	familial atrial fibrillation	targetBased	305610	3878	0.584915503283993	198
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	familial atrial fibrillation	targetBased	305610	1082	0.584915503283993	198
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	familial atrial fibrillation	targetBased	305610	2592	0.557484038987195	108
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	familial long QT syndrome	targetBased	305610	3878	0.858261017924304	1652
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	familial long QT syndrome	targetBased	305610	1082	0.858261017924304	1652
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	familial long QT syndrome	targetBased	305610	1552	0.810413609236612	888
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	familial long QT syndrome	targetBased	343666	1267	0.810413609236612	888
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	familial long QT syndrome	targetBased	342084	3260	0.810413609236612	888
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	familial long QT syndrome	targetBased	305610	2592	0.399973484574095	407
HTS of Smad transcription factor inhibitors	SMAD3	familial thoracic aortic aneurysm and aortic dissection	targetBased	88033	251	0.777860473513668	1211
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	coronary atherosclerosis	targetBased	339297	1446	0.577168330395272	6
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Romano-Ward syndrome	targetBased	305610	3878	0.917575767779804	689
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Romano-Ward syndrome	targetBased	305610	1082	0.917575767779804	689
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Romano-Ward syndrome	targetBased	305610	1552	0.93814629135582	1206
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Romano-Ward syndrome	targetBased	343666	1267	0.93814629135582	1206
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Romano-Ward syndrome	targetBased	342084	3260	0.93814629135582	1206
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Familial progressive cardiac conduction defect	targetBased	305610	3878	0.425086943408605	8
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Familial progressive cardiac conduction defect	targetBased	305610	1082	0.425086943408605	8
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Familial short QT syndrome	targetBased	305610	3878	0.764568393200508	60
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Familial short QT syndrome	targetBased	305610	1082	0.764568393200508	60
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Familial short QT syndrome	targetBased	305610	1552	0.828402105198518	351
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Familial short QT syndrome	targetBased	343666	1267	0.828402105198518	351
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Familial short QT syndrome	targetBased	342084	3260	0.828402105198518	351
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	Familial short QT syndrome	targetBased	305610	2592	0.699555539533156	30
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	Rare familial disorder with hypertrophic cardiomyopathy	targetBased	335239	801	0.622584838782076	123
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	Rare familial disorder with hypertrophic cardiomyopathy	targetBased	335238	390	0.622584838782076	123
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	heart disease	pathwayBased	70898	707	0.267588911577723	55
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	heart disease	pathwayBased	131324	544	0.267588911577723	55
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	heart disease	targetBased	64908	1225	0.295511338182346	54
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	heart disease	targetBased	64908	359	0.295511338182346	54
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	heart disease	targetBased	194628	267	0.324902614329253	459
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	heart disease	targetBased	369953	2602	0.266850434050765	68
Factor XIa 1536 HTS	F11_modulation	vascular disease	targetBased	218707	302	0.261925524783603	92
Factor XIIa 1536 HTS	F12_modulation	vascular disease	targetBased	217430	649	0.29737794501814	65
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	vascular disease	targetBased	194152	656	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	vascular disease	targetBased	194152	1288	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	vascular disease	targetBased	194152	814	0.307418870150215	258
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	congenital heart disease	targetBased	305610	3878	0.32583345778383	977
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	congenital heart disease	targetBased	305610	1082	0.32583345778383	977
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	congenital heart disease	targetBased	305610	2592	0.309305482466369	384
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Abnormal cardiovascular system physiology	targetBased	305610	3878	0.255900041100298	715
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Abnormal cardiovascular system physiology	targetBased	305610	1082	0.255900041100298	715
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Abnormal cardiovascular system physiology	targetBased	305610	1552	0.292071884654771	1238
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Abnormal cardiovascular system physiology	targetBased	343666	1267	0.292071884654771	1238
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Abnormal cardiovascular system physiology	targetBased	342084	3260	0.292071884654771	1238
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Abnormality of cardiovascular system electrophysiology	targetBased	305610	1552	0.291052991639106	1235
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Abnormality of cardiovascular system electrophysiology	targetBased	343666	1267	0.291052991639106	1235
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Abnormality of cardiovascular system electrophysiology	targetBased	342084	3260	0.291052991639106	1235
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	arterial disorder	targetBased	335531	328	0.263043575919809	683
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	arterial disorder	targetBased	339674	2841	0.307605371317295	175
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	heart conduction disease	targetBased	305610	3878	0.27147277959172	184
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	heart conduction disease	targetBased	305610	1082	0.27147277959172	184
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	cardiac rhythm disease	targetBased	305610	3878	0.278174095876582	223
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	cardiac rhythm disease	targetBased	305610	1082	0.278174095876582	223
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	cardiac rhythm disease	targetBased	305610	1552	0.280032584227586	211
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	cardiac rhythm disease	targetBased	343666	1267	0.280032584227586	211
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	cardiac rhythm disease	targetBased	342084	3260	0.280032584227586	211
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	cardiac rhythm disease	targetBased	305610	2592	0.297439427831753	156
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	cardiac rhythm disease	targetBased	335531	328	0.304830752442955	74
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	congenital anomaly of cardiovascular system	targetBased	305610	3878	0.32583345778383	977
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	congenital anomaly of cardiovascular system	targetBased	305610	1082	0.32583345778383	977
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	congenital anomaly of cardiovascular system	targetBased	305610	1552	0.270770606427675	331
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	congenital anomaly of cardiovascular system	targetBased	343666	1267	0.270770606427675	331
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	congenital anomaly of cardiovascular system	targetBased	342084	3260	0.270770606427675	331
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	congenital anomaly of cardiovascular system	targetBased	305610	2592	0.309305482466369	384
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	congenital anomaly of cardiovascular system	targetBased	369953	2602	0.266500325775173	60
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	Glycogen storage disease with hypertrophic cardiomyopathy	targetBased	199169	715	0.305413139539117	1578
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	Glycogen storage disease with hypertrophic cardiomyopathy	targetBased	302297	1165	0.305413139539117	1578
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	Lysosomal disease with hypertrophic cardiomyopathy	targetBased	199169	715	0.305413139539117	1578
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	Lysosomal disease with hypertrophic cardiomyopathy	targetBased	302297	1165	0.305413139539117	1578
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Rare genetic cardiac disease	targetBased	305610	3878	0.314483144382057	259
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Rare genetic cardiac disease	targetBased	305610	1082	0.314483144382057	259
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Rare genetic cardiac disease	targetBased	305610	1552	0.319539417013411	532
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Rare genetic cardiac disease	targetBased	343666	1267	0.319539417013411	532
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Rare genetic cardiac disease	targetBased	342084	3260	0.319539417013411	532
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	Rare genetic cardiac disease	targetBased	305610	2592	0.304986033813229	316
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	Rare genetic cardiac disease	targetBased	199169	715	0.305534076087638	1590
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	Rare genetic cardiac disease	targetBased	302297	1165	0.305534076087638	1590
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	Rare familial disorder with hypertrophic cardiomyopathy	targetBased	199169	715	0.305428913809152	1579
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	Rare familial disorder with hypertrophic cardiomyopathy	targetBased	302297	1165	0.305428913809152	1579

Some of these associations have also gone through clinical trials, as those in the graph below.

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH)	PLA2G7	PLA2G7	Platelet-activating factor acetylhydrolase	acute coronary syndrome	DARAPLADIB	targetBased	3	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01000727	0.7	LoF	protect
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH)	PLA2G7	PLA2G7	Platelet-activating factor acetylhydrolase	atherosclerosis	DARAPLADIB	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00799903	0.7	LoF	protect
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH)	PLA2G7	PLA2G7	Platelet-activating factor acetylhydrolase	endothelial dysfunction	DARAPLADIB	targetBased	3	Completed	04/02/2010	https://clinicaltrials.gov/study/NCT01067339	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	acute myocardial infarction	VERAPAMIL	targetBased	4	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00712894	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart disease	VERAPAMIL	targetBased	4	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02454491	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Paroxysmal supraventricular tachycardia	VERAPAMIL	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01655316	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	VERAPAMIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08DA01	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	VERAPAMIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08DA51	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	VERAPAMIL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	VERAPAMIL	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00313157	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	VERAPAMIL	targetBased	4	Withdrawn	01/12/2021	https://clinicaltrials.gov/study/NCT04234477	1	LoF	protect	The study was not IRB approved and there were anticipated challenges in recruiting participants.
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	VERAPAMIL	targetBased	4	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01655303	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	VERAPAMIL	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiac arrhythmia	VERAPAMIL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiac arrhythmia	VERAPAMIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92f7adf1-cb8c-4c6e-95d1-9afd28fe5116	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	VERAPAMIL	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d776d5d1-cb5b-80f9-e00c-75d4c3ae4d20	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=189d8bed-8a53-4126-9409-41ef48678dc9	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b4b1dd5-8a6f-4f0e-a2ea-506c60d6fce9	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7023927e-1829-49c0-5c81-693489000d1c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39bad727-af4c-4d20-933b-7f287e88099a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=081e2fd0-242e-4b80-9847-86ba0c36d1b3	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92f7adf1-cb8c-4c6e-95d1-9afd28fe5116	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acbd40bf-fdae-4bd2-a63c-0a82cbe15795	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f77f9742-9100-4b64-ac73-dff94079b888	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL	targetBased	4	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00235001	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Coronary Vasospasm	DILTIAZEM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af12246f-890c-4c31-bb77-136f47dda222	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Coronary Vasospasm	DILTIAZEM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1042fa13-e6af-46b9-8008-6c941f0978b1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Coronary Vasospasm	DILTIAZEM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14a67570-6820-46ee-920c-b6d3663609d9	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Coronary Vasospasm	DILTIAZEM	targetBased	4	Completed	01/01/2018	https://clinicaltrials.gov/study/NCT03930433	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Coronary Vasospasm	DILTIAZEM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3e7ecef-f360-4987-a4f5-933214130ab2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	acute myocardial infarction	DILTIAZEM	targetBased	4	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00712894	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atherosclerosis	DILTIAZEM	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial flutter	DILTIAZEM	targetBased	4	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02025465	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	DILTIAZEM	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	DILTIAZEM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08DB01	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DILTIAZEM	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00313157	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DILTIAZEM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d8e8b1e-f67b-57d2-e053-2991aa0a8d12	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DILTIAZEM	targetBased	4	Unknown status	01/08/2009	https://clinicaltrials.gov/study/NCT00834925	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DILTIAZEM	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DILTIAZEM	targetBased	4	Withdrawn	01/12/2021	https://clinicaltrials.gov/study/NCT04234477	1	LoF	protect	The study was not IRB approved and there were anticipated challenges in recruiting participants.
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DILTIAZEM	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DILTIAZEM	targetBased	4	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02025465	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DILTIAZEM	targetBased	4	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01655303	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DILTIAZEM	targetBased	4	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT02695992	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Myocardial Ischemia	DILTIAZEM	targetBased	3	Completed	01/11/1990	https://clinicaltrials.gov/study/NCT00000478	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiac arrhythmia	DILTIAZEM	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	DILTIAZEM	targetBased	4	Unknown status	01/09/2013	https://clinicaltrials.gov/study/NCT01162902	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	DILTIAZEM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=001826f4-f531-454e-a37a-e4e0b147f61b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hemorrhoid	DILTIAZEM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C05AE03	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	DILTIAZEM	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	DILTIAZEM	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	DILTIAZEM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7cf9276-4b4c-10b2-e053-2995a90a3738	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	DILTIAZEM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9942f1a2-f66d-4d9e-9794-49bee8abf5ab	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	DILTIAZEM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1042fa13-e6af-46b9-8008-6c941f0978b1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	DILTIAZEM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e180dc7-c871-4efc-8755-cae882976c8d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	DILTIAZEM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af12246f-890c-4c31-bb77-136f47dda222	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	DILTIAZEM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c567fe7e-887e-4291-a0d1-2dd3f25cbf25	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	PROPRANOLOL	targetBased	3	Completed	01/09/1977	https://clinicaltrials.gov/study/NCT00000493	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	PROPRANOLOL	targetBased	3	Completed	01/09/1977	https://clinicaltrials.gov/study/NCT00000492	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	PROPRANOLOL	targetBased	3	Completed	01/09/1977	https://clinicaltrials.gov/study/NCT00000492	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	PROPRANOLOL	targetBased	4	Recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06263452	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	PROPRANOLOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C07AA05	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Wolff-Parkinson-White Syndrome	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f0f5fb3-5292-4d04-b590-3c90a663eec8	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	angina pectoris	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=582fe781-0759-4622-8fa6-b7d90e94e696	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	angina pectoris	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35d28979-36b1-4630-b85e-a44e0a443734	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart disease	PROPRANOLOL	targetBased	3	Completed	01/09/1977	https://clinicaltrials.gov/study/NCT00000492	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	coronary atherosclerosis	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=582fe781-0759-4622-8fa6-b7d90e94e696	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	coronary atherosclerosis	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35d28979-36b1-4630-b85e-a44e0a443734	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ventricular fibrillation	PROPRANOLOL	targetBased	3	Completed	01/09/1977	https://clinicaltrials.gov/study/NCT00000492	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Supraventricular tachycardia	PROPRANOLOL	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00390546	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Myocardial Ischemia	PROPRANOLOL	targetBased	3	Completed	01/09/1977	https://clinicaltrials.gov/study/NCT00000493	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Myocardial Ischemia	PROPRANOLOL	targetBased	3	Completed	01/09/1977	https://clinicaltrials.gov/study/NCT00000492	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	coronary artery disease	PROPRANOLOL	targetBased	3	Completed	01/09/1977	https://clinicaltrials.gov/study/NCT00000493	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	coronary artery disease	PROPRANOLOL	targetBased	3	Completed	01/09/1977	https://clinicaltrials.gov/study/NCT00000492	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiac arrhythmia	PROPRANOLOL	targetBased	3	Completed	01/09/1977	https://clinicaltrials.gov/study/NCT00000492	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiac arrhythmia	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f0f5fb3-5292-4d04-b590-3c90a663eec8	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90656b7e-c3b6-46f9-9428-421b7d61d0cc	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac196ff5-9215-402b-bc57-69aa87f8bade	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d15bb34-f5d0-4cd0-8b08-27a0c265d9a5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35d28979-36b1-4630-b85e-a44e0a443734	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84050954-e94c-4d90-b3b3-6f47fd14e492	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=582fe781-0759-4622-8fa6-b7d90e94e696	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	PROPRANOLOL	targetBased	4	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01655303	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Ischemic stroke	LABETALOL	targetBased	4	Active, not recruiting	18/06/2020	https://clinicaltrials.gov/study/NCT04205305	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	LABETALOL	targetBased	4	Completed	19/01/2019	https://clinicaltrials.gov/study/NCT03809065	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	LABETALOL	targetBased	4	Completed	01/04/2021	https://clinicaltrials.gov/study/NCT05368376	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	LABETALOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C07AG01	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	LABETALOL	targetBased	3	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02426177	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	LABETALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4195473-51a9-40f1-8678-1478ebca2d84	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	LABETALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75d74177-4e71-cef2-e053-2991aa0a9a97	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	LABETALOL	targetBased	3	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01538875	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	LABETALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01735685-40e0-4323-af5a-91db399f6451	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	ISOPROTERENOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01CA02	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	ISOPROTERENOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f570cea-dbf2-41e0-9789-5bf948c2eb7a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	ISOPROTERENOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=046f2941-3bc0-4755-861c-71bedb49e706	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Ischemic stroke	BUSPIRONE	targetBased	3	Terminated	01/07/2013	https://clinicaltrials.gov/study/NCT01833312	0.7	GoF	protect	Slow recruitment, cessation of funding
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Ischemic stroke	BUSPIRONE	targetBased	3	Terminated	01/07/2013	https://clinicaltrials.gov/study/NCT01833312	0.7	GoF	protect	Slow recruitment, cessation of funding
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	congestive heart failure	THALIDOMIDE	targetBased	4	Unknown status	01/07/2012	https://clinicaltrials.gov/study/NCT01640639	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	coronary artery disease	THALIDOMIDE	targetBased	4	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT01638078	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	vascular malformation	THALIDOMIDE	targetBased	3	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02707484	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	SOTALOL	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	SOTALOL	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	SOTALOL	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	SOTALOL	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	SOTALOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C07AA07	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	myocardial infarction	SOTALOL	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	myocardial infarction	SOTALOL	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	myocardial infarction	SOTALOL	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart failure	SOTALOL	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart failure	SOTALOL	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart failure	SOTALOL	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	SOTALOL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	SOTALOL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	SOTALOL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	SOTALOL	targetBased	4	Not yet recruiting	01/08/2019	https://clinicaltrials.gov/study/NCT03895411	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	SOTALOL	targetBased	4	Not yet recruiting	01/08/2019	https://clinicaltrials.gov/study/NCT03895411	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	SOTALOL	targetBased	4	Not yet recruiting	01/08/2019	https://clinicaltrials.gov/study/NCT03895411	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart disease	SOTALOL	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	sudden cardiac arrest	SOTALOL	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	sudden cardiac arrest	SOTALOL	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	sudden cardiac arrest	SOTALOL	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	sudden cardiac arrest	SOTALOL	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	sudden cardiac arrest	SOTALOL	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	sudden cardiac arrest	SOTALOL	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ventricular fibrillation	SOTALOL	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ventricular fibrillation	SOTALOL	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=253da1e1-022a-4175-bd7f-e7673cba0767	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=253da1e1-022a-4175-bd7f-e7673cba0767	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=253da1e1-022a-4175-bd7f-e7673cba0767	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c24cdf0-4648-4e5d-993c-1f428ce56a65	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c24cdf0-4648-4e5d-993c-1f428ce56a65	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c24cdf0-4648-4e5d-993c-1f428ce56a65	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f33f900-0777-4a92-a7f7-00cf3d57d95c	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f33f900-0777-4a92-a7f7-00cf3d57d95c	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f33f900-0777-4a92-a7f7-00cf3d57d95c	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2577dd8d-ab1b-4a55-990a-18c69395edfe	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2577dd8d-ab1b-4a55-990a-18c69395edfe	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2577dd8d-ab1b-4a55-990a-18c69395edfe	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62a71c8c-d92d-4122-848f-9ae35f8bbe2b	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62a71c8c-d92d-4122-848f-9ae35f8bbe2b	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62a71c8c-d92d-4122-848f-9ae35f8bbe2b	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff3061ab-d930-4318-a5be-684e38be229e	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff3061ab-d930-4318-a5be-684e38be229e	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff3061ab-d930-4318-a5be-684e38be229e	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart disease	SOTALOL	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart disease	SOTALOL	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart disease	SOTALOL	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2577dd8d-ab1b-4a55-990a-18c69395edfe	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff3061ab-d930-4318-a5be-684e38be229e	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62a71c8c-d92d-4122-848f-9ae35f8bbe2b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f33f900-0777-4a92-a7f7-00cf3d57d95c	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c24cdf0-4648-4e5d-993c-1f428ce56a65	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Ventricular arrhythmia	SOTALOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=253da1e1-022a-4175-bd7f-e7673cba0767	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiac arrhythmia	SOTALOL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiac arrhythmia	SOTALOL	targetBased	4	Not yet recruiting	01/08/2019	https://clinicaltrials.gov/study/NCT03895411	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiovascular disease	SOTALOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C07AA07	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiovascular disease	SOTALOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C07AA07	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiovascular disease	SOTALOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C07AA07	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Completed	03/03/2015	https://clinicaltrials.gov/study/NCT02389218	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Completed	03/03/2015	https://clinicaltrials.gov/study/NCT02389218	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Completed	03/03/2015	https://clinicaltrials.gov/study/NCT02389218	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00540787	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00540787	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00540787	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02145546	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02145546	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02145546	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00523978	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00523978	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00523978	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00035451	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00035451	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00035451	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Recruiting	31/12/2020	https://clinicaltrials.gov/study/NCT02347111	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Recruiting	31/12/2020	https://clinicaltrials.gov/study/NCT02347111	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Recruiting	31/12/2020	https://clinicaltrials.gov/study/NCT02347111	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Withdrawn	01/12/2011	https://clinicaltrials.gov/study/NCT01505296	1	LoF	protect	Never initiated
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Withdrawn	01/12/2011	https://clinicaltrials.gov/study/NCT01505296	1	LoF	protect	Never initiated
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Withdrawn	01/12/2011	https://clinicaltrials.gov/study/NCT01505296	1	LoF	protect	Never initiated
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Recruiting	02/01/2021	https://clinicaltrials.gov/study/NCT04473807	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Recruiting	02/01/2021	https://clinicaltrials.gov/study/NCT04473807	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Recruiting	02/01/2021	https://clinicaltrials.gov/study/NCT04473807	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00340314	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00340314	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00340314	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01477983	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01477983	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01477983	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	SOTALOL	targetBased	4	Active, not recruiting	01/10/2016	https://clinicaltrials.gov/study/NCT02830360	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	SOTALOL	targetBased	4	Active, not recruiting	01/10/2016	https://clinicaltrials.gov/study/NCT02830360	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	SOTALOL	targetBased	4	Active, not recruiting	01/10/2016	https://clinicaltrials.gov/study/NCT02830360	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	SOTALOL	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00257959	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	SOTALOL	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00257959	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	SOTALOL	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00257959	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	SOTALOL	targetBased	4	Unknown status	01/01/2013	https://clinicaltrials.gov/study/NCT01780311	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	SOTALOL	targetBased	4	Unknown status	01/01/2013	https://clinicaltrials.gov/study/NCT01780311	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	SOTALOL	targetBased	4	Unknown status	01/01/2013	https://clinicaltrials.gov/study/NCT01780311	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	SOTALOL	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	SOTALOL	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	SOTALOL	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	SOTALOL	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	SOTALOL	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	SOTALOL	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	SOTALOL	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	SOTALOL	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	SOTALOL	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	SOTALOL	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00035451	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	SOTALOL	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00540787	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	SOTALOL	targetBased	4	Withdrawn	01/12/2011	https://clinicaltrials.gov/study/NCT01505296	1	LoF	protect	Never initiated
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	SOTALOL	targetBased	4	Recruiting	31/12/2020	https://clinicaltrials.gov/study/NCT02347111	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	SOTALOL	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00340314	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	SOTALOL	targetBased	4	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02145546	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	SOTALOL	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01477983	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	SOTALOL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	SOTALOL	targetBased	4	Recruiting	02/01/2021	https://clinicaltrials.gov/study/NCT04473807	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	SOTALOL	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	SOTALOL	targetBased	4	Completed	03/03/2015	https://clinicaltrials.gov/study/NCT02389218	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	SOTALOL	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00523978	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ventricular tachycardia	SOTALOL	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00257959	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ventricular tachycardia	SOTALOL	targetBased	4	Unknown status	01/01/2013	https://clinicaltrials.gov/study/NCT01780311	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ventricular tachycardia	SOTALOL	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ventricular tachycardia	SOTALOL	targetBased	4	Active, not recruiting	01/10/2016	https://clinicaltrials.gov/study/NCT02830360	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart failure	DOFETILIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart failure	DOFETILIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart failure	DOFETILIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	DOFETILIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01BD04	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	DOFETILIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01BD04	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	DOFETILIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01BD04	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	DOFETILIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/tikosyn	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	DOFETILIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/tikosyn	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	DOFETILIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/tikosyn	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	DOFETILIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01f9fb69-2438-481c-b5ec-adebe7825253	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	DOFETILIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01f9fb69-2438-481c-b5ec-adebe7825253	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	DOFETILIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01f9fb69-2438-481c-b5ec-adebe7825253	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	DOFETILIDE	targetBased	4	Withdrawn	01/12/2011	https://clinicaltrials.gov/study/NCT01505296	1	LoF	protect	Never initiated
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	DOFETILIDE	targetBased	4	Withdrawn	01/12/2011	https://clinicaltrials.gov/study/NCT01505296	1	LoF	protect	Never initiated
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	DOFETILIDE	targetBased	4	Withdrawn	01/12/2011	https://clinicaltrials.gov/study/NCT01505296	1	LoF	protect	Never initiated
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	DOFETILIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/tikosyn	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	DOFETILIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/tikosyn	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	DOFETILIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/tikosyn	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	DOFETILIDE	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00540787	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	DOFETILIDE	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00540787	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	DOFETILIDE	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00540787	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	DOFETILIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01f9fb69-2438-481c-b5ec-adebe7825253	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	DOFETILIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01f9fb69-2438-481c-b5ec-adebe7825253	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	DOFETILIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01f9fb69-2438-481c-b5ec-adebe7825253	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	DOFETILIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	DOFETILIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	DOFETILIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	DOFETILIDE	targetBased	3	Suspended	01/04/2006	https://clinicaltrials.gov/study/NCT00392106	0.35	LoF	protect	voluntarily by Sponsor to investigate an anticipated SAE
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	DOFETILIDE	targetBased	3	Suspended	01/04/2006	https://clinicaltrials.gov/study/NCT00392106	0.35	LoF	protect	voluntarily by Sponsor to investigate an anticipated SAE
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	DOFETILIDE	targetBased	3	Suspended	01/04/2006	https://clinicaltrials.gov/study/NCT00392106	0.35	LoF	protect	voluntarily by Sponsor to investigate an anticipated SAE
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	myocardial infarction	MORPHINE	targetBased	4	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02217878	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	myocardial infarction	MORPHINE	targetBased	4	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02217878	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	myocardial infarction	MORPHINE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01369186	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	myocardial infarction	MORPHINE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01369186	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	myocardial infarction	MORPHINE	targetBased	4	Unknown status	12/12/2014	https://clinicaltrials.gov/study/NCT02913469	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	myocardial infarction	MORPHINE	targetBased	4	Unknown status	12/12/2014	https://clinicaltrials.gov/study/NCT02913469	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heart disease	MORPHINE	targetBased	4	Terminated	11/07/2016	https://clinicaltrials.gov/study/NCT02734940	1	GoF	protect	Unable to find participants who met inclusion/exclusion criteria
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heart disease	MORPHINE	targetBased	4	Terminated	11/07/2016	https://clinicaltrials.gov/study/NCT02734940	1	GoF	protect	Unable to find participants who met inclusion/exclusion criteria
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	coronary artery disease	MORPHINE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02403830	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	coronary artery disease	MORPHINE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02403830	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute myocardial infarction	MORPHINE	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01186445	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute myocardial infarction	MORPHINE	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01186445	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	angina pectoris	MORPHINE	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02939248	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	angina pectoris	MORPHINE	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02939248	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	angina pectoris	MORPHINE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02939235	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	angina pectoris	MORPHINE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02939235	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intermediate coronary syndrome	MORPHINE	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT04442919	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intermediate coronary syndrome	MORPHINE	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT04442919	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute coronary syndrome	MORPHINE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00718406	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute coronary syndrome	MORPHINE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00718406	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute coronary syndrome	MORPHINE	targetBased	4	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02198378	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute coronary syndrome	MORPHINE	targetBased	4	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02198378	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	angina pectoris	NALOXONE	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02939248	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	angina pectoris	NALOXONE	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02939248	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	angina pectoris	NALOXONE	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02939248	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Myocardial Ischemia	TAMOXIFEN	targetBased	3	Completed	01/05/1992	https://clinicaltrials.gov/study/NCT00000529	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Myocardial Ischemia	TAMOXIFEN	targetBased	3	Completed	01/05/1992	https://clinicaltrials.gov/study/NCT00000529	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypertension	TAMOXIFEN	targetBased	3	Completed	01/05/1992	https://clinicaltrials.gov/study/NCT00000529	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypertension	TAMOXIFEN	targetBased	3	Completed	01/05/1992	https://clinicaltrials.gov/study/NCT00000529	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	TAMOXIFEN	targetBased	3	Completed	01/05/1992	https://clinicaltrials.gov/study/NCT00000529	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	TAMOXIFEN	targetBased	3	Completed	01/05/1992	https://clinicaltrials.gov/study/NCT00000529	0.7		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	myocardial infarction	METOCLOPRAMIDE	targetBased	4	Unknown status	12/12/2014	https://clinicaltrials.gov/study/NCT02913469	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	myocardial infarction	METOCLOPRAMIDE	targetBased	4	Unknown status	12/12/2014	https://clinicaltrials.gov/study/NCT02913469	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	myocardial infarction	METOCLOPRAMIDE	targetBased	4	Unknown status	12/12/2014	https://clinicaltrials.gov/study/NCT02913469	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	myocardial infarction	METOCLOPRAMIDE	targetBased	4	Unknown status	12/12/2014	https://clinicaltrials.gov/study/NCT02913469	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	myocardial infarction	METOCLOPRAMIDE	targetBased	4	Unknown status	12/12/2014	https://clinicaltrials.gov/study/NCT02913469	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	myocardial infarction	METOCLOPRAMIDE	targetBased	4	Unknown status	12/12/2014	https://clinicaltrials.gov/study/NCT02913469	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	acute myocardial infarction	METOCLOPRAMIDE	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02627950	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	acute myocardial infarction	METOCLOPRAMIDE	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02627950	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acute myocardial infarction	METOCLOPRAMIDE	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02627950	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acute myocardial infarction	METOCLOPRAMIDE	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02627950	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acute myocardial infarction	METOCLOPRAMIDE	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02627950	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acute myocardial infarction	METOCLOPRAMIDE	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02627950	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	angina pectoris	METOCLOPRAMIDE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02939235	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	angina pectoris	METOCLOPRAMIDE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02939235	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	angina pectoris	METOCLOPRAMIDE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02939235	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	angina pectoris	METOCLOPRAMIDE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02939235	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	angina pectoris	METOCLOPRAMIDE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02939235	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	angina pectoris	METOCLOPRAMIDE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02939235	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peripheral arterial disease	PACLITAXEL	targetBased	3	Recruiting	01/05/2015	https://clinicaltrials.gov/study/NCT02464501	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peripheral arterial disease	PACLITAXEL	targetBased	3	Completed	02/03/2017	https://clinicaltrials.gov/study/NCT03064126	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	myocardial infarction	PACLITAXEL	targetBased	3	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00433966	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ischemia	PACLITAXEL	targetBased	3	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT02835586	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	coronary artery disease	PACLITAXEL	targetBased	4	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00611286	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	coronary artery disease	PACLITAXEL	targetBased	4	Active, not recruiting	01/12/2009	https://clinicaltrials.gov/study/NCT00997503	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Coronary Restenosis	PACLITAXEL	targetBased	3	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT03667313	0.7	LoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	ischemia	ALPROSTADIL	targetBased	4	Not yet recruiting	01/04/2020	https://clinicaltrials.gov/study/NCT04312555	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	ischemia	ALPROSTADIL	targetBased	4	Not yet recruiting	01/04/2020	https://clinicaltrials.gov/study/NCT04312555	1	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	Patent ductus arteriosus	ALPROSTADIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb155759-3889-4cb3-9695-42a588f4f689	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	Patent ductus arteriosus	ALPROSTADIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb155759-3889-4cb3-9695-42a588f4f689	1	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	myocardial infarction	ALPROSTADIL	targetBased	4	Unknown status	01/09/2017	https://clinicaltrials.gov/study/NCT03252665	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	myocardial infarction	ALPROSTADIL	targetBased	4	Unknown status	01/09/2017	https://clinicaltrials.gov/study/NCT03252665	1	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	myocardial infarction	ALPROSTADIL	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT03296670	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	myocardial infarction	ALPROSTADIL	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT03296670	1	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	Myocardial Ischemia	ALPROSTADIL	targetBased	4	Unknown status	01/01/2017	https://clinicaltrials.gov/study/NCT03159559	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	Myocardial Ischemia	ALPROSTADIL	targetBased	4	Unknown status	01/01/2017	https://clinicaltrials.gov/study/NCT03159559	1	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	heart failure	ALPROSTADIL	targetBased	3	Not yet recruiting	01/10/2023	https://clinicaltrials.gov/study/NCT00610051	0.7	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	heart failure	ALPROSTADIL	targetBased	3	Not yet recruiting	01/10/2023	https://clinicaltrials.gov/study/NCT00610051	0.7	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	arterial occlusive disease	ALPROSTADIL	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00596752	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	arterial occlusive disease	ALPROSTADIL	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00596752	1	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	thrombotic disease	ALPROSTADIL	targetBased	4	Unknown status	01/07/2008	https://clinicaltrials.gov/study/NCT00733434	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	thrombotic disease	ALPROSTADIL	targetBased	4	Unknown status	01/07/2008	https://clinicaltrials.gov/study/NCT00733434	1	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	cardiovascular disease	ALPROSTADIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01EA01	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	cardiovascular disease	ALPROSTADIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01EA01	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	TIMOLOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C07AA06	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	PINDOLOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C07AA03	1	GoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	familial long QT syndrome	IBUTILIDE	targetBased	4	Completed	26/03/2019	https://clinicaltrials.gov/study/NCT03834883	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	familial long QT syndrome	IBUTILIDE	targetBased	4	Completed	26/03/2019	https://clinicaltrials.gov/study/NCT03834883	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	familial long QT syndrome	IBUTILIDE	targetBased	4	Completed	26/03/2019	https://clinicaltrials.gov/study/NCT03834883	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	familial long QT syndrome	IBUTILIDE	targetBased	4	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02513940	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	familial long QT syndrome	IBUTILIDE	targetBased	4	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02513940	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	familial long QT syndrome	IBUTILIDE	targetBased	4	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02513940	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	familial long QT syndrome	IBUTILIDE	targetBased	4	Recruiting	02/09/2021	https://clinicaltrials.gov/study/NCT04675788	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	familial long QT syndrome	IBUTILIDE	targetBased	4	Recruiting	02/09/2021	https://clinicaltrials.gov/study/NCT04675788	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	familial long QT syndrome	IBUTILIDE	targetBased	4	Recruiting	02/09/2021	https://clinicaltrials.gov/study/NCT04675788	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	IBUTILIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01BD05	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	IBUTILIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01BD05	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	IBUTILIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01BD05	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	IBUTILIDE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01447862	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	IBUTILIDE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01447862	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	IBUTILIDE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01447862	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	OXPRENOLOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C07AA02	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Non-ST Elevation Myocardial Infarction	COLCHICINE	targetBased	3	Active, not recruiting	01/02/2018	https://clinicaltrials.gov/study/NCT03048825	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Ischemic stroke	COLCHICINE	targetBased	4	Recruiting	12/01/2023	https://clinicaltrials.gov/study/NCT06102720	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ST Elevation Myocardial Infarction	COLCHICINE	targetBased	4	Recruiting	28/07/2023	https://clinicaltrials.gov/study/NCT06020300	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ST Elevation Myocardial Infarction	COLCHICINE	targetBased	3	Active, not recruiting	01/02/2018	https://clinicaltrials.gov/study/NCT03048825	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	ST Elevation Myocardial Infarction	COLCHICINE	targetBased	4	Recruiting	01/06/2022	https://clinicaltrials.gov/study/NCT05709509	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pericardial effusion	COLCHICINE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01266694	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pericardial effusion	COLCHICINE	targetBased	4	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02260206	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	vasculitis	COLCHICINE	targetBased	3	Recruiting	12/11/2019	https://clinicaltrials.gov/study/NCT04008316	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	atrial fibrillation	COLCHICINE	targetBased	3	Recruiting	21/09/2021	https://clinicaltrials.gov/study/NCT04870424	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	atrial fibrillation	COLCHICINE	targetBased	3	Recruiting	14/04/2024	https://clinicaltrials.gov/study/NCT05890664	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	atrial fibrillation	COLCHICINE	targetBased	3	Terminated	02/10/2017	https://clinicaltrials.gov/study/NCT03015831	0.35	LoF	protect	Statistical analysis of interim data showed no advantage of colchicine
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	atrial fibrillation	COLCHICINE	targetBased	3	Withdrawn	02/12/2017	https://clinicaltrials.gov/study/NCT02582190	0.7	LoF	protect	Investigational Medicinal Product Supplies
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	atrial fibrillation	COLCHICINE	targetBased	3	Recruiting	03/07/2023	https://clinicaltrials.gov/study/NCT05928728	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	atrial fibrillation	COLCHICINE	targetBased	3	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT01985425	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	atrial fibrillation	COLCHICINE	targetBased	3	Recruiting	14/01/2020	https://clinicaltrials.gov/study/NCT04160117	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	atrial fibrillation	COLCHICINE	targetBased	3	Recruiting	20/06/2022	https://clinicaltrials.gov/study/NCT05459974	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	heart failure	COLCHICINE	targetBased	3	Completed	08/02/2021	https://clinicaltrials.gov/study/NCT04705987	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	heart failure	COLCHICINE	targetBased	3	Recruiting	29/01/2024	https://clinicaltrials.gov/study/NCT05873881	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute coronary syndrome	COLCHICINE	targetBased	4	Completed	03/05/2021	https://clinicaltrials.gov/study/NCT04848857	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute coronary syndrome	COLCHICINE	targetBased	4	Completed	15/06/2021	https://clinicaltrials.gov/study/NCT04949516	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute coronary syndrome	COLCHICINE	targetBased	4	Completed	30/05/2013	https://clinicaltrials.gov/study/NCT02594111	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute coronary syndrome	COLCHICINE	targetBased	4	Unknown status	01/06/2013	https://clinicaltrials.gov/study/NCT01906749	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	myocardial infarction	COLCHICINE	targetBased	4	Withdrawn	01/05/2017	https://clinicaltrials.gov/study/NCT02995512	1	LoF	protect	feasibility
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	myocardial infarction	COLCHICINE	targetBased	3	Not yet recruiting	01/10/2024	https://clinicaltrials.gov/study/NCT06279000	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	myocardial infarction	COLCHICINE	targetBased	4	Completed	01/02/2022	https://clinicaltrials.gov/study/NCT05200052	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute myocardial infarction	COLCHICINE	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02281305	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute myocardial infarction	COLCHICINE	targetBased	4	Unknown status	01/07/2013	https://clinicaltrials.gov/study/NCT01936285	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cardiovascular disease	COLCHICINE	targetBased	3	Recruiting	21/12/2022	https://clinicaltrials.gov/study/NCT05633810	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	coronary artery disease	COLCHICINE	targetBased	4	Completed	10/10/2023	https://clinicaltrials.gov/study/NCT06078904	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	coronary artery disease	COLCHICINE	targetBased	4	Completed	30/05/2013	https://clinicaltrials.gov/study/NCT01709981	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	coronary artery disease	COLCHICINE	targetBased	4	Recruiting	01/08/2023	https://clinicaltrials.gov/study/NCT05618353	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	coronary artery disease	COLCHICINE	targetBased	3	Not yet recruiting	24/06/2024	https://clinicaltrials.gov/study/NCT06469528	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	coronary artery disease	COLCHICINE	targetBased	3	Not yet recruiting	06/07/2024	https://clinicaltrials.gov/study/NCT06472908	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	coronary artery disease	COLCHICINE	targetBased	3	Recruiting	01/03/2023	https://clinicaltrials.gov/study/NCT05739929	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	coronary artery disease	COLCHICINE	targetBased	3	Recruiting	29/01/2024	https://clinicaltrials.gov/study/NCT06095765	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	coronary artery disease	COLCHICINE	targetBased	3	Not yet recruiting	06/12/2022	https://clinicaltrials.gov/study/NCT05175274	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	coronary artery disease	COLCHICINE	targetBased	4	Completed	30/05/2013	https://clinicaltrials.gov/study/NCT02594111	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	coronary artery disease	COLCHICINE	targetBased	4	Recruiting	07/12/2023	https://clinicaltrials.gov/study/NCT05850091	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	coronary artery disease	COLCHICINE	targetBased	4	Active, not recruiting	15/03/2023	https://clinicaltrials.gov/study/NCT06342609	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pericarditis	COLCHICINE	targetBased	4	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00235079	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pericarditis	COLCHICINE	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00128453	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pericarditis	COLCHICINE	targetBased	3	Not yet recruiting	01/02/2023	https://clinicaltrials.gov/study/NCT05737680	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pericarditis	COLCHICINE	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00128414	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cardiac arrhythmia	COLCHICINE	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT03021343	0.7	LoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	coronary artery disease	DEXTROTHYROXINE	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	heart disease	DEXTROTHYROXINE	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	myocardial infarction	DEXTROTHYROXINE	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	cardiovascular disease	DEXTROTHYROXINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C10AX01	1	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	Myocardial Ischemia	DEXTROTHYROXINE	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Patent ductus arteriosus	ACETAMINOPHEN	targetBased	3	Terminated	01/06/2016	https://clinicaltrials.gov/study/NCT03537144	0.7		protect	Difficulty enrolling patients
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Patent ductus arteriosus	ACETAMINOPHEN	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01536158	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Patent ductus arteriosus	ACETAMINOPHEN	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT03022253	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Patent ductus arteriosus	ACETAMINOPHEN	targetBased	4	Unknown status	01/06/2015	https://clinicaltrials.gov/study/NCT03265782	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	hypertension	ACETAMINOPHEN	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00631514	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	hypertension	ACETAMINOPHEN	targetBased	4	Terminated	15/03/2017	https://clinicaltrials.gov/study/NCT02902172	1		protect	Unable to recruit necessary number of patients
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	ST Elevation Myocardial Infarction	ACETAMINOPHEN	targetBased	4	Completed	16/02/2018	https://clinicaltrials.gov/study/NCT03400267	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	third-degree atrioventricular block	ACETAMINOPHEN	targetBased	4	Completed	20/12/2021	https://clinicaltrials.gov/study/NCT04931693	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	acute coronary syndrome	ACETAMINOPHEN	targetBased	4	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02198378	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	coronary artery disease	ACETAMINOPHEN	targetBased	4	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00534651	1		protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	cardiovascular disease	FENOLDOPAM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01CA19	1	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	cardiovascular disease	FENOLDOPAM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01CA19	1	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	cardiovascular disease	FENOLDOPAM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01CA19	1	GoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	coronary artery disease	FENOLDOPAM	targetBased	4	Unknown status	01/09/2012	https://clinicaltrials.gov/study/NCT01690832	1	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	coronary artery disease	FENOLDOPAM	targetBased	4	Unknown status	01/09/2012	https://clinicaltrials.gov/study/NCT01690832	1	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	coronary artery disease	FENOLDOPAM	targetBased	4	Unknown status	01/09/2012	https://clinicaltrials.gov/study/NCT01690832	1	GoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	hypertension	FENOLDOPAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df4cd207-c3b8-4008-5290-02f296c2b4a6	1	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	hypertension	FENOLDOPAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df4cd207-c3b8-4008-5290-02f296c2b4a6	1	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	hypertension	FENOLDOPAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df4cd207-c3b8-4008-5290-02f296c2b4a6	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hypertension	PIOGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hypertension	PIOGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hypertension	PIOGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hypertension	PIOGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hypertension	PIOGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hypertension	PIOGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	coronary artery disease	PIOGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	coronary artery disease	PIOGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	coronary artery disease	PIOGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	coronary artery disease	PIOGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	coronary artery disease	PIOGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	coronary artery disease	PIOGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	PIOGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	PIOGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	PIOGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	PIOGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	PIOGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	PIOGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heart disease	FENTANYL	targetBased	4	Terminated	11/07/2016	https://clinicaltrials.gov/study/NCT02734940	1	GoF	protect	Unable to find participants who met inclusion/exclusion criteria
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heart disease	FENTANYL	targetBased	4	Terminated	11/07/2016	https://clinicaltrials.gov/study/NCT02734940	1	GoF	protect	Unable to find participants who met inclusion/exclusion criteria
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	coronary artery disease	FENTANYL	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02683707	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	coronary artery disease	FENTANYL	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02683707	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hypotension	FENTANYL	targetBased	4	Recruiting	01/10/2021	https://clinicaltrials.gov/study/NCT05051007	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hypotension	FENTANYL	targetBased	4	Recruiting	01/10/2021	https://clinicaltrials.gov/study/NCT05051007	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Aortic Coarctation	FENTANYL	targetBased	3	Completed	01/02/2020	https://clinicaltrials.gov/study/NCT04128540	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Aortic Coarctation	FENTANYL	targetBased	3	Completed	01/02/2020	https://clinicaltrials.gov/study/NCT04128540	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ST Elevation Myocardial Infarction	FENTANYL	targetBased	4	Completed	16/02/2018	https://clinicaltrials.gov/study/NCT03400267	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ST Elevation Myocardial Infarction	FENTANYL	targetBased	4	Completed	16/02/2018	https://clinicaltrials.gov/study/NCT03400267	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	cardiovascular disease	ROSIGLITAZONE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00140647	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	cardiovascular disease	ROSIGLITAZONE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00140647	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	cardiovascular disease	ROSIGLITAZONE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00140647	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	cardiovascular disease	ROSIGLITAZONE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00140647	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	cardiovascular disease	ROSIGLITAZONE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00140647	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	cardiovascular disease	ROSIGLITAZONE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00140647	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hypertension	ROSIGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hypertension	ROSIGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hypertension	ROSIGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hypertension	ROSIGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hypertension	ROSIGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hypertension	ROSIGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	coronary artery disease	ROSIGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	coronary artery disease	ROSIGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	coronary artery disease	ROSIGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	coronary artery disease	ROSIGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	coronary artery disease	ROSIGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	coronary artery disease	ROSIGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	coronary artery disease	ROSIGLITAZONE	targetBased	4	Terminated	01/06/2006	https://clinicaltrials.gov/study/NCT00343395	1	GoF	protect	FDA concerns regarding Avandamet
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	coronary artery disease	ROSIGLITAZONE	targetBased	4	Terminated	01/06/2006	https://clinicaltrials.gov/study/NCT00343395	1	GoF	protect	FDA concerns regarding Avandamet
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	coronary artery disease	ROSIGLITAZONE	targetBased	4	Terminated	01/06/2006	https://clinicaltrials.gov/study/NCT00343395	1	GoF	protect	FDA concerns regarding Avandamet
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	coronary artery disease	ROSIGLITAZONE	targetBased	4	Terminated	01/06/2006	https://clinicaltrials.gov/study/NCT00343395	1	GoF	protect	FDA concerns regarding Avandamet
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	coronary artery disease	ROSIGLITAZONE	targetBased	4	Terminated	01/06/2006	https://clinicaltrials.gov/study/NCT00343395	1	GoF	protect	FDA concerns regarding Avandamet
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	coronary artery disease	ROSIGLITAZONE	targetBased	4	Terminated	01/06/2006	https://clinicaltrials.gov/study/NCT00343395	1	GoF	protect	FDA concerns regarding Avandamet
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00140647	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00140647	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00140647	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00140647	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00140647	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00140647	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00116831	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00116831	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00116831	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00116831	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00116831	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00116831	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Ischemic stroke	MEPERIDINE	targetBased	3	Terminated	01/07/2013	https://clinicaltrials.gov/study/NCT01833312	0.7	GoF	protect	Slow recruitment, cessation of funding
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Ischemic stroke	MEPERIDINE	targetBased	3	Terminated	01/07/2013	https://clinicaltrials.gov/study/NCT01833312	0.7	GoF	protect	Slow recruitment, cessation of funding
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	arteriosclerosis disorder	DEXTROAMPHETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35744538-1704-4ee0-954d-52710cf3456d	1		protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	PROPAFENONE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	PROPAFENONE	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	PROPAFENONE	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ventricular fibrillation	PROPAFENONE	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Ventricular arrhythmia	PROPAFENONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a313c111-e539-47bc-9d57-c3767f74bcca	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiac arrhythmia	PROPAFENONE	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiac arrhythmia	PROPAFENONE	targetBased	4	Not yet recruiting	01/08/2019	https://clinicaltrials.gov/study/NCT03895411	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiac arrhythmia	PROPAFENONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01BC03	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	PROPAFENONE	targetBased	4	Completed	03/03/2015	https://clinicaltrials.gov/study/NCT02389218	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	PROPAFENONE	targetBased	4	Withdrawn	01/12/2011	https://clinicaltrials.gov/study/NCT01505296	1	LoF	protect	Never initiated
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	PROPAFENONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e4412a6a-ed4d-410d-8abb-86e1d7b72a3c	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	PROPAFENONE	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00540787	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	PROPAFENONE	targetBased	3	Suspended	01/04/2006	https://clinicaltrials.gov/study/NCT00392106	0.35	LoF	protect	voluntarily by Sponsor to investigate an anticipated SAE
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	PROPAFENONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bb1bc4a-a019-49c8-af81-be899822428f	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	PROPAFENONE	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01477983	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	PROPAFENONE	targetBased	4	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02145546	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	PROPAFENONE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00523978	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	PROPAFENONE	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	PROPAFENONE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	PROPAFENONE	targetBased	4	Recruiting	01/09/2019	https://clinicaltrials.gov/study/NCT05720572	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ventricular tachycardia	PROPAFENONE	targetBased	4	Unknown status	01/01/2013	https://clinicaltrials.gov/study/NCT01780311	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	congestive heart failure	AMIODARONE	targetBased	3	Completed	01/05/1997	https://clinicaltrials.gov/study/NCT00000609	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	congestive heart failure	AMIODARONE	targetBased	3	Completed	01/05/1997	https://clinicaltrials.gov/study/NCT00000609	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	congestive heart failure	AMIODARONE	targetBased	3	Completed	01/05/1997	https://clinicaltrials.gov/study/NCT00000609	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	myocardial infarction	AMIODARONE	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	myocardial infarction	AMIODARONE	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	myocardial infarction	AMIODARONE	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart failure	AMIODARONE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart failure	AMIODARONE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart failure	AMIODARONE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart failure	AMIODARONE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00729911	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart failure	AMIODARONE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00729911	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart failure	AMIODARONE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00729911	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	AMIODARONE	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	AMIODARONE	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	AMIODARONE	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	AMIODARONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01BD01	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	AMIODARONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01BD01	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	AMIODARONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01BD01	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	sudden cardiac arrest	AMIODARONE	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	sudden cardiac arrest	AMIODARONE	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	sudden cardiac arrest	AMIODARONE	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	sudden cardiac arrest	AMIODARONE	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	sudden cardiac arrest	AMIODARONE	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	sudden cardiac arrest	AMIODARONE	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	sudden cardiac arrest	AMIODARONE	targetBased	3	Completed	01/05/1997	https://clinicaltrials.gov/study/NCT00000609	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	sudden cardiac arrest	AMIODARONE	targetBased	3	Completed	01/05/1997	https://clinicaltrials.gov/study/NCT00000609	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	sudden cardiac arrest	AMIODARONE	targetBased	3	Completed	01/05/1997	https://clinicaltrials.gov/study/NCT00000609	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	AMIODARONE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00953212	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	AMIODARONE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00953212	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	AMIODARONE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00953212	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d4d66f7-fa14-e832-e053-2a95a90a8b62	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d4d66f7-fa14-e832-e053-2a95a90a8b62	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d4d66f7-fa14-e832-e053-2a95a90a8b62	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57df7b65-7829-4364-894f-ae4c2772c733	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57df7b65-7829-4364-894f-ae4c2772c733	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57df7b65-7829-4364-894f-ae4c2772c733	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart disease	AMIODARONE	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart disease	AMIODARONE	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart disease	AMIODARONE	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrest	AMIODARONE	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01401647	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrest	AMIODARONE	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01401647	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrest	AMIODARONE	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01401647	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrest	AMIODARONE	targetBased	3	Recruiting	01/04/2021	https://clinicaltrials.gov/study/NCT04845607	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrest	AMIODARONE	targetBased	3	Recruiting	01/04/2021	https://clinicaltrials.gov/study/NCT04845607	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrest	AMIODARONE	targetBased	3	Recruiting	01/04/2021	https://clinicaltrials.gov/study/NCT04845607	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Suspended	01/04/2006	https://clinicaltrials.gov/study/NCT00392106	0.35	LoF	protect	voluntarily by Sponsor to investigate an anticipated SAE
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Suspended	01/04/2006	https://clinicaltrials.gov/study/NCT00392106	0.35	LoF	protect	voluntarily by Sponsor to investigate an anticipated SAE
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Suspended	01/04/2006	https://clinicaltrials.gov/study/NCT00392106	0.35	LoF	protect	voluntarily by Sponsor to investigate an anticipated SAE
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02145546	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02145546	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02145546	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00668759	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00668759	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00668759	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Unknown status	01/08/2008	https://clinicaltrials.gov/study/NCT00724581	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Unknown status	01/08/2008	https://clinicaltrials.gov/study/NCT00724581	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Unknown status	01/08/2008	https://clinicaltrials.gov/study/NCT00724581	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00420017	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00420017	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00420017	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Unknown status	01/03/2016	https://clinicaltrials.gov/study/NCT02715687	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Unknown status	01/03/2016	https://clinicaltrials.gov/study/NCT02715687	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Unknown status	01/03/2016	https://clinicaltrials.gov/study/NCT02715687	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00953212	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00953212	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00953212	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06262932	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06262932	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06262932	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT03432663	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT03432663	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT03432663	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Recruiting	13/12/2019	https://clinicaltrials.gov/study/NCT04223739	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Recruiting	13/12/2019	https://clinicaltrials.gov/study/NCT04223739	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Recruiting	13/12/2019	https://clinicaltrials.gov/study/NCT04223739	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00489736	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00489736	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00489736	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00127712	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00127712	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00127712	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00540787	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00540787	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00540787	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/08/2000	https://clinicaltrials.gov/study/NCT00845780	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/08/2000	https://clinicaltrials.gov/study/NCT00845780	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/08/2000	https://clinicaltrials.gov/study/NCT00845780	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00784316	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00784316	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00784316	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000556	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Recruiting	29/05/2022	https://clinicaltrials.gov/study/NCT05169866	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Recruiting	29/05/2022	https://clinicaltrials.gov/study/NCT05169866	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Recruiting	29/05/2022	https://clinicaltrials.gov/study/NCT05169866	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Unknown status	01/05/2013	https://clinicaltrials.gov/study/NCT01817439	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Unknown status	01/05/2013	https://clinicaltrials.gov/study/NCT01817439	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Unknown status	01/05/2013	https://clinicaltrials.gov/study/NCT01817439	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Terminated	02/11/2021	https://clinicaltrials.gov/study/NCT05004077	1	LoF	protect	limited enrollment
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Terminated	02/11/2021	https://clinicaltrials.gov/study/NCT05004077	1	LoF	protect	limited enrollment
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Terminated	02/11/2021	https://clinicaltrials.gov/study/NCT05004077	1	LoF	protect	limited enrollment
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT04748991	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT04748991	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT04748991	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Not yet recruiting	01/02/2024	https://clinicaltrials.gov/study/NCT05543278	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Not yet recruiting	01/02/2024	https://clinicaltrials.gov/study/NCT05543278	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Not yet recruiting	01/02/2024	https://clinicaltrials.gov/study/NCT05543278	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00287209	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00287209	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00287209	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT01198275	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT01198275	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT01198275	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/02/1999	https://clinicaltrials.gov/study/NCT00251706	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/02/1999	https://clinicaltrials.gov/study/NCT00251706	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/02/1999	https://clinicaltrials.gov/study/NCT00251706	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Recruiting	13/06/2024	https://clinicaltrials.gov/study/NCT05841056	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Recruiting	13/06/2024	https://clinicaltrials.gov/study/NCT05841056	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Recruiting	13/06/2024	https://clinicaltrials.gov/study/NCT05841056	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Recruiting	05/01/2022	https://clinicaltrials.gov/study/NCT05287191	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Recruiting	05/01/2022	https://clinicaltrials.gov/study/NCT05287191	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Recruiting	05/01/2022	https://clinicaltrials.gov/study/NCT05287191	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00340314	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00340314	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00340314	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Recruiting	03/02/2022	https://clinicaltrials.gov/study/NCT04594746	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Recruiting	03/02/2022	https://clinicaltrials.gov/study/NCT04594746	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Recruiting	03/02/2022	https://clinicaltrials.gov/study/NCT04594746	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Unknown status	01/04/2011	https://clinicaltrials.gov/study/NCT01341353	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Unknown status	01/04/2011	https://clinicaltrials.gov/study/NCT01341353	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Unknown status	01/04/2011	https://clinicaltrials.gov/study/NCT01341353	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02132767	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02132767	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02132767	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01173809	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01173809	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01173809	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT01461733	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT01461733	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT01461733	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Active, not recruiting	01/04/2016	https://clinicaltrials.gov/study/NCT02750319	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Active, not recruiting	01/04/2016	https://clinicaltrials.gov/study/NCT02750319	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	3	Active, not recruiting	01/04/2016	https://clinicaltrials.gov/study/NCT02750319	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Terminated	01/01/2016	https://clinicaltrials.gov/study/NCT02341105	1	LoF	protect	low recruitment rate
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Terminated	01/01/2016	https://clinicaltrials.gov/study/NCT02341105	1	LoF	protect	low recruitment rate
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Terminated	01/01/2016	https://clinicaltrials.gov/study/NCT02341105	1	LoF	protect	low recruitment rate
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Withdrawn	01/09/2012	https://clinicaltrials.gov/study/NCT01627106	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Withdrawn	01/09/2012	https://clinicaltrials.gov/study/NCT01627106	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Withdrawn	01/09/2012	https://clinicaltrials.gov/study/NCT01627106	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Recruiting	01/03/2017	https://clinicaltrials.gov/study/NCT03868150	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Recruiting	01/03/2017	https://clinicaltrials.gov/study/NCT03868150	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE	targetBased	4	Recruiting	01/03/2017	https://clinicaltrials.gov/study/NCT03868150	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04efa7dc-7be0-495c-85a4-3d9d6ed5840a	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04efa7dc-7be0-495c-85a4-3d9d6ed5840a	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04efa7dc-7be0-495c-85a4-3d9d6ed5840a	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0915ecd6-1c36-420a-bd59-32d48587e137	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0915ecd6-1c36-420a-bd59-32d48587e137	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0915ecd6-1c36-420a-bd59-32d48587e137	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00257959	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00257959	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00257959	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcc8658c-761a-443f-8c32-1499d86028ec	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcc8658c-761a-443f-8c32-1499d86028ec	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcc8658c-761a-443f-8c32-1499d86028ec	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=304d0be4-0c13-4dbb-8ffb-b2e7caa7fb1e	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=304d0be4-0c13-4dbb-8ffb-b2e7caa7fb1e	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=304d0be4-0c13-4dbb-8ffb-b2e7caa7fb1e	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5d11e6d-d78f-40f0-87bd-6909088141d0	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5d11e6d-d78f-40f0-87bd-6909088141d0	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5d11e6d-d78f-40f0-87bd-6909088141d0	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdd50dc7-f712-4248-b0e3-ba247cf08cee	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdd50dc7-f712-4248-b0e3-ba247cf08cee	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdd50dc7-f712-4248-b0e3-ba247cf08cee	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9108958-b8d7-4fba-87c3-9a32990de551	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9108958-b8d7-4fba-87c3-9a32990de551	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9108958-b8d7-4fba-87c3-9a32990de551	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51772745-9ea9-42cd-97e6-7266f41ae3ca	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51772745-9ea9-42cd-97e6-7266f41ae3ca	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51772745-9ea9-42cd-97e6-7266f41ae3ca	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4	Active, not recruiting	01/10/2016	https://clinicaltrials.gov/study/NCT02830360	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4	Active, not recruiting	01/10/2016	https://clinicaltrials.gov/study/NCT02830360	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	4	Active, not recruiting	01/10/2016	https://clinicaltrials.gov/study/NCT02830360	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	3	Terminated	01/08/2010	https://clinicaltrials.gov/study/NCT01097330	0.7	LoF	protect	Anticipated non-feasibility of recruitment objectives
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	3	Terminated	01/08/2010	https://clinicaltrials.gov/study/NCT01097330	0.7	LoF	protect	Anticipated non-feasibility of recruitment objectives
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE	targetBased	3	Terminated	01/08/2010	https://clinicaltrials.gov/study/NCT01097330	0.7	LoF	protect	Anticipated non-feasibility of recruitment objectives
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51772745-9ea9-42cd-97e6-7266f41ae3ca	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51772745-9ea9-42cd-97e6-7266f41ae3ca	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51772745-9ea9-42cd-97e6-7266f41ae3ca	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0eb6c22-7553-4e3f-a06d-20a186ced99a	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0eb6c22-7553-4e3f-a06d-20a186ced99a	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0eb6c22-7553-4e3f-a06d-20a186ced99a	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9108958-b8d7-4fba-87c3-9a32990de551	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9108958-b8d7-4fba-87c3-9a32990de551	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9108958-b8d7-4fba-87c3-9a32990de551	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	3	Completed	01/04/1987	https://clinicaltrials.gov/study/NCT00000464	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdd50dc7-f712-4248-b0e3-ba247cf08cee	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdd50dc7-f712-4248-b0e3-ba247cf08cee	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdd50dc7-f712-4248-b0e3-ba247cf08cee	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d4d66f7-fa14-e832-e053-2a95a90a8b62	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d4d66f7-fa14-e832-e053-2a95a90a8b62	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d4d66f7-fa14-e832-e053-2a95a90a8b62	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5d11e6d-d78f-40f0-87bd-6909088141d0	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5d11e6d-d78f-40f0-87bd-6909088141d0	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5d11e6d-d78f-40f0-87bd-6909088141d0	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8d04647-8e25-4127-8ecf-360ce1991c2f	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8d04647-8e25-4127-8ecf-360ce1991c2f	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8d04647-8e25-4127-8ecf-360ce1991c2f	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04efa7dc-7be0-495c-85a4-3d9d6ed5840a	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04efa7dc-7be0-495c-85a4-3d9d6ed5840a	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04efa7dc-7be0-495c-85a4-3d9d6ed5840a	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=304d0be4-0c13-4dbb-8ffb-b2e7caa7fb1e	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=304d0be4-0c13-4dbb-8ffb-b2e7caa7fb1e	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=304d0be4-0c13-4dbb-8ffb-b2e7caa7fb1e	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0915ecd6-1c36-420a-bd59-32d48587e137	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0915ecd6-1c36-420a-bd59-32d48587e137	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0915ecd6-1c36-420a-bd59-32d48587e137	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcc8658c-761a-443f-8c32-1499d86028ec	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcc8658c-761a-443f-8c32-1499d86028ec	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcc8658c-761a-443f-8c32-1499d86028ec	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000531	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	NEBIVOLOL	targetBased	4	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00517725	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	NEBIVOLOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C07AB12	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Non-ST Elevation Myocardial Infarction	NEBIVOLOL	targetBased	4	Recruiting	17/12/2018	https://clinicaltrials.gov/study/NCT03778554	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	acute myocardial infarction	NEBIVOLOL	targetBased	4	Recruiting	17/12/2018	https://clinicaltrials.gov/study/NCT03778554	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	coronary artery disease	NEBIVOLOL	targetBased	4	Terminated	01/05/2009	https://clinicaltrials.gov/study/NCT00893984	1	LoF	protect	Lack of patient recruitment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Coronary Vasospasm	NEBIVOLOL	targetBased	4	Completed	01/01/2018	https://clinicaltrials.gov/study/NCT03930433	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	3	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01508026	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	3	Terminated	31/10/2007	https://clinicaltrials.gov/study/NCT00547300	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT00999102	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=673f5ad2-c09b-4a89-9407-efdadd007917	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00942487	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01920282	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	3	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00200473	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb47560d-9e35-4b0f-b12b-6ea478684a5b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00145236	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	3	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00200460	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01595516	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	15/05/2008	https://clinicaltrials.gov/study/NCT00673790	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	30/08/2010	https://clinicaltrials.gov/study/NCT03635125	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	12/05/2022	https://clinicaltrials.gov/study/NCT05513937	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Unknown status	01/12/2010	https://clinicaltrials.gov/study/NCT02057328	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Terminated	01/09/2010	https://clinicaltrials.gov/study/NCT01206439	1	LoF	protect	Slow enrollment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01157234	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01202175	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00734630	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT00992056	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00200434	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00770861	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00785512	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	3	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT05170061	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02710071	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00295542	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b8ad213-1dc8-454e-a524-075685c0e1a8	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00648895	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01395329	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01049009	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	3	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT00200499	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01057251	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00142584	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	3	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01415505	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT01248338	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01041287	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01415531	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00145210	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	28/04/2021	https://clinicaltrials.gov/study/NCT05257148	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Terminated	01/06/2012	https://clinicaltrials.gov/study/NCT01605370	1	LoF	protect	Difficulty in identifying subjects satisfying the inclusion criteria.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Recruiting	02/10/2023	https://clinicaltrials.gov/study/NCT06104423	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=895cb85a-5ec8-4070-babf-d1325c028677	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01218100	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ST Elevation Myocardial Infarction	NEBIVOLOL	targetBased	4	Recruiting	17/12/2018	https://clinicaltrials.gov/study/NCT03778554	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atherosclerosis	NEBIVOLOL	targetBased	4	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01230892	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Ventricular arrhythmia	METHADONE	targetBased	4	Active, not recruiting	07/05/2015	https://clinicaltrials.gov/study/NCT04254731	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Ventricular arrhythmia	METHADONE	targetBased	4	Active, not recruiting	07/05/2015	https://clinicaltrials.gov/study/NCT04254731	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	heart disease	ESTRADIOL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	heart disease	ESTRADIOL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	cardiovascular disease	ESTRADIOL	targetBased	4	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01109979	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	cardiovascular disease	ESTRADIOL	targetBased	4	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01109979	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	paroxysmal familial ventricular fibrillation	ESTRADIOL	targetBased	4	Recruiting	24/02/2024	https://clinicaltrials.gov/study/NCT06181305	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	paroxysmal familial ventricular fibrillation	ESTRADIOL	targetBased	4	Recruiting	24/02/2024	https://clinicaltrials.gov/study/NCT06181305	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Myocardial Ischemia	ESTRADIOL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Myocardial Ischemia	ESTRADIOL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypertension	ESTRADIOL	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00102141	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypertension	ESTRADIOL	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00102141	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	ESTRADIOL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	ESTRADIOL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	aortic stenosis	SUFENTANIL	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT02053818	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	aortic stenosis	SUFENTANIL	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT02053818	1	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cerebral atherosclerosis	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e3ea1dbc-47cc-462d-a360-a3944f80b14c	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cerebral atherosclerosis	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87db36f3-c831-4a84-a3c5-e9d6cc7191af	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cerebral atherosclerosis	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfd129ae-8b0a-f118-b7d0-45d106290b63	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cerebral atherosclerosis	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17f205dd-0feb-4c49-a0e1-2d0c362c6bd7	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cerebral atherosclerosis	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13602c1d-d1c9-496b-baa6-8dee92519d67	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cerebral atherosclerosis	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=461e6444-189e-62ed-6c61-1c36a04459c6	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cerebral atherosclerosis	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14452da8-3b48-497d-9017-bdfb967b7f56	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPINEPHRINE	targetBased	4	Completed	01/09/2018	https://clinicaltrials.gov/study/NCT03704909	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPINEPHRINE	targetBased	4	Not yet recruiting	15/02/2024	https://clinicaltrials.gov/study/NCT06248593	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPINEPHRINE	targetBased	4	Recruiting	05/03/2024	https://clinicaltrials.gov/study/NCT06334549	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPINEPHRINE	targetBased	4	Recruiting	21/03/2022	https://clinicaltrials.gov/study/NCT05279703	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	EPINEPHRINE	targetBased	3	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00446017	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ed35d7d-616c-43cd-9776-705821afc1f0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f03ce427-2dfa-460c-a1a9-c659d7a35b67	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c07b20c-d222-4b42-87b8-9667705a2945	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd5ede55-10de-491e-a73f-17a77f89891a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=daa651e5-40e1-4e87-9775-3f7cc44dff32	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de6a969a-7e0f-4e5f-8d12-de5c7129d39c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a01c237d-ae30-4326-9731-fde72505a4a6	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8da22eb1-0965-4d4e-b15d-91db7193548e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=353f2d30-4b74-43eb-a2ff-26d593d283f8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3af22732-ff86-4ae2-813a-d2bcf0924471	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d785beac-3f68-4df1-926f-34da6773f295	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da3009a0-9eed-4254-90f9-b4b024073828	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e609bab7-c671-424d-bd9d-ced0affa0b4d	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0babff47-11ed-47b6-a57d-502ca3c86973	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=070d391a-0525-4172-add9-5cb45e0c5d67	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74b3e639-cd9d-46b0-8505-86b0214cb20b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sudden cardiac arrest	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b3d99dc-cb35-4331-96cd-fedb95b96750	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	EPINEPHRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01CA24	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	acute coronary syndrome	EPINEPHRINE	targetBased	4	Completed	01/01/2021	https://clinicaltrials.gov/study/NCT04699110	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiac arrhythmia	EPINEPHRINE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT01719978	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hemorrhoid	EPINEPHRINE	targetBased	4	Terminated	01/04/2014	https://clinicaltrials.gov/study/NCT02104414	1	GoF	protect	low enrollment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiac arrest	EPINEPHRINE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00729794	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiac arrest	EPINEPHRINE	targetBased	4	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00127907	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiac arrest	EPINEPHRINE	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00358579	0.7	GoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Ischemic stroke	DALFAMPRIDINE	targetBased	3	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02271217	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Ischemic stroke	DALFAMPRIDINE	targetBased	3	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02271217	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ischemic stroke	DALFAMPRIDINE	targetBased	3	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02271217	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ischemic stroke	DALFAMPRIDINE	targetBased	3	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02271217	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ischemic stroke	DALFAMPRIDINE	targetBased	3	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02271217	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Ischemic stroke	DALFAMPRIDINE	targetBased	3	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02271217	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Ischemic stroke	DALFAMPRIDINE	targetBased	3	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02271217	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	ventricular tachycardia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	ventricular tachycardia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	cardiac arrhythmia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	cardiac arrhythmia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cardiac arrhythmia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cardiac arrhythmia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cardiac arrhythmia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cardiac arrhythmia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	cardiac arrhythmia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	ALBUTEROL	targetBased	3	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT02885636	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ventricular septal defect	ALBUTEROL	targetBased	4	Completed	15/10/2016	https://clinicaltrials.gov/study/NCT02914652	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	ALBUTEROL	targetBased	3	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT02885636	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	CELIPROLOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C07AB08	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	left ventricular hypertrophy	CARVEDILOL	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00108082	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fdb12700-116b-4203-8d74-9a94b9401fe6	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c57982f2-c7da-488a-7ea9-b9609439ac68	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	4	Terminated	01/04/2007	https://clinicaltrials.gov/study/NCT00402376	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd818d91-cddf-474f-aa68-43e416da8b8e	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	3	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT01178528	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4647b22-9a70-4259-a8f6-fac0ce1ac5c5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00272805	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f431723b-4849-408b-884a-43e3a52bb13c	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	4	Not yet recruiting	01/05/2019	https://clinicaltrials.gov/study/NCT03948685	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	4	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00517725	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9a12198-b016-42ae-b9dc-d98fead7b79e	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d068b6a4-63c0-40fc-b3a3-7145bde7ed72	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	3	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02012075	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40a98410-9568-4278-959e-ca3517a9b119	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68c275e8-992a-4520-8065-ab6d615d89cc	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2834ce85-fbe6-4e37-b925-d7f8713bcd4c	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	4	Unknown status	27/10/2016	https://clinicaltrials.gov/study/NCT03209180	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9bb93e9a-1bac-4a2e-a5fe-16197e129367	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=494be2b0-1458-481f-e054-00144ff88e88	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f193c24-7204-4249-bbef-713090cff100	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e79c3175-cf13-4a20-874b-5b9a019ce30a	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5b907f8-84a0-5fb2-e7ec-4c82246195f5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1da0dc6d-1f09-4888-a04f-c6a8170e2b7b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2b6f293-dd31-454b-8729-6e453a23a854	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84e7ab5-bd6a-44a0-bc57-a61b7bc96dc5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da8b8c20-0130-4aa9-924d-4a4f28c3f767	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b2638f5-8975-4259-be52-0da5c263bcc0	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea60885e-a8c3-4120-97dd-a59ae2251b8b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f2646b7e-94b7-42b1-8960-ba83fd34b2c2	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=354d1689-53f9-42d3-8308-08b6d9a04404	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e453c21-a8a8-dc54-5591-74c972d41727	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0db9d532-d62c-46c5-b4b9-855d78d01314	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d068b6a4-63c0-40fc-b3a3-7145bde7ed72	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2834ce85-fbe6-4e37-b925-d7f8713bcd4c	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fdb12700-116b-4203-8d74-9a94b9401fe6	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7cc14b86-0833-4c3c-91f3-7963d7052fd5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adca4651-75f9-44bb-bfa9-4a4219948cfa	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5a28e57-7304-4e23-98a3-bae14d8ed25f	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=264a3dc1-596c-43ab-a20c-65c80ab22f2a	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc6a2d33-aa04-4a04-9cde-901b744d24ca	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f431723b-4849-408b-884a-43e3a52bb13c	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f997a0b-a4c9-4be8-9add-8d90c1c465e5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bbf4dd22-f1e3-4101-89fb-31f5df3bfbc4	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=494be2b0-1458-481f-e054-00144ff88e88	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ba6d893-ae2a-4535-b904-667d206f93af	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4	Completed	17/05/2017	https://clinicaltrials.gov/study/NCT03169426	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06400a4c-42b4-440a-92b4-1f47f98ac7ba	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9bab0a6b-8ed4-46e4-8326-2f9e3c87559b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5026c19-733f-41a4-a0c9-e48a9a742460	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e843534e-47a2-46e3-92bb-d079467be606	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a570b8ea-530d-4565-a091-bb9dbe4a6d8d	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=155d9cbb-c74c-49b0-840d-fd79c0f13e4f	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7736758-ad06-4ddb-bdf0-eda27a0acae5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=106ff38f-526a-4993-9779-8399e8a0f765	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee2ea175-52b1-e57e-281a-d3ad3405ddd2	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a103502-c809-41ae-93a3-f7485605d0fe	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad96f237-1e3a-45ff-9c47-fed3544dc943	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8640adde-d071-44a4-97d0-fa8a8548debe	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=577b23c1-bd6d-41a4-a7c5-ebe7b92e37bd	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da8a670b-a9ce-445f-af31-7588c6c67e29	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c57982f2-c7da-488a-7ea9-b9609439ac68	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c03bd9d7-1e0b-49da-a14a-32e712dc3a2d	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=473d1684-944c-4a65-aef4-6379f97a0178	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f71ca3a6-3d92-4379-b5eb-99a70deaa44b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d8912b-6fcd-498f-a1b6-d55315db9ee8	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9a12198-b016-42ae-b9dc-d98fead7b79e	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a27a7950-66d3-4894-8527-2345bb1c7ebc	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef3e2389-6a86-42f7-88e7-981fd0c10e5a	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62408fc0-65d5-42f6-91a3-2c13f7697b39	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b5bc309-a943-45a5-9cb9-0338c1735a01	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4a21f67-7812-4634-beba-f8e85c63c5f2	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b23021d4-c00a-e0ef-eb93-1dc824ae56ca	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7f2f7-7309-4825-b868-13c6ef89fe86	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6686069e-7e43-4963-8a66-961e0b36d84d	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01155635	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99f4bdbc-ed07-4c98-a119-94588e53f2ef	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=506005f3-d79d-4de1-8bd2-71ade18b8d47	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5822e3c-413c-4c7e-bbec-d0d42d2028ba	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adc1a112-8620-45ac-beb1-c75b63ab4e13	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd8313e3-7b77-4e44-b2f8-9f504cf1da9f	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be5f4eed-742a-4257-98ff-633111dc877d	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0effe5d-c12e-48f1-a25d-d9c94c97dc35	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40a98410-9568-4278-959e-ca3517a9b119	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29082d8c-bbde-4620-924f-02dcf1764919	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a2ad30a-e7a1-4888-9e71-f9b0b67838d9	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4647b22-9a70-4259-a8f6-fac0ce1ac5c5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=81bc612d-5674-45b9-a1f5-2cb4fa625747	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fbbab179-d1eb-48a6-8e2b-1c71606fe50d	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e68c9b18-e7fd-45f7-a8f5-1d815e32680b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a97a2467-7525-467c-8969-38246903690c	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5319aa4-ed6a-4bcc-bc72-b692891a6dae	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b21829b-9a54-4e78-9f44-05456da5ef73	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf777244-1f06-439a-a9e1-19da761f193d	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d485d38-5d43-4a54-bc63-82734035c66a	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a5a9e29-1954-47a2-baa2-b34594130869	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac7f5b87-9dee-4f4d-8b71-e334c87e8e59	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68c275e8-992a-4520-8065-ab6d615d89cc	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd818d91-cddf-474f-aa68-43e416da8b8e	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9bb93e9a-1bac-4a2e-a5fe-16197e129367	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3acd97e-2a2c-4796-8561-ba7f268d3aed	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=205da5d0-05d9-440d-bb5a-b30b826900ab	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0787d56-11fc-4643-83ac-1b17bb2a9817	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8da1445a-1d21-4c4f-aa55-da9957bf8cb1	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=25566ff0-3747-4f32-8d4f-de0dfbbb5530	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	CARVEDILOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C07AG02	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Non-ST Elevation Myocardial Infarction	CARVEDILOL	targetBased	4	Recruiting	17/12/2018	https://clinicaltrials.gov/study/NCT03778554	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	acute coronary syndrome	CARVEDILOL	targetBased	4	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02809820	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Reduced left ventricular ejection fraction	CARVEDILOL	targetBased	4	Unknown status	27/10/2016	https://clinicaltrials.gov/study/NCT03209180	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	angina pectoris	CARVEDILOL	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT02547597	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	acute myocardial infarction	CARVEDILOL	targetBased	4	Recruiting	17/12/2018	https://clinicaltrials.gov/study/NCT03778554	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	coronary artery disease	CARVEDILOL	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	essential hypertension	CARVEDILOL	targetBased	3	Unknown status	01/01/2011	https://clinicaltrials.gov/study/NCT01413048	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c03bd9d7-1e0b-49da-a14a-32e712dc3a2d	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	3	Unknown status	01/10/2013	https://clinicaltrials.gov/study/NCT01970059	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=205da5d0-05d9-440d-bb5a-b30b826900ab	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a27a7950-66d3-4894-8527-2345bb1c7ebc	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7cc14b86-0833-4c3c-91f3-7963d7052fd5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f193c24-7204-4249-bbef-713090cff100	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=506005f3-d79d-4de1-8bd2-71ade18b8d47	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9bab0a6b-8ed4-46e4-8326-2f9e3c87559b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea60885e-a8c3-4120-97dd-a59ae2251b8b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29082d8c-bbde-4620-924f-02dcf1764919	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00347360	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63065e30-4a50-42b0-9622-a393923c1e98	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4647b22-9a70-4259-a8f6-fac0ce1ac5c5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a570b8ea-530d-4565-a091-bb9dbe4a6d8d	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00669279	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd8313e3-7b77-4e44-b2f8-9f504cf1da9f	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3992a3f-8347-476d-993e-16958c74efb3	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	3	Completed	05/01/2006	https://clinicaltrials.gov/study/NCT00273052	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c57982f2-c7da-488a-7ea9-b9609439ac68	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9bb93e9a-1bac-4a2e-a5fe-16197e129367	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5a28e57-7304-4e23-98a3-bae14d8ed25f	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0effe5d-c12e-48f1-a25d-d9c94c97dc35	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT00060918	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	3	Withdrawn	01/07/2021	https://clinicaltrials.gov/study/NCT04121299	0.7	LoF	protect	lack of funding
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d485d38-5d43-4a54-bc63-82734035c66a	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00827775	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2834ce85-fbe6-4e37-b925-d7f8713bcd4c	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=473d1684-944c-4a65-aef4-6379f97a0178	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e79c3175-cf13-4a20-874b-5b9a019ce30a	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be5f4eed-742a-4257-98ff-633111dc877d	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT02056626	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d068b6a4-63c0-40fc-b3a3-7145bde7ed72	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ba6d893-ae2a-4535-b904-667d206f93af	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6686069e-7e43-4963-8a66-961e0b36d84d	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f2646b7e-94b7-42b1-8960-ba83fd34b2c2	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5026c19-733f-41a4-a0c9-e48a9a742460	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f71ca3a6-3d92-4379-b5eb-99a70deaa44b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8da1445a-1d21-4c4f-aa55-da9957bf8cb1	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0db9d532-d62c-46c5-b4b9-855d78d01314	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00657241	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da8b8c20-0130-4aa9-924d-4a4f28c3f767	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT00060931	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b5bc309-a943-45a5-9cb9-0338c1735a01	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad96f237-1e3a-45ff-9c47-fed3544dc943	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7f2f7-7309-4825-b868-13c6ef89fe86	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=354d1689-53f9-42d3-8308-08b6d9a04404	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00496834	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40a98410-9568-4278-959e-ca3517a9b119	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b23021d4-c00a-e0ef-eb93-1dc824ae56ca	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84e7ab5-bd6a-44a0-bc57-a61b7bc96dc5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06400a4c-42b4-440a-92b4-1f47f98ac7ba	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00624065	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc6a2d33-aa04-4a04-9cde-901b744d24ca	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00295542	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a97a2467-7525-467c-8969-38246903690c	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd818d91-cddf-474f-aa68-43e416da8b8e	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8640adde-d071-44a4-97d0-fa8a8548debe	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99f4bdbc-ed07-4c98-a119-94588e53f2ef	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68c275e8-992a-4520-8065-ab6d615d89cc	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4	Unknown status	01/11/2010	https://clinicaltrials.gov/study/NCT01243827	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=25566ff0-3747-4f32-8d4f-de0dfbbb5530	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5b907f8-84a0-5fb2-e7ec-4c82246195f5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a2ad30a-e7a1-4888-9e71-f9b0b67838d9	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=264a3dc1-596c-43ab-a20c-65c80ab22f2a	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f997a0b-a4c9-4be8-9add-8d90c1c465e5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3acd97e-2a2c-4796-8561-ba7f268d3aed	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adc1a112-8620-45ac-beb1-c75b63ab4e13	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4a21f67-7812-4634-beba-f8e85c63c5f2	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=106ff38f-526a-4993-9779-8399e8a0f765	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=577b23c1-bd6d-41a4-a7c5-ebe7b92e37bd	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d8912b-6fcd-498f-a1b6-d55315db9ee8	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5319aa4-ed6a-4bcc-bc72-b692891a6dae	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da8a670b-a9ce-445f-af31-7588c6c67e29	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7736758-ad06-4ddb-bdf0-eda27a0acae5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=81bc612d-5674-45b9-a1f5-2cb4fa625747	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a5a9e29-1954-47a2-baa2-b34594130869	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e843534e-47a2-46e3-92bb-d079467be606	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fdb12700-116b-4203-8d74-9a94b9401fe6	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1da0dc6d-1f09-4888-a04f-c6a8170e2b7b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01756430	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b21829b-9a54-4e78-9f44-05456da5ef73	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fbbab179-d1eb-48a6-8e2b-1c71606fe50d	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee2ea175-52b1-e57e-281a-d3ad3405ddd2	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e68c9b18-e7fd-45f7-a8f5-1d815e32680b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf777244-1f06-439a-a9e1-19da761f193d	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bbf4dd22-f1e3-4101-89fb-31f5df3bfbc4	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e453c21-a8a8-dc54-5591-74c972d41727	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f431723b-4849-408b-884a-43e3a52bb13c	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9a12198-b016-42ae-b9dc-d98fead7b79e	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5822e3c-413c-4c7e-bbec-d0d42d2028ba	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a103502-c809-41ae-93a3-f7485605d0fe	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0787d56-11fc-4643-83ac-1b17bb2a9817	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b2638f5-8975-4259-be52-0da5c263bcc0	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adca4651-75f9-44bb-bfa9-4a4219948cfa	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62408fc0-65d5-42f6-91a3-2c13f7697b39	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef3e2389-6a86-42f7-88e7-981fd0c10e5a	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac7f5b87-9dee-4f4d-8b71-e334c87e8e59	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	ST Elevation Myocardial Infarction	CARVEDILOL	targetBased	4	Recruiting	17/12/2018	https://clinicaltrials.gov/study/NCT03778554	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	CARVEDILOL	targetBased	3	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT02832089	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	CARVEDILOL	targetBased	4	Unknown status	01/12/2016	https://clinicaltrials.gov/study/NCT02251509	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	CARVEDILOL	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00313157	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	CARVEDILOL	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atherosclerosis	CARVEDILOL	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3acd97e-2a2c-4796-8561-ba7f268d3aed	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	CARVEDILOL	targetBased	3	Terminated	01/07/2005	https://clinicaltrials.gov/study/NCT00123903	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7736758-ad06-4ddb-bdf0-eda27a0acae5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f431723b-4849-408b-884a-43e3a52bb13c	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	CARVEDILOL	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00129363	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	CARVEDILOL	targetBased	3	Completed	01/05/2000	https://clinicaltrials.gov/study/NCT00052026	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d8912b-6fcd-498f-a1b6-d55315db9ee8	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d485d38-5d43-4a54-bc63-82734035c66a	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29082d8c-bbde-4620-924f-02dcf1764919	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	CARVEDILOL	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00323037	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b23021d4-c00a-e0ef-eb93-1dc824ae56ca	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	CARVEDILOL	targetBased	4	Terminated	01/01/2007	https://clinicaltrials.gov/study/NCT00433043	1	LoF	protect	Insufficient enrollment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9a12198-b016-42ae-b9dc-d98fead7b79e	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5b907f8-84a0-5fb2-e7ec-4c82246195f5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc6a2d33-aa04-4a04-9cde-901b744d24ca	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	CARVEDILOL	targetBased	4	Completed	16/12/2002	https://clinicaltrials.gov/study/NCT00344513	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	CARVEDILOL	targetBased	4	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00381030	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	CARVEDILOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad96f237-1e3a-45ff-9c47-fed3544dc943	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Abnormal cardiovascular system morphology	KETAMINE	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01827020	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		coronary artery disease	KETAMINE	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT02113150	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		heart disease	KETAMINE	targetBased	4	Terminated	11/07/2016	https://clinicaltrials.gov/study/NCT02734940	1	LoF	protect	Unable to find participants who met inclusion/exclusion criteria
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		heart disease	KETAMINE	targetBased	4	Terminated	01/05/2012	https://clinicaltrials.gov/study/NCT02664922	1	LoF	protect	Poor study design and too many study groups.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		hemorrhoid	KETAMINE	targetBased	4	Recruiting	15/06/2020	https://clinicaltrials.gov/study/NCT04248205	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	ESMOLOL	targetBased	4	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02967029	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	ESMOLOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C07AB09	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	acute coronary syndrome	ESMOLOL	targetBased	4	Unknown status	01/10/2010	https://clinicaltrials.gov/study/NCT01171911	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	coronary artery disease	ESMOLOL	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00348101	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	coronary artery disease	ESMOLOL	targetBased	4	Unknown status	01/10/2010	https://clinicaltrials.gov/study/NCT01171911	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	ESMOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9a3e69ab-3ffe-33af-e053-2a95a90a6524	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Myocardial Ischemia	TAMOXIFEN CITRATE	targetBased	3	Completed	01/05/1992	https://clinicaltrials.gov/study/NCT00000529	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Myocardial Ischemia	TAMOXIFEN CITRATE	targetBased	3	Completed	01/05/1992	https://clinicaltrials.gov/study/NCT00000529	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypertension	TAMOXIFEN CITRATE	targetBased	3	Completed	01/05/1992	https://clinicaltrials.gov/study/NCT00000529	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypertension	TAMOXIFEN CITRATE	targetBased	3	Completed	01/05/1992	https://clinicaltrials.gov/study/NCT00000529	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	TAMOXIFEN CITRATE	targetBased	3	Completed	01/05/1992	https://clinicaltrials.gov/study/NCT00000529	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	TAMOXIFEN CITRATE	targetBased	3	Completed	01/05/1992	https://clinicaltrials.gov/study/NCT00000529	0.7		protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	cardiovascular disease	FASUDIL	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=C04AX32	0.7	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	myocardial infarction	FASUDIL	targetBased	4	Not yet recruiting	01/07/2019	https://clinicaltrials.gov/study/NCT03753269	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Ischemic stroke	MEMANTINE	targetBased	3	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT02535611	0.7	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	cardiovascular disease	BEZAFIBRATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C10AB02	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	cardiovascular disease	BEZAFIBRATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C10AB02	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	cardiovascular disease	BEZAFIBRATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C10AB02	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	cardiovascular disease	BEZAFIBRATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C10AB02	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	cardiovascular disease	BEZAFIBRATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C10AB02	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	cardiovascular disease	BEZAFIBRATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C10AB02	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	acute myocardial infarction	BEZAFIBRATE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT02291796	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	acute myocardial infarction	BEZAFIBRATE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT02291796	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	acute myocardial infarction	BEZAFIBRATE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT02291796	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	acute myocardial infarction	BEZAFIBRATE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT02291796	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	acute myocardial infarction	BEZAFIBRATE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT02291796	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	acute myocardial infarction	BEZAFIBRATE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT02291796	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	CARTEOLOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C07AA15	1	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE MALEATE	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00116831	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE MALEATE	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00116831	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE MALEATE	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00116831	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE MALEATE	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00116831	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE MALEATE	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00116831	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	atherosclerosis	ROSIGLITAZONE MALEATE	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00116831	0.7	GoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	cardiovascular disease	MIBEFRADIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08CX01	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	coronary artery disease	DABIGATRAN	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02389582	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	venous thromboembolism	DABIGATRAN	targetBased	4	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01210755	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	venous thromboembolism	DABIGATRAN	targetBased	3	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01431456	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	pulmonary embolism	DABIGATRAN	targetBased	4	Terminated	01/01/2016	https://clinicaltrials.gov/study/NCT02596555	1	LoF	protect	1. Interim results suggested a reduction of sample size. 2. Anticipated length of enrolment period with resulting funding issues to pose a threat to the study.
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN	targetBased	3	Unknown status	01/12/2014	https://clinicaltrials.gov/study/NCT02313584	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN	targetBased	4	Completed	07/11/2014	https://clinicaltrials.gov/study/NCT01994265	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN	targetBased	4	Unknown status	01/07/2013	https://clinicaltrials.gov/study/NCT02331602	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02067182	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN	targetBased	4	Completed	13/07/2011	https://clinicaltrials.gov/study/NCT01468155	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN	targetBased	4	Recruiting	28/02/2018	https://clinicaltrials.gov/study/NCT03463317	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00808067	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN	targetBased	3	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02544932	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00262600	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN	targetBased	4	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02982850	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01339819	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	coronary artery disease	SARPOGRELATE	targetBased	4	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02607436	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	peripheral arterial disease	SARPOGRELATE	targetBased	4	Unknown status	01/12/2016	https://clinicaltrials.gov/study/NCT02959606	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	peripheral arterial disease	SARPOGRELATE	targetBased	4	Completed	11/10/2018	https://clinicaltrials.gov/study/NCT03509922	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	peripheral arterial disease	SARPOGRELATE	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT02393612	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	cardiovascular disease	SARPOGRELATE	targetBased	4	Unknown status	01/08/2012	https://clinicaltrials.gov/study/NCT01674686	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	DOBUTAMINE	targetBased	4	Unknown status	01/06/2011	https://clinicaltrials.gov/study/NCT01427686	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	DOBUTAMINE	targetBased	4	Withdrawn	01/05/2018	https://clinicaltrials.gov/study/NCT02767024	1	GoF	protect	No patients enrolled
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	DOBUTAMINE	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00348504	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	DOBUTAMINE	targetBased	4	Unknown status	01/01/2010	https://clinicaltrials.gov/study/NCT01042873	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	DOBUTAMINE	targetBased	4	Unknown status	01/10/2013	https://clinicaltrials.gov/study/NCT01930734	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	DOBUTAMINE	targetBased	4	Suspended	01/06/2011	https://clinicaltrials.gov/study/NCT01375335	1	GoF	protect	Insufficient patient eligible for recruitment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	DOBUTAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01CA07	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	DOBUTAMINE	targetBased	4	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02012946	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	mitral valve stenosis	DOBUTAMINE	targetBased	4	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT01969071	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	DOBUTAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0dd68b3-20af-464d-b3ba-34eb886df6ae	1	GoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	angina pectoris	CAPSAICIN	targetBased	3	Terminated	01/10/2010	https://clinicaltrials.gov/study/NCT01231750	0.7		protect	Unable to identify study population to achieve number expected
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heart disease	REMIFENTANIL	targetBased	4	Terminated	01/05/2012	https://clinicaltrials.gov/study/NCT02664922	1	GoF	protect	Poor study design and too many study groups.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heart disease	REMIFENTANIL	targetBased	4	Terminated	01/05/2012	https://clinicaltrials.gov/study/NCT02664922	1	GoF	protect	Poor study design and too many study groups.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heart disease	REMIFENTANIL	targetBased	3	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02481791	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heart disease	REMIFENTANIL	targetBased	3	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02481791	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	coronary artery disease	REMIFENTANIL	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT02113150	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	coronary artery disease	REMIFENTANIL	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT02113150	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hypotension	REMIFENTANIL	targetBased	4	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02967029	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hypotension	REMIFENTANIL	targetBased	4	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02967029	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	aortic stenosis	REMIFENTANIL	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT02053818	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	aortic stenosis	REMIFENTANIL	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT02053818	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ventricular tachycardia	REMIFENTANIL	targetBased	4	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01901575	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ventricular tachycardia	REMIFENTANIL	targetBased	4	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01901575	1	GoF	protect
Modulation of AMPAR-stargazin complexes	AMPAStargazinComplexModulators	CACNG2	Voltage-dependent calcium channel gamma-2 subunit	cardiovascular disease	BEPRIDIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08EA02	1	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	cardiovascular disease	BEPRIDIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08EA02	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	cardiovascular disease	BEPRIDIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08EA02	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	BEPRIDIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08EA02	1	LoF	protect
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	MTOR	Serine/threonine-protein kinase mTOR	cardiovascular disease	PERHEXILINE	pathwayBased	4			https://www.whocc.no/atc_ddd_index/?code=C08EX02	1	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	coronary artery disease	FENOLDOPAM MESYLATE	targetBased	4	Unknown status	01/09/2012	https://clinicaltrials.gov/study/NCT01690832	1	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	coronary artery disease	FENOLDOPAM MESYLATE	targetBased	4	Unknown status	01/09/2012	https://clinicaltrials.gov/study/NCT01690832	1	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	coronary artery disease	FENOLDOPAM MESYLATE	targetBased	4	Unknown status	01/09/2012	https://clinicaltrials.gov/study/NCT01690832	1	GoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	hypertension	FENOLDOPAM MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df4cd207-c3b8-4008-5290-02f296c2b4a6	1	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	hypertension	FENOLDOPAM MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df4cd207-c3b8-4008-5290-02f296c2b4a6	1	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	hypertension	FENOLDOPAM MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df4cd207-c3b8-4008-5290-02f296c2b4a6	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	myocardial infarction	CALCIFEDIOL	targetBased	3	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT02548364	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	hypertension	CHOLECALCIFEROL	targetBased	4	Unknown status	01/07/2011	https://clinicaltrials.gov/study/NCT01472796	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	peripheral arterial disease	CHOLECALCIFEROL	targetBased	4	Completed	11/03/2019	https://clinicaltrials.gov/study/NCT03615833	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	peripheral arterial disease	CHOLECALCIFEROL	targetBased	4	Terminated	01/11/2011	https://clinicaltrials.gov/study/NCT01559974	1	GoF	protect	Insufficient recruitment
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	cardiovascular disease	CHOLECALCIFEROL	targetBased	3	Unknown status	01/10/2012	https://clinicaltrials.gov/study/NCT02178410	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	heart failure	CHOLECALCIFEROL	targetBased	3	Terminated	01/12/2012	https://clinicaltrials.gov/study/NCT01535196	0.7	GoF	protect	financial reasons / insufficient enrollment activity
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	heart failure	CHOLECALCIFEROL	targetBased	4	Terminated	01/10/2010	https://clinicaltrials.gov/study/NCT01230307	1	GoF	protect	Unable to recruit sufficient number of patients.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	heart failure	CHOLECALCIFEROL	targetBased	3	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02271230	0.7	GoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	intermediate coronary syndrome	ARGATROBAN	targetBased	4	Completed	18/04/2017	https://clinicaltrials.gov/study/NCT05740371	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	thrombotic disease	ARGATROBAN	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00039858	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	thrombotic disease	ARGATROBAN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0dedf95-8395-46bf-b94a-dcf2dd085942	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	Ischemic stroke	ARGATROBAN	targetBased	3	Active, not recruiting	15/10/2019	https://clinicaltrials.gov/study/NCT03735979	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	cardiovascular disease	ARGATROBAN	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01163604	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	cardiovascular disease	ARGATROBAN	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01980316	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	coronary artery disease	ISOFLURANE	targetBased	4	Recruiting	20/11/2019	https://clinicaltrials.gov/study/NCT04039854	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	coronary artery disease	ISOFLURANE	targetBased	4	Recruiting	20/11/2019	https://clinicaltrials.gov/study/NCT04039854	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	hypotension	ISOFLURANE	targetBased	4	Terminated	01/05/2009	https://clinicaltrials.gov/study/NCT00922844	1		protect	too slow recruitment; lack of funding
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	Myocardial Ischemia	ISOFLURANE	targetBased	4	Recruiting	01/03/2013	https://clinicaltrials.gov/study/NCT01819012	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	Myocardial Ischemia	ISOFLURANE	targetBased	4	Recruiting	01/03/2013	https://clinicaltrials.gov/study/NCT01819012	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	hypotension	ISOFLURANE	targetBased	4	Terminated	01/05/2009	https://clinicaltrials.gov/study/NCT00922844	1		protect	too slow recruitment; lack of funding
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	VERAPAMIL HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiac arrhythmia	VERAPAMIL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92f7adf1-cb8c-4c6e-95d1-9afd28fe5116	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	VERAPAMIL HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b4b1dd5-8a6f-4f0e-a2ea-506c60d6fce9	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f77f9742-9100-4b64-ac73-dff94079b888	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=189d8bed-8a53-4126-9409-41ef48678dc9	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=081e2fd0-242e-4b80-9847-86ba0c36d1b3	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acbd40bf-fdae-4bd2-a63c-0a82cbe15795	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d776d5d1-cb5b-80f9-e00c-75d4c3ae4d20	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92f7adf1-cb8c-4c6e-95d1-9afd28fe5116	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7023927e-1829-49c0-5c81-693489000d1c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	VERAPAMIL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39bad727-af4c-4d20-933b-7f287e88099a	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	PENBUTOLOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C07AA23	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Brugada syndrome	AMIFAMPRIDINE	targetBased	3	Terminated	12/09/2008	https://clinicaltrials.gov/study/NCT00701077	0.7	LoF	protect	recruitments issues
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Brugada syndrome	AMIFAMPRIDINE	targetBased	3	Terminated	12/09/2008	https://clinicaltrials.gov/study/NCT00701077	0.7	LoF	protect	recruitments issues
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Brugada syndrome	AMIFAMPRIDINE	targetBased	3	Terminated	12/09/2008	https://clinicaltrials.gov/study/NCT00701077	0.7	LoF	protect	recruitments issues
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Brugada syndrome	AMIFAMPRIDINE	targetBased	3	Terminated	12/09/2008	https://clinicaltrials.gov/study/NCT00701077	0.7	LoF	protect	recruitments issues
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Brugada syndrome	AMIFAMPRIDINE	targetBased	3	Terminated	12/09/2008	https://clinicaltrials.gov/study/NCT00701077	0.7	LoF	protect	recruitments issues
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Brugada syndrome	AMIFAMPRIDINE	targetBased	3	Terminated	12/09/2008	https://clinicaltrials.gov/study/NCT00701077	0.7	LoF	protect	recruitments issues
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Brugada syndrome	AMIFAMPRIDINE	targetBased	3	Terminated	12/09/2008	https://clinicaltrials.gov/study/NCT00701077	0.7	LoF	protect	recruitments issues
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Lambert-Eaton myasthenic syndrome	AMIFAMPRIDINE	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02970162	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Lambert-Eaton myasthenic syndrome	AMIFAMPRIDINE	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02970162	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Lambert-Eaton myasthenic syndrome	AMIFAMPRIDINE	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02970162	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Lambert-Eaton myasthenic syndrome	AMIFAMPRIDINE	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02970162	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Lambert-Eaton myasthenic syndrome	AMIFAMPRIDINE	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02970162	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Lambert-Eaton myasthenic syndrome	AMIFAMPRIDINE	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02970162	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Lambert-Eaton myasthenic syndrome	AMIFAMPRIDINE	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02970162	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=236d4549-f44b-4677-b857-acedd10b9920	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE	targetBased	4	Recruiting	29/03/2023	https://clinicaltrials.gov/study/NCT05655468	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01199081	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00259428	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE	targetBased	3	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00697086	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01140581	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE	targetBased	4	Unknown status	01/03/2010	https://clinicaltrials.gov/study/NCT01070667	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE	targetBased	4	Terminated	15/05/2021	https://clinicaltrials.gov/study/NCT04704050	1	LoF	protect	Sponsor withdrew funding
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE	targetBased	3	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01151137	0.35	LoF	protect	The study was stopped because of safety concerns
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE	targetBased	4	Terminated	01/09/2010	https://clinicaltrials.gov/study/NCT01198873	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE	targetBased	4	Terminated	01/11/2009	https://clinicaltrials.gov/study/NCT01026090	1	LoF	protect	'Sponsor decision following recruitment issues, not related to any safety concerns in the study
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00174785	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00489736	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE	targetBased	4	Active, not recruiting	29/10/2021	https://clinicaltrials.gov/study/NCT05130268	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01182376	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE	targetBased	4	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01135017	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01047566	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00259376	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial flutter	DRONEDARONE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00259428	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial flutter	DRONEDARONE	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00174785	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial flutter	DRONEDARONE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00259376	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	congestive heart failure	DRONEDARONE	targetBased	3	Terminated	01/06/2002	https://clinicaltrials.gov/study/NCT00696631	0.35	LoF	protect	Terminated as the active treatment was associated with an increased hazard
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	congestive heart failure	DRONEDARONE	targetBased	3	Terminated	01/06/2002	https://clinicaltrials.gov/study/NCT00696631	0.35	LoF	protect	Terminated as the active treatment was associated with an increased hazard
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00259428	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=236d4549-f44b-4677-b857-acedd10b9920	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00489736	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE	targetBased	4	Recruiting	29/03/2023	https://clinicaltrials.gov/study/NCT05655468	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE	targetBased	4	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01135017	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01199081	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE	targetBased	4	Terminated	01/09/2010	https://clinicaltrials.gov/study/NCT01198873	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01140581	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE	targetBased	4	Unknown status	01/03/2010	https://clinicaltrials.gov/study/NCT01070667	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE	targetBased	3	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01151137	0.35	LoF	protect	The study was stopped because of safety concerns
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE	targetBased	3	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00697086	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01182376	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00259376	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00174785	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01047566	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE	targetBased	4	Active, not recruiting	29/10/2021	https://clinicaltrials.gov/study/NCT05130268	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE	targetBased	4	Terminated	01/11/2009	https://clinicaltrials.gov/study/NCT01026090	1	LoF	protect	'Sponsor decision following recruitment issues, not related to any safety concerns in the study
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE	targetBased	4	Terminated	15/05/2021	https://clinicaltrials.gov/study/NCT04704050	1	LoF	protect	Sponsor withdrew funding
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial flutter	DRONEDARONE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00259376	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial flutter	DRONEDARONE	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00174785	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial flutter	DRONEDARONE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00259428	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	cardiac arrhythmia	DRONEDARONE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=C01BD07	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiac arrhythmia	DRONEDARONE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=C01BD07	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE	targetBased	4	Completed	01/09/2018	https://clinicaltrials.gov/study/NCT03704909	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE	targetBased	4	Recruiting	15/07/2022	https://clinicaltrials.gov/study/NCT05498857	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE	targetBased	4	Completed	10/01/2022	https://clinicaltrials.gov/study/NCT05127876	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213536s000lbl.pdf	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE	targetBased	4	Not yet recruiting	15/02/2024	https://clinicaltrials.gov/study/NCT06257316	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE	targetBased	4	Unknown status	02/01/2019	https://clinicaltrials.gov/study/NCT03719625	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE	targetBased	4	Recruiting	05/03/2024	https://clinicaltrials.gov/study/NCT06334549	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE	targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01794273	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=25828db2-4942-4f7c-a0d5-dc66f82cfb71	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1323592-dc57-4c9d-b84d-442648a7b114	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78c1daef-6e1e-5f2c-e053-2a91aa0a0dba	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE	targetBased	3	Recruiting	15/09/2022	https://clinicaltrials.gov/study/NCT05497700	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98531820-a85c-4ee7-9338-2be264219afe	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE	targetBased	4	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT02477501	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	EPHEDRINE	targetBased	4	Completed	23/02/2017	https://clinicaltrials.gov/study/NCT03421860	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	EPHEDRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01CA26	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Bradycardia	EPHEDRINE	targetBased	4	Completed	25/06/2019	https://clinicaltrials.gov/study/NCT03984526	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Bradycardia	EPHEDRINE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02522858	1	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	NIMODIPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08CA06	1	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	heart disease	VASOPRESSIN	targetBased	3	Active, not recruiting	05/11/2020	https://clinicaltrials.gov/study/NCT04501861	0.7	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	cardiac arrest	VASOPRESSIN	targetBased	3	Recruiting	17/11/2021	https://clinicaltrials.gov/study/NCT05139849	0.7	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	cardiac arrest	VASOPRESSIN	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00729794	0.7	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	cardiac arrest	VASOPRESSIN	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00358579	0.7	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	cardiac arrest	VASOPRESSIN	targetBased	4	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00127907	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	4	Completed	03/05/2018	https://clinicaltrials.gov/study/NCT03706755	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	3	Completed	10/11/2019	https://clinicaltrials.gov/study/NCT04789005	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	4	Recruiting	23/11/2023	https://clinicaltrials.gov/study/NCT06080178	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	3	Recruiting	06/10/2019	https://clinicaltrials.gov/study/NCT04067817	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	4	Recruiting	01/06/2019	https://clinicaltrials.gov/study/NCT03872570	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	3	Completed	27/04/2022	https://clinicaltrials.gov/study/NCT05335954	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	3	Recruiting	15/09/2022	https://clinicaltrials.gov/study/NCT05497700	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	4	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT02969239	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	4	Unknown status	02/01/2019	https://clinicaltrials.gov/study/NCT03719625	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	3	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT03215797	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	4	Completed	01/07/2021	https://clinicaltrials.gov/study/NCT04789330	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	4	Completed	11/03/2022	https://clinicaltrials.gov/study/NCT05290740	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	4	Recruiting	05/03/2024	https://clinicaltrials.gov/study/NCT06334549	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	4	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02854787	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	4	Not yet recruiting	01/09/2023	https://clinicaltrials.gov/study/NCT05970770	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	4	Completed	20/01/2021	https://clinicaltrials.gov/study/NCT05248932	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	4	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT02477501	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	4	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01536470	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	4	Not yet recruiting	15/02/2024	https://clinicaltrials.gov/study/NCT06248593	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	NOREPINEPHRINE	targetBased	4	Completed	01/02/2021	https://clinicaltrials.gov/study/NCT04701190	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	NOREPINEPHRINE	targetBased	4	Completed	23/02/2017	https://clinicaltrials.gov/study/NCT03421860	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	NOREPINEPHRINE	targetBased	4	Recruiting	01/09/2022	https://clinicaltrials.gov/study/NCT05492968	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	NOREPINEPHRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01CA03	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart disease	NOREPINEPHRINE	targetBased	3	Active, not recruiting	05/11/2020	https://clinicaltrials.gov/study/NCT04501861	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	acute hypotension	NOREPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=256264b1-ddf6-42b7-8a09-194fffea65e2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congenital heart disease	NOREPINEPHRINE	targetBased	3	Completed	10/10/2020	https://clinicaltrials.gov/study/NCT04536194	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	myocardial infarction	EXENATIDE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00835848	1	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	myocardial infarction	EXENATIDE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00835848	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	myocardial infarction	EXENATIDE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00835848	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	myocardial infarction	EXENATIDE	targetBased	4	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT01580514	1	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	myocardial infarction	EXENATIDE	targetBased	4	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT01580514	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	myocardial infarction	EXENATIDE	targetBased	4	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT01580514	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	acute myocardial infarction	EXENATIDE	targetBased	3	Unknown status	01/11/2009	https://clinicaltrials.gov/study/NCT01254123	0.7	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	acute myocardial infarction	EXENATIDE	targetBased	3	Unknown status	01/11/2009	https://clinicaltrials.gov/study/NCT01254123	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	acute myocardial infarction	EXENATIDE	targetBased	3	Unknown status	01/11/2009	https://clinicaltrials.gov/study/NCT01254123	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	acute myocardial infarction	EXENATIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02404376	0.7	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	acute myocardial infarction	EXENATIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02404376	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	acute myocardial infarction	EXENATIDE	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02404376	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	coronary artery disease	EXENATIDE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01373216	0.7	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	coronary artery disease	EXENATIDE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01373216	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	coronary artery disease	EXENATIDE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01373216	0.7	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atherosclerosis	FELODIPINE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	FELODIPINE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	FELODIPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08CA02	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2aad9cdf-6431-4661-5cb4-f69e735f47e4	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55637724-8757-11de-8a39-0800200c9a66	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5f56c59-04d5-4c5d-9441-5a93d3bdec82	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60fb803e-ccf7-46f2-b506-e157ce440f87	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fb93832-0cab-4c23-a1b0-c40157904ff4	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=777d89bb-c376-46e6-a701-825bcb3979ae	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f94ae052-5d59-4750-aab7-1fdb989503aa	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00861016	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aac77fa1-04ad-497e-bbed-a21f538064c3	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00507845	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01520285	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b951455c-c235-4e23-9e21-08672d108726	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4d6ab4c-6bc9-42d4-acf2-9fb0e871fd8c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bef7cf2-012b-4804-ac93-0a8b333035db	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6902c76-c851-4086-8013-9642436023fb	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff61238c-1997-460f-8ed6-6752c6a46a64	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4602657-d23d-43d9-8a4f-cdb390a010d4	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71dde844-9dd0-406c-943e-9995a28c43c7	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32bcc6c7-2f4f-8674-631e-3b33395a547d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9cd06d37-5515-444e-b561-64e5cc6e9539	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c128098-92cc-4628-90ec-2e859d0d4315	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1824844-b6ae-4287-aef0-5a23c411d0a7	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=103d9fb6-8433-4386-9f2e-d07f4c560aea	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bfc1982-6fe6-4d6d-99f2-f2d1cd708540	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33de7317-dbe6-4660-9d7e-2babc9c9f657	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd39c559-5c5d-4d3b-9228-c44085e1699f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ad2c521-537b-4f5e-b63d-49c1b4d703d5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	FELODIPINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00841880	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	acute coronary syndrome	NICARDIPINE	targetBased	4	Unknown status	01/10/2010	https://clinicaltrials.gov/study/NCT01171911	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	NICARDIPINE	targetBased	4	Unknown status	01/10/2010	https://clinicaltrials.gov/study/NCT01171911	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	NICARDIPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08CA04	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Ischemic stroke	NICARDIPINE	targetBased	4	Active, not recruiting	18/06/2020	https://clinicaltrials.gov/study/NCT04205305	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4	Unknown status	01/01/2004	https://clinicaltrials.gov/study/NCT00325793	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e61159ba-ff6b-4696-a642-4f64c79c4708	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6512740-17e0-4f22-a233-4ac084277879	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7dfde10-01d4-11de-87af-0800200c9a66	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be9e2dda-80da-4e0d-a3ee-ab2bd9f3f2ee	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b54643f-55b2-404a-b282-39fc6b2d8121	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT01872039	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=613c79eb-b34d-4fea-82d0-61b8c4840182	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8ef8420-01d2-11de-a455-0002a5d5c51b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=52e42bf6-34a3-4b95-9907-5e8d19108d47	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c84cda13-e2fb-46d6-a9a2-5a3311387ff8	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2388174b-8983-4be5-a4b5-f2ec45f3e19c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72c19612-6dc6-4413-80a2-3f85953e4763	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18fb1c2b-0c1e-436c-a5b6-d4840b5da228	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13b13720-f64d-11df-93a0-0002a5d5c51b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76fcb7e0-9034-4fcd-be14-ce7e9ccaee2a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d58f812-37bf-439f-b3f2-c31f8eefe22e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a7c6372-a22b-4501-a6c6-539457a6cd9d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	3	Unknown status	01/06/2007	https://clinicaltrials.gov/study/NCT00409253	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	3	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00093925	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0eb7d839-63d9-4b51-bf7b-4a8fde6339b5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2f0b90f-9495-48c5-b21f-86e487a04854	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abee4a34-89cc-d886-192c-32582ab8f024	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7545204-1357-4543-aa05-c01fc890bc24	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd311bf0-c5c8-4f0b-9f8f-e855bb32a71e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c0eb8b2-3fe4-4df4-b21a-09b18a652860	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39e3f327-faab-4f1c-b6a6-f7116bb902b5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4be76756-4114-4d50-a36c-fd410f6c773d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	3	Completed	01/08/1993	https://clinicaltrials.gov/study/NCT00000542	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=062bf1a0-9a29-4dee-a8cb-f0d051f4c0b1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5562b3f5-8757-11de-8a39-0800200c9a66	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f33bb26-7a40-4cdb-bb50-35efdeeaa810	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=003dd1ec-16f8-4f96-b6a8-c4689d35892a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3bb9dd10-e07c-4433-b6a7-c1c6fc4f05a7	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=680209f4-ad4c-4f97-8b6b-04f648bfb97c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18686fa-be94-472e-8404-c69e6869ed10	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35086164-bf92-4b3c-9845-f8cd7464c7d6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc0fa546-063a-434f-b8c0-bfca5b34462c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08b1aa59-7892-451a-ad74-0388632e8235	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=322f926c-99ac-49f8-9cc5-584594f2891f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18d7820d-471f-4ee2-9ec6-25d8d27c77de	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa7e7d95-520a-461c-b1b3-e588aeb6a613	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01139e81-a4fa-4e13-acdf-c75c79a1aa9c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f48911e0-705f-11dc-afc9-0002a5d5c51b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e698930-5c05-421f-a408-2a2fbfff0948	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=edf9b22c-e37e-4b4e-8a64-20bb036c7d2d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=999aefc6-8842-4a02-a5bb-6601fe8db6e6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f9c46a7-3833-44c8-9a15-5bed7d2008ba	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e04b0eb9-83b5-4b33-a1e7-1c1e84f0c897	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb5e7668-0ce4-4276-8416-0c313b59bb73	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2784f6dd-9115-4def-ad94-7141dbb6f738	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51e87d92-0c8a-46fa-a2d6-a8abf555201f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3201369-1c77-4a05-bbd0-0dd333305ace	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44e5ad27-e062-461a-bdf4-192d852fbc49	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fdb1322-d867-4182-b7d5-30c2a27893f0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c75cd90-7dac-4876-bfbd-50d842176475	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=180ee374-24f2-4b9c-9d54-8815f2b1dc9b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a542f10-2d9f-44a2-ad71-12032c99e225	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac0dd8fb-ebe1-4d02-bd0d-4f979c6e3608	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b00570ff-4081-4514-b45b-eb6f753450f5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b52e2905-f906-4c46-bb24-2c7754c5d75b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bef1a169-9186-43e9-b673-64fdb658984f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a74239bf-4684-424c-ba4e-6087e363265b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48072673-1f7f-4fa8-aebb-00b4dba4a0ae	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b55da654-3c8e-4670-a503-e98e1d67d204	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42881d5b-7e35-496e-aeeb-8da760d4267c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0141c088-8fc2-4041-880e-a79ce0de6fdd	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8fcacc3f-80a8-4a2a-bccb-c1edb2e2764d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ee23c50-1183-414f-bb20-6285b04884e9	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8157ca93-d926-4264-b606-f73b2b38842a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0478c750-ad55-42e6-adf5-a88aad78c055	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4b30c56-7403-4f69-9a8e-3d82a37e8bc5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=090f3e51-8129-4b5d-97f9-ab410e14df2d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59464d24-16e5-42d3-acd4-6f3b2f4e3bf6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb2e6030-c1f4-44bb-9279-3c7368785009	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f4703c0-0b9e-41a0-8b70-da26683d9ed2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e83de08-b0f6-492a-a2db-e8d33a7a28aa	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a10fa641-ac6b-466d-bcba-31c678a74be8	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7cafaf24-3f61-45ac-82db-025616171759	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24e90827-104e-436c-81ac-78d3758e5723	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5859daf-d6e1-4f8f-a246-5282b81be78d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9d9d64a-3a3c-44ad-b40d-02789f29eb04	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=767c1e67-4cfb-4358-a963-3d58122c8e83	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bac4ec4-9542-4927-8121-a7cd1858075b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6f298ba-2d7e-4a3c-9edb-8b60aba716d6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d3d4ee8-5657-4b7c-9478-8b29c13a8c9e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3911a46c-80fe-4b70-a4ba-416de597481b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cec7a02-b7a5-49e1-ab64-3a4dab4149d2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3357a72-a68f-4ee5-be56-03f1dd8bef83	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=003dd1ec-16f8-4f96-b6a8-c4689d35892a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc7d39d7-e006-4ed6-a31c-827452603002	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cacb3551-c579-41cb-bed6-4b4d8b0644fc	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c83b8444-0558-44e5-8701-9919848072be	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11bde4d6-fb19-4783-8664-c0d116ddd2d1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2275ed71-a964-42b0-b9cb-46ab88da8687	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37b4cfba-6673-402e-bb5a-82b4ab6ef49b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6b1bbe5-78b0-407f-b953-92a131e3a4aa	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f573c43b-2dc7-4f0a-a54a-d60a5fe76458	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2829814d-739d-4ff4-9371-bee70bf32248	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=790129ef-6a1b-45cb-8b02-25fa8a40c2ba	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2224a34b-b24f-4c23-a1b3-fdb148fc773b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abd6a2ca-40c2-485c-bc53-db1c652505ed	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01139e81-a4fa-4e13-acdf-c75c79a1aa9c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dacd31a3-d6df-4b00-b23c-8da4a17eebf0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8373e558-b5a6-4389-b5e1-f8f20ec32651	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=273c6f4d-604f-4797-8961-c5f918542e3a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=efd9eda5-f497-45a3-ae13-dee729add999	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e062d365-fda8-4c9e-b4b8-3d273153c50c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06df17aa-6831-498c-9c28-37502a1f3260	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3294d91-4aa9-4a94-be6a-28ccf2d74326	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3d9dd95-d250-4201-8e95-466fd321c37e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5402d355-caff-f5e7-4cb4-7e61c57bf39d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41ceef84-9aae-4d7c-ba50-06beb85c415d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd6f9f66-148a-4ecc-9fb9-a58e2b6fbc79	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c0ff5b6-de91-4c37-bd8f-a9b1341ebc96	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=551c5efd-9e40-4015-92f8-6fbb229b548e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f699d501-3f23-4261-904a-4877ba200c38	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d14c6b5-a70a-477f-b332-fa5b93a6296f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc73172f-a915-4ac4-a033-0de2a0223dc6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=638f6fc5-3374-477b-84de-63f93b8e1942	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d233a645-805b-45be-ae20-534367bc15ff	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=213502a2-f667-4da6-a4b9-462eb303c401	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a27c8d30-fa25-4927-86fd-fdcfec8fd03a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=759d754e-48eb-4e37-a28a-9b79ac20416b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=353a319e-2d1b-4bb6-8e3f-fc74d5b78523	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7aaf923d-5b82-4a85-bb10-5850087da487	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9abf41f1-66f9-4be4-a6d7-6c9aa0d5d387	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02f30d6b-0eb0-4f01-9539-6645118bc286	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4ab4f05-1c18-442a-8618-c2c92e589703	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c32059ed-73cd-4a2c-9690-276e7068041e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fda0739d-b355-478c-acae-8f773a3ec4b3	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5409b296-3bed-47cd-abba-9fe6f6833af6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f7c5855-aa5a-4535-8b37-cf97e09ed883	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c1ecc118-b372-40c6-819e-56092cafe595	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4336a551-afff-4d92-b05b-2a8e2000feef	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61837ac5-0a0b-4ea9-b71c-d4c753294ed6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fabb27ef-aba2-c76a-cf6b-beb8826fd381	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d8304ba-1f38-428c-afc6-63a132e559ca	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47114f60-4151-43d4-ac2d-adc49492a679	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff042130-c43a-4281-a731-809a54a1a7f1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f173ff13-7417-415b-8725-3c2f2dd3e5b5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=873b5b9a-b198-46f7-abe0-898ad0809b47	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc285a1f-9b43-4bdf-8679-44e25654b84c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=992fd3c4-ce10-4653-9c32-451209422510	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3518853a-4c5b-4161-a178-8da7f656f009	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fe3b576-567d-4589-9d4c-620b834b8746	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atherosclerosis	AMLODIPINE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	05/06/2008	https://clinicaltrials.gov/study/NCT00667719	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01663233	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	4	Recruiting	30/08/2022	https://clinicaltrials.gov/study/NCT05683301	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT01001572	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00220220	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	4	Not yet recruiting	14/09/2023	https://clinicaltrials.gov/study/NCT06041529	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01785472	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT02058446	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02062645	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	4	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01180413	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	4	Recruiting	04/04/2024	https://clinicaltrials.gov/study/NCT05917275	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01615198	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02368665	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02738632	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	4	Unknown status	01/10/2007	https://clinicaltrials.gov/study/NCT01011660	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00890591	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01113047	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01599104	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00437645	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	05/07/2022	https://clinicaltrials.gov/study/NCT05476354	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	14/07/2022	https://clinicaltrials.gov/study/NCT05475665	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00902538	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02368652	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	17/06/2019	https://clinicaltrials.gov/study/NCT03991442	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	14/05/2018	https://clinicaltrials.gov/study/NCT05288400	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	4	Unknown status	01/07/2008	https://clinicaltrials.gov/study/NCT00716950	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00311155	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00923091	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	4	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00509470	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	4	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT01241487	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02152306	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00819104	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	4	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01131546	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01556997	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00220233	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01237223	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	congestive heart failure	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47114f60-4151-43d4-ac2d-adc49492a679	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c32059ed-73cd-4a2c-9690-276e7068041e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f173ff13-7417-415b-8725-3c2f2dd3e5b5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bef1a169-9186-43e9-b673-64fdb658984f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f573c43b-2dc7-4f0a-a54a-d60a5fe76458	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fda0739d-b355-478c-acae-8f773a3ec4b3	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02f30d6b-0eb0-4f01-9539-6645118bc286	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48072673-1f7f-4fa8-aebb-00b4dba4a0ae	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e83de08-b0f6-492a-a2db-e8d33a7a28aa	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11bde4d6-fb19-4783-8664-c0d116ddd2d1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d3d4ee8-5657-4b7c-9478-8b29c13a8c9e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb2e6030-c1f4-44bb-9279-3c7368785009	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42881d5b-7e35-496e-aeeb-8da760d4267c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e062d365-fda8-4c9e-b4b8-3d273153c50c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fdb1322-d867-4182-b7d5-30c2a27893f0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=efd9eda5-f497-45a3-ae13-dee729add999	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f4703c0-0b9e-41a0-8b70-da26683d9ed2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f9c46a7-3833-44c8-9a15-5bed7d2008ba	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6b1bbe5-78b0-407f-b953-92a131e3a4aa	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc7d39d7-e006-4ed6-a31c-827452603002	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b55da654-3c8e-4670-a503-e98e1d67d204	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d233a645-805b-45be-ae20-534367bc15ff	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c83b8444-0558-44e5-8701-9919848072be	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fabb27ef-aba2-c76a-cf6b-beb8826fd381	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abee4a34-89cc-d886-192c-32582ab8f024	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=003dd1ec-16f8-4f96-b6a8-c4689d35892a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=180ee374-24f2-4b9c-9d54-8815f2b1dc9b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cacb3551-c579-41cb-bed6-4b4d8b0644fc	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fe3b576-567d-4589-9d4c-620b834b8746	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01139e81-a4fa-4e13-acdf-c75c79a1aa9c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61837ac5-0a0b-4ea9-b71c-d4c753294ed6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc73172f-a915-4ac4-a033-0de2a0223dc6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4be76756-4114-4d50-a36c-fd410f6c773d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b52e2905-f906-4c46-bb24-2c7754c5d75b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abd6a2ca-40c2-485c-bc53-db1c652505ed	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dacd31a3-d6df-4b00-b23c-8da4a17eebf0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44e5ad27-e062-461a-bdf4-192d852fbc49	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9d9d64a-3a3c-44ad-b40d-02789f29eb04	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=759d754e-48eb-4e37-a28a-9b79ac20416b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0478c750-ad55-42e6-adf5-a88aad78c055	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb5e7668-0ce4-4276-8416-0c313b59bb73	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a542f10-2d9f-44a2-ad71-12032c99e225	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e04b0eb9-83b5-4b33-a1e7-1c1e84f0c897	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f699d501-3f23-4261-904a-4877ba200c38	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=213502a2-f667-4da6-a4b9-462eb303c401	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4336a551-afff-4d92-b05b-2a8e2000feef	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3294d91-4aa9-4a94-be6a-28ccf2d74326	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4b30c56-7403-4f69-9a8e-3d82a37e8bc5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7aaf923d-5b82-4a85-bb10-5850087da487	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59464d24-16e5-42d3-acd4-6f3b2f4e3bf6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8157ca93-d926-4264-b606-f73b2b38842a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bac4ec4-9542-4927-8121-a7cd1858075b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c0ff5b6-de91-4c37-bd8f-a9b1341ebc96	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6f298ba-2d7e-4a3c-9edb-8b60aba716d6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3911a46c-80fe-4b70-a4ba-416de597481b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06df17aa-6831-498c-9c28-37502a1f3260	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=992fd3c4-ce10-4653-9c32-451209422510	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2784f6dd-9115-4def-ad94-7141dbb6f738	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd6f9f66-148a-4ecc-9fb9-a58e2b6fbc79	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=551c5efd-9e40-4015-92f8-6fbb229b548e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7cafaf24-3f61-45ac-82db-025616171759	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3518853a-4c5b-4161-a178-8da7f656f009	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41ceef84-9aae-4d7c-ba50-06beb85c415d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=353a319e-2d1b-4bb6-8e3f-fc74d5b78523	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=873b5b9a-b198-46f7-abe0-898ad0809b47	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5402d355-caff-f5e7-4cb4-7e61c57bf39d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4	Unknown status	01/07/2010	https://clinicaltrials.gov/study/NCT01120327	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=999aefc6-8842-4a02-a5bb-6601fe8db6e6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac0dd8fb-ebe1-4d02-bd0d-4f979c6e3608	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5859daf-d6e1-4f8f-a246-5282b81be78d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ee23c50-1183-414f-bb20-6285b04884e9	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b00570ff-4081-4514-b45b-eb6f753450f5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4ab4f05-1c18-442a-8618-c2c92e589703	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9abf41f1-66f9-4be4-a6d7-6c9aa0d5d387	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2275ed71-a964-42b0-b9cb-46ab88da8687	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=edf9b22c-e37e-4b4e-8a64-20bb036c7d2d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc285a1f-9b43-4bdf-8679-44e25654b84c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2829814d-739d-4ff4-9371-bee70bf32248	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2224a34b-b24f-4c23-a1b3-fdb148fc773b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51e87d92-0c8a-46fa-a2d6-a8abf555201f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24e90827-104e-436c-81ac-78d3758e5723	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3201369-1c77-4a05-bbd0-0dd333305ace	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8373e558-b5a6-4389-b5e1-f8f20ec32651	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff042130-c43a-4281-a731-809a54a1a7f1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e698930-5c05-421f-a408-2a2fbfff0948	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c75cd90-7dac-4876-bfbd-50d842176475	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=767c1e67-4cfb-4358-a963-3d58122c8e83	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8fcacc3f-80a8-4a2a-bccb-c1edb2e2764d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f568859-64e6-454f-801b-c0a0a647dc3d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=790129ef-6a1b-45cb-8b02-25fa8a40c2ba	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=062bf1a0-9a29-4dee-a8cb-f0d051f4c0b1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=090f3e51-8129-4b5d-97f9-ab410e14df2d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a27c8d30-fa25-4927-86fd-fdcfec8fd03a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a74239bf-4684-424c-ba4e-6087e363265b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f7c5855-aa5a-4535-8b37-cf97e09ed883	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37b4cfba-6673-402e-bb5a-82b4ab6ef49b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0141c088-8fc2-4041-880e-a79ce0de6fdd	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c1ecc118-b372-40c6-819e-56092cafe595	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5409b296-3bed-47cd-abba-9fe6f6833af6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3d9dd95-d250-4201-8e95-466fd321c37e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=273c6f4d-604f-4797-8961-c5f918542e3a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d14c6b5-a70a-477f-b332-fa5b93a6296f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3357a72-a68f-4ee5-be56-03f1dd8bef83	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cec7a02-b7a5-49e1-ab64-3a4dab4149d2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=638f6fc5-3374-477b-84de-63f93b8e1942	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	AMLODIPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08CA01	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	AMLODIPINE	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02734355	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Myocardial Ischemia	AMLODIPINE	targetBased	4	Completed	01/04/2001	https://clinicaltrials.gov/study/NCT00143195	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Myocardial Ischemia	AMLODIPINE	targetBased	3	Completed	01/08/1993	https://clinicaltrials.gov/study/NCT00000542	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Myocardial Ischemia	AMLODIPINE	targetBased	4	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01203696	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Reduced left ventricular ejection fraction	AMLODIPINE	targetBased	3	Completed	15/06/2015	https://clinicaltrials.gov/study/NCT02468232	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Reduced left ventricular ejection fraction	AMLODIPINE	targetBased	4	Completed	12/07/2016	https://clinicaltrials.gov/study/NCT02768298	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Reduced left ventricular ejection fraction	AMLODIPINE	targetBased	3	Completed	16/10/2014	https://clinicaltrials.gov/study/NCT02226120	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Reduced left ventricular ejection fraction	AMLODIPINE	targetBased	3	Terminated	01/12/2009	https://clinicaltrials.gov/study/NCT01035255	0.35	LoF	protect	Early termination was approved due to compelling efficacy of LCZ696 in patients with HF & reduced EF after final pre-specified interim analysis 28-Mar-2014.
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Reduced left ventricular ejection fraction	AMLODIPINE	targetBased	4	Completed	12/02/2016	https://clinicaltrials.gov/study/NCT02661217	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cacb3551-c579-41cb-bed6-4b4d8b0644fc	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb5e7668-0ce4-4276-8416-0c313b59bb73	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8373e558-b5a6-4389-b5e1-f8f20ec32651	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=999aefc6-8842-4a02-a5bb-6601fe8db6e6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2829814d-739d-4ff4-9371-bee70bf32248	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f4703c0-0b9e-41a0-8b70-da26683d9ed2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc7d39d7-e006-4ed6-a31c-827452603002	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01139e81-a4fa-4e13-acdf-c75c79a1aa9c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3294d91-4aa9-4a94-be6a-28ccf2d74326	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3201369-1c77-4a05-bbd0-0dd333305ace	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b52e2905-f906-4c46-bb24-2c7754c5d75b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06df17aa-6831-498c-9c28-37502a1f3260	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fe3b576-567d-4589-9d4c-620b834b8746	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ee23c50-1183-414f-bb20-6285b04884e9	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9abf41f1-66f9-4be4-a6d7-6c9aa0d5d387	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c32059ed-73cd-4a2c-9690-276e7068041e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5409b296-3bed-47cd-abba-9fe6f6833af6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d3d4ee8-5657-4b7c-9478-8b29c13a8c9e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=873b5b9a-b198-46f7-abe0-898ad0809b47	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02f30d6b-0eb0-4f01-9539-6645118bc286	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff042130-c43a-4281-a731-809a54a1a7f1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=759d754e-48eb-4e37-a28a-9b79ac20416b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9d9d64a-3a3c-44ad-b40d-02789f29eb04	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a27c8d30-fa25-4927-86fd-fdcfec8fd03a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41ceef84-9aae-4d7c-ba50-06beb85c415d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fda0739d-b355-478c-acae-8f773a3ec4b3	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac0dd8fb-ebe1-4d02-bd0d-4f979c6e3608	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=003dd1ec-16f8-4f96-b6a8-c4689d35892a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=551c5efd-9e40-4015-92f8-6fbb229b548e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e04b0eb9-83b5-4b33-a1e7-1c1e84f0c897	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e698930-5c05-421f-a408-2a2fbfff0948	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7aaf923d-5b82-4a85-bb10-5850087da487	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47114f60-4151-43d4-ac2d-adc49492a679	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d14c6b5-a70a-477f-b332-fa5b93a6296f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00159718	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8157ca93-d926-4264-b606-f73b2b38842a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c83b8444-0558-44e5-8701-9919848072be	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2275ed71-a964-42b0-b9cb-46ab88da8687	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d8304ba-1f38-428c-afc6-63a132e559ca	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dacd31a3-d6df-4b00-b23c-8da4a17eebf0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cec7a02-b7a5-49e1-ab64-3a4dab4149d2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5859daf-d6e1-4f8f-a246-5282b81be78d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Ischemic stroke	AMLODIPINE	targetBased	4	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00754429	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	AMLODIPINE	targetBased	4	Completed	12/07/2016	https://clinicaltrials.gov/study/NCT02768298	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	AMLODIPINE	targetBased	4	Completed	02/03/2017	https://clinicaltrials.gov/study/NCT02816736	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	AMLODIPINE	targetBased	3	Terminated	01/12/2009	https://clinicaltrials.gov/study/NCT01035255	0.35	LoF	protect	Early termination was approved due to compelling efficacy of LCZ696 in patients with HF & reduced EF after final pre-specified interim analysis 28-Mar-2014.
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5562b3f5-8757-11de-8a39-0800200c9a66	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	AMLODIPINE	targetBased	3	Completed	16/10/2014	https://clinicaltrials.gov/study/NCT02226120	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01139e81-a4fa-4e13-acdf-c75c79a1aa9c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	AMLODIPINE	targetBased	4	Completed	12/02/2016	https://clinicaltrials.gov/study/NCT02661217	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	AMLODIPINE	targetBased	3	Completed	23/11/2016	https://clinicaltrials.gov/study/NCT02884206	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	AMLODIPINE	targetBased	3	Completed	18/07/2014	https://clinicaltrials.gov/study/NCT01920711	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c83b8444-0558-44e5-8701-9919848072be	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	AMLODIPINE	targetBased	3	Completed	15/06/2015	https://clinicaltrials.gov/study/NCT02468232	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	AMLODIPINE	targetBased	3	Terminated	07/05/2019	https://clinicaltrials.gov/study/NCT03909295	0.7	LoF	protect	This study was terminated early because the primary endpoint of PARAGON-HF was not met.
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f48911e0-705f-11dc-afc9-0002a5d5c51b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	AMLODIPINE	targetBased	3	Completed	01/08/1993	https://clinicaltrials.gov/study/NCT00000542	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eaa2bbbc-5fcc-4f15-a51c-c4e1bf320c90	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00171535	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe4734a2-6219-8bf5-9c3a-d392910db4dc	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00409643	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00931710	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	18/01/2013	https://clinicaltrials.gov/study/NCT02644395	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	15/01/2019	https://clinicaltrials.gov/study/NCT03683069	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Unknown status	01/04/2008	https://clinicaltrials.gov/study/NCT00669435	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fdb1322-d867-4182-b7d5-30c2a27893f0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39e3f327-faab-4f1c-b6a6-f7116bb902b5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc0fa546-063a-434f-b8c0-bfca5b34462c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00425997	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3518853a-4c5b-4161-a178-8da7f656f009	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59464d24-16e5-42d3-acd4-6f3b2f4e3bf6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4ab4f05-1c18-442a-8618-c2c92e589703	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01964079	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d84c3fd-697f-4bc2-aa18-d7a9adcc9ca8	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	20/03/2013	https://clinicaltrials.gov/study/NCT03038451	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00553267	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8157ca93-d926-4264-b606-f73b2b38842a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00791258	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=968c611b-43a7-40f0-9ed3-aa67ee88364b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT02586311	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00351130	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e4682a6e-9624-48b0-978f-95da00cfb78f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b55da654-3c8e-4670-a503-e98e1d67d204	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=680209f4-ad4c-4f97-8b6b-04f648bfb97c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Withdrawn	01/05/2015	https://clinicaltrials.gov/study/NCT01922141	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Recruiting	22/08/2023	https://clinicaltrials.gov/study/NCT05920005	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c0eb8b2-3fe4-4df4-b21a-09b18a652860	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb2e6030-c1f4-44bb-9279-3c7368785009	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0141c088-8fc2-4041-880e-a79ce0de6fdd	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abd6a2ca-40c2-485c-bc53-db1c652505ed	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb5e7668-0ce4-4276-8416-0c313b59bb73	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42881d5b-7e35-496e-aeeb-8da760d4267c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00136851	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01167153	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a74239bf-4684-424c-ba4e-6087e363265b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00765947	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b5efcb5-7f6c-4264-8623-8ce100889c2c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1dd4f8bf-51cc-468f-a1cb-2427a8c71ad7	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11bde4d6-fb19-4783-8664-c0d116ddd2d1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c20ce12-06d3-4060-9936-ea847a525053	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Unknown status	01/08/2010	https://clinicaltrials.gov/study/NCT01180205	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f9c46a7-3833-44c8-9a15-5bed7d2008ba	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00548067	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7378a01-f825-4905-9134-6ff13cac10c9	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bef1a169-9186-43e9-b673-64fdb658984f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Terminated	01/04/2006	https://clinicaltrials.gov/study/NCT00313547	1	LoF	protect	Very difficult to recruit patients/slow recruitment(2 patients in nearly 2 years).
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00527514	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e83de08-b0f6-492a-a2db-e8d33a7a28aa	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01911780	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	07/06/2017	https://clinicaltrials.gov/study/NCT02742467	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Withdrawn	09/05/2017	https://clinicaltrials.gov/study/NCT02969265	0.7	LoF	protect	Business reasons unrelated to product safety
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00661895	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT01518855	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc73172f-a915-4ac4-a033-0de2a0223dc6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00281580	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00400777	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	23/10/2020	https://clinicaltrials.gov/study/NCT04559074	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d14c6b5-a70a-477f-b332-fa5b93a6296f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT05416840	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f40161f0-7b9e-4131-92d6-893cb9473e71	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43464a6b-a3b8-445b-b020-cf60f0b5e8a4	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00550953	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02f30d6b-0eb0-4f01-9539-6645118bc286	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00224549	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00942994	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Recruiting	04/01/2022	https://clinicaltrials.gov/study/NCT05165251	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6f298ba-2d7e-4a3c-9edb-8b60aba716d6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01222520	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01030458	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Not yet recruiting	30/06/2024	https://clinicaltrials.gov/study/NCT04974151	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca60a4d5-ace7-4889-94ee-e2265fd63811	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4b30c56-7403-4f69-9a8e-3d82a37e8bc5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=992fd3c4-ce10-4653-9c32-451209422510	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48072673-1f7f-4fa8-aebb-00b4dba4a0ae	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a97fefa6-99e6-4eb7-9393-ab2252a2c7d8	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00170976	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a542f10-2d9f-44a2-ad71-12032c99e225	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00171002	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c1ecc118-b372-40c6-819e-56092cafe595	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dacd31a3-d6df-4b00-b23c-8da4a17eebf0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fe3b576-567d-4589-9d4c-620b834b8746	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00421863	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00327145	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18d7820d-471f-4ee2-9ec6-25d8d27c77de	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b294ae51-53a3-4a58-9c30-3e8268cc8536	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Unknown status	01/04/2010	https://clinicaltrials.gov/study/NCT01271374	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02353806	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c75cd90-7dac-4876-bfbd-50d842176475	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02620163	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Unknown status	01/04/2016	https://clinicaltrials.gov/study/NCT02710552	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24e90827-104e-436c-81ac-78d3758e5723	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00492128	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d233a645-805b-45be-ae20-534367bc15ff	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=999aefc6-8842-4a02-a5bb-6601fe8db6e6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01593787	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00171054	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=241e7477-ecae-4f84-8410-bbfaa9f57ed0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00739596	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=630a292e-ec00-48f1-8aa8-00fbd176b187	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00649389	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e59a70d3-d9f2-43ea-92e7-271a2b2d4b1a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00443456	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00353912	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT01127217	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=efd9eda5-f497-45a3-ae13-dee729add999	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=178f8088-43ef-4e2c-a108-d86cd43df1ae	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2784f6dd-9115-4def-ad94-7141dbb6f738	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00409851	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8373e558-b5a6-4389-b5e1-f8f20ec32651	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Active, not recruiting	15/11/2018	https://clinicaltrials.gov/study/NCT03738878	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00360178	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00446524	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b52e2905-f906-4c46-bb24-2c7754c5d75b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f568859-64e6-454f-801b-c0a0a647dc3d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	25/11/1999	https://clinicaltrials.gov/study/NCT03276598	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a10fa641-ac6b-466d-bcba-31c678a74be8	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00666536	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f7c5855-aa5a-4535-8b37-cf97e09ed883	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff042130-c43a-4281-a731-809a54a1a7f1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=776a1619-c3af-65ff-a5ad-2cd807656205	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7aaf923d-5b82-4a85-bb10-5850087da487	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3294d91-4aa9-4a94-be6a-28ccf2d74326	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=273c6f4d-604f-4797-8961-c5f918542e3a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Withdrawn		https://clinicaltrials.gov/study/NCT01089452	1	LoF	protect	Study not started due to administrative reasons.
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2275ed71-a964-42b0-b9cb-46ab88da8687	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd311bf0-c5c8-4f0b-9f8f-e855bb32a71e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Unknown status	01/04/2016	https://clinicaltrials.gov/study/NCT02710539	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ee23c50-1183-414f-bb20-6285b04884e9	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48622cd3-1e25-4b08-b5bc-f2552e436d1f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=767c1e67-4cfb-4358-a963-3d58122c8e83	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98cc3e47-3463-4162-96ac-bf97d77eb041	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f173ff13-7417-415b-8725-3c2f2dd3e5b5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Unknown status	01/04/2000	https://clinicaltrials.gov/study/NCT00198562	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00237588	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94ae6054-b7ae-4212-a567-4f803af8f2c7	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9d9d64a-3a3c-44ad-b40d-02789f29eb04	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00558428	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00778921	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01611077	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b00570ff-4081-4514-b45b-eb6f753450f5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=224e9b5b-fa1f-452d-8ce7-d630b18f967f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000620	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/04/1998	https://clinicaltrials.gov/study/NCT02177409	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd3f7aa4-4b0a-464f-920e-7285acebc6ea	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00426478	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00624052	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Unknown status	01/04/2017	https://clinicaltrials.gov/study/NCT03578042	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2224a34b-b24f-4c23-a1b3-fdb148fc773b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	12/05/2022	https://clinicaltrials.gov/study/NCT05513937	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT01819220	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3201369-1c77-4a05-bbd0-0dd333305ace	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Unknown status	01/11/2009	https://clinicaltrials.gov/study/NCT01048047	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=edf9b22c-e37e-4b4e-8a64-20bb036c7d2d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT01091753	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e062d365-fda8-4c9e-b4b8-3d273153c50c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02377661	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01646671	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00591266	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4be76756-4114-4d50-a36c-fd410f6c773d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06df17aa-6831-498c-9c28-37502a1f3260	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=627146d8-fa8e-4c8b-b703-29ee080a6d5b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/08/1993	https://clinicaltrials.gov/study/NCT00000542	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cacb3551-c579-41cb-bed6-4b4d8b0644fc	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01070030	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01613209	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00171366	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00327587	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37b4cfba-6673-402e-bb5a-82b4ab6ef49b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00940680	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00240474	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abee4a34-89cc-d886-192c-32582ab8f024	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4336a551-afff-4d92-b05b-2a8e2000feef	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4da56a43-99aa-46df-aafc-ea193c46e442	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5409b296-3bed-47cd-abba-9fe6f6833af6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51e87d92-0c8a-46fa-a2d6-a8abf555201f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00700271	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d0c2df4-e9db-4622-95e8-33aa8a08f593	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47114f60-4151-43d4-ac2d-adc49492a679	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f4703c0-0b9e-41a0-8b70-da26683d9ed2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac0dd8fb-ebe1-4d02-bd0d-4f979c6e3608	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00940667	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd6f9f66-148a-4ecc-9fb9-a58e2b6fbc79	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6b1bbe5-78b0-407f-b953-92a131e3a4aa	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00367939	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Unknown status	06/08/2018	https://clinicaltrials.gov/study/NCT03626259	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Unknown status	01/09/2014	https://clinicaltrials.gov/study/NCT02373163	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00185133	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00877929	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00627952	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=790129ef-6a1b-45cb-8b02-25fa8a40c2ba	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Terminated	01/12/2016	https://clinicaltrials.gov/study/NCT02940548	1	LoF	protect	The patient recruitment and follow-ups were influenced with the pandemic of COVID-19
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=090f3e51-8129-4b5d-97f9-ab410e14df2d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3357a72-a68f-4ee5-be56-03f1dd8bef83	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00413049	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98c34c61-4965-427e-8eea-42f8a15dd79d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00170963	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=551c5efd-9e40-4015-92f8-6fbb229b548e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fabb27ef-aba2-c76a-cf6b-beb8826fd381	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f48911e0-705f-11dc-afc9-0002a5d5c51b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Terminated	01/10/2003	https://clinicaltrials.gov/study/NCT00170950	0.35	LoF	protect	The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35086164-bf92-4b3c-9845-f8cd7464c7d6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01625494	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7545204-1357-4543-aa05-c01fc890bc24	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	02/04/2018	https://clinicaltrials.gov/study/NCT03461003	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a5c7e83-3b17-4412-89fb-ff2235cbe77c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=638f6fc5-3374-477b-84de-63f93b8e1942	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8fcacc3f-80a8-4a2a-bccb-c1edb2e2764d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Unknown status	01/12/2015	https://clinicaltrials.gov/study/NCT02996916	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c0ff5b6-de91-4c37-bd8f-a9b1341ebc96	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3817371-3b20-4437-8fdb-8e3dd95863ea	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00402103	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=180506ee-0d90-4399-bc7b-fb1489951551	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00860262	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00460915	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=871e47cb-a828-9ba7-e053-2991aa0a96ea	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=873b5b9a-b198-46f7-abe0-898ad0809b47	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=782bcaf4-0aa4-4527-b36f-d350ceb95637	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08b1aa59-7892-451a-ad74-0388632e8235	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78a3bdb0-c945-45cf-b75d-066dbf1d152c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00134160	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa7e7d95-520a-461c-b1b3-e588aeb6a613	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5562b3f5-8757-11de-8a39-0800200c9a66	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bd2b07b-0da6-47a2-858b-e18851d566fb	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00741078	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c95fe9f4-fb64-41b1-a61f-85b102d09929	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00185120	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01139e81-a4fa-4e13-acdf-c75c79a1aa9c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=353a319e-2d1b-4bb6-8e3f-fc74d5b78523	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17261391-6671-4462-93da-24dd36d4af96	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211340s000lbl.pdf	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00159692	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15f7cde7-8dc2-4b07-83a9-9b86d6ec7f43	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56831e08-1445-4798-b661-0a780349085a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc7d39d7-e006-4ed6-a31c-827452603002	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00614380	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=653623d7-ed10-4505-a32d-6360d3be8b3d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41ceef84-9aae-4d7c-ba50-06beb85c415d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00523744	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Recruiting	03/02/2022	https://clinicaltrials.gov/study/NCT04840342	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00687973	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01180413	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Withdrawn	12/07/2022	https://clinicaltrials.gov/study/NCT05275907	1	LoF	protect	Screened participants did not meet inclusion criteria prior to study completion date
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5402d355-caff-f5e7-4cb4-7e61c57bf39d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4653cabc-f249-4b4e-95b6-5fb4ddc0ad5d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0478c750-ad55-42e6-adf5-a88aad78c055	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=213502a2-f667-4da6-a4b9-462eb303c401	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00853957	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e04b0eb9-83b5-4b33-a1e7-1c1e84f0c897	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cec7a02-b7a5-49e1-ab64-3a4dab4149d2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a27c8d30-fa25-4927-86fd-fdcfec8fd03a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	26/06/2021	https://clinicaltrials.gov/study/NCT04518293	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d3d4ee8-5657-4b7c-9478-8b29c13a8c9e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00392262	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00699192	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7cafaf24-3f61-45ac-82db-025616171759	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99ed4927-9a34-4e8d-8eea-60b63c867d46	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00439738	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00841672	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bac4ec4-9542-4927-8121-a7cd1858075b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=831c406d-1ba2-48f5-84ed-7d96b290cc18	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca014f06-982c-6fe1-9948-a3701dd35d34	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00368277	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00777946	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3911a46c-80fe-4b70-a4ba-416de597481b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d6d859b-e0c2-46f7-9bf5-f430d28ea12e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01977794	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	15/10/2021	https://clinicaltrials.gov/study/NCT05279807	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c83b8444-0558-44e5-8701-9919848072be	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	30/05/2011	https://clinicaltrials.gov/study/NCT01277822	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Unknown status	01/03/1999	https://clinicaltrials.gov/study/NCT00813722	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00956644	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35bf4392-eb96-4091-b7e9-50c1f2e52467	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=254b2202-b14d-9279-8311-cabcb0e75fc8	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f699d501-3f23-4261-904a-4877ba200c38	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44e5ad27-e062-461a-bdf4-192d852fbc49	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00957554	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00765674	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01103960	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00289406	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f33bb26-7a40-4cdb-bb50-35efdeeaa810	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc285a1f-9b43-4bdf-8679-44e25654b84c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00409760	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01204398	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=180ee374-24f2-4b9c-9d54-8815f2b1dc9b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d8304ba-1f38-428c-afc6-63a132e559ca	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=003dd1ec-16f8-4f96-b6a8-c4689d35892a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00772499	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Withdrawn	01/07/2021	https://clinicaltrials.gov/study/NCT04121299	0.7	LoF	protect	lack of funding
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fda0739d-b355-478c-acae-8f773a3ec4b3	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02294539	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00902304	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=563eff16-a16f-470c-94ca-08877e4d42f7	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5859daf-d6e1-4f8f-a246-5282b81be78d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00415623	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f573c43b-2dc7-4f0a-a54a-d60a5fe76458	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	22/04/2015	https://clinicaltrials.gov/study/NCT02651870	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01975246	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00739973	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Unknown status	01/10/2016	https://clinicaltrials.gov/study/NCT02900729	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT04952051	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61837ac5-0a0b-4ea9-b71c-d4c753294ed6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c32059ed-73cd-4a2c-9690-276e7068041e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00304226	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15ba7c1c-dd10-4d09-b6e2-284c1b67f4da	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6bb6b9a0-8de1-47cc-8534-7d1852d4243b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	26/06/2014	https://clinicaltrials.gov/study/NCT02172040	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00350168	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00867490	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00367978	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02973035	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	20/02/2017	https://clinicaltrials.gov/study/NCT02774460	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	07/11/2005	https://clinicaltrials.gov/study/NCT00338338	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Terminated	20/08/2015	https://clinicaltrials.gov/study/NCT03106597	1	LoF	protect	Difficulty in enrolling subjects
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f12f18bb-7ddb-e7dc-4edd-32f4ac212bca	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT02847338	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01101009	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Not yet recruiting	30/06/2024	https://clinicaltrials.gov/study/NCT04974138	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15416229-d7d3-5bfb-a373-71575c36d5cf	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3bb9dd10-e07c-4433-b6a7-c1c6fc4f05a7	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT01070043	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01286558	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01030081	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00558064	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT01865188	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Unknown status	01/09/2017	https://clinicaltrials.gov/study/NCT03294070	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01876368	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01134393	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00413413	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18686fa-be94-472e-8404-c69e6869ed10	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9abf41f1-66f9-4be4-a6d7-6c9aa0d5d387	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3d9dd95-d250-4201-8e95-466fd321c37e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	06/06/2021	https://clinicaltrials.gov/study/NCT04518306	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cb15b9d-1c45-4491-bfcc-a902a491b288	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e11652b8-6ce6-4366-9519-a43a0d36f235	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2829814d-739d-4ff4-9371-bee70bf32248	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02995954	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00140959	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02209439-fe92-42de-81e3-51a8288debc0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01302691	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=062bf1a0-9a29-4dee-a8cb-f0d051f4c0b1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=759d754e-48eb-4e37-a28a-9b79ac20416b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6f37813-40bb-4fe8-99e2-ad2339b8e04a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e698930-5c05-421f-a408-2a2fbfff0948	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df8e23c8-6c8f-4293-8a37-5ad3d48dba94	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	LERCANIDIPINE	targetBased	4	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01180413	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	LERCANIDIPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08CA13	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	LERCANIDIPINE	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT02594410	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	LERCANIDIPINE	targetBased	4	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01180413	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	LERCANIDIPINE	targetBased	4	Terminated	01/01/2011	https://clinicaltrials.gov/study/NCT01211314	1	LoF	protect	sponsor decision
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	LERCANIDIPINE	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01928628	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	LERCANIDIPINE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01520285	1	LoF	protect
Modulation of AMPAR-stargazin complexes	AMPAStargazinComplexModulators	CACNG2	Voltage-dependent calcium channel gamma-2 subunit	cardiovascular disease	SULOCTIDIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AX19	1	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	cardiovascular disease	SULOCTIDIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AX19	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	cardiovascular disease	SULOCTIDIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AX19	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	SULOCTIDIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AX19	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Coronary Vasospasm	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d592c37-b38c-4fb6-a1d3-96531384ae8d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Coronary Vasospasm	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ebcb33c-f43b-4b36-9f94-9774b2a59e06	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Raynaud disease	NIFEDIPINE	targetBased	3	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000530	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	pulmonary hypertension	NIFEDIPINE	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00519870	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	NIFEDIPINE	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02031861	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	NIFEDIPINE	targetBased	4	Unknown status	01/12/2014	https://clinicaltrials.gov/study/NCT02357615	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	NIFEDIPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08CA55	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	NIFEDIPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08CA05	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	NIFEDIPINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT01435161	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Myocardial Ischemia	NIFEDIPINE	targetBased	3	Completed	01/11/1990	https://clinicaltrials.gov/study/NCT00000478	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01071122	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02641821	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00661895	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=983bd055-d289-4fb1-a69c-5a7f178a07d1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b95cd483-64ca-4840-948d-eaf1e13e58b2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49040b3a-0802-4a7d-b0c9-c7f47c1bbe10	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=445fbfa9-ef9a-42d3-a7d5-5a48f8b0af21	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adaa3246-d0fc-417c-9a16-81d76f153903	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e74cdfd-c2ce-4346-b38e-e52b8bb49c3e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	3	Withdrawn	01/12/2017	https://clinicaltrials.gov/study/NCT02047019	0.7	LoF	protect	GPDC decided to terminate the study
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4	Completed	26/03/2015	https://clinicaltrials.gov/study/NCT02413515	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d592c37-b38c-4fb6-a1d3-96531384ae8d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98466838-76b5-4fdf-9b94-4f4f7e984240	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4	Unknown status	01/12/2009	https://clinicaltrials.gov/study/NCT01021501	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27c1b010-1c0a-418f-9520-54a228333925	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42696694-ffc2-4f2d-8d2c-82924c7ac5d2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01830530	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa950a8e-06b7-4adf-ab5d-fe485772a850	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f4fef2-e500-4a6b-8350-a73d5e4772e1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01167153	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8d582f9-12d0-4aab-9a64-c8bd072a7741	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa952140-c9f6-472d-a04f-96c44fe9bca8	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6d04375-aec5-41df-ae7a-8cb87cf32d86	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6139bd81-c3f3-41dd-b69a-6d98c756a3cf	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4	Unknown status		https://clinicaltrials.gov/study/NCT00173667	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00750113	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad65c43d-91c7-4c7c-b16f-5025c764cad6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06b49bab-1918-44ef-bf24-9530dac0f1bf	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd327f77-eb4e-4b53-91f2-433b0e7cc16a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28a716b5-4bcd-44c1-be8b-546ab3e238cf	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28b487c2-0f7b-4e65-88bf-1f30856b588e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT02499822	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01355367	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4617417a-08df-4417-a944-dfc30de183db	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=997db376-9f25-4a99-a5b8-52c88f23baf6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb70b7ff-f9f0-41d0-901a-f4c04ae9ed46	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75f6811d-0906-4ed4-8619-eb3eed103d9b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=453ac443-4fd4-4b5c-b7b4-06d34dc38e0d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3bf4282f-b063-4d35-8ef0-6f48b98e9deb	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	3	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02426177	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcabfaee-df20-4e7c-b951-8a454f0d355e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT00993109	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e80b790-a57e-46ee-a257-4f59ca6502ce	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00672113	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	3	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01294215	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=409af9d8-67ee-4532-903f-a7bd5ad3d2e2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cfc501a8-59cf-4e28-9e74-30e8c17472c3	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01287260	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ebcb33c-f43b-4b36-9f94-9774b2a59e06	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f515d1c3-1846-4701-ad79-a81d49c102c6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=912b0ad4-86e3-4993-88d1-006ffca3f4a0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e740c6e-483b-4e7d-833f-2e8bdd36d625	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8dc63e02-43c6-47ef-9c82-8edccedabcbc	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35e4dff3-f430-4761-b8ff-5875c52495cd	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT01518855	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8343a631-be3a-43a6-9f43-03fdf7458f24	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01030081	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	3	Completed	14/02/2013	https://clinicaltrials.gov/study/NCT01788358	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6fafbe75-fcae-4afd-9745-02e641cefb31	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d247bfb-8309-4cb8-847c-b4619a3d36d8	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4	Terminated	01/12/2016	https://clinicaltrials.gov/study/NCT02940548	1	LoF	protect	The patient recruitment and follow-ups were influenced with the pandemic of COVID-19
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f62c7b36-6134-47b8-ae82-e8fb5e5522d1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NIFEDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=323351d8-de18-4cd6-9497-c2d5e8666414	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	pericarditis	HYDROXYCHLOROQUINE	targetBased	3	Not yet recruiting	01/02/2023	https://clinicaltrials.gov/study/NCT05737680	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	coronary artery disease	HYDROXYCHLOROQUINE	targetBased	4	Completed	08/10/2017	https://clinicaltrials.gov/study/NCT02874287	1	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	acute coronary syndrome	ERGOCALCIFEROL	targetBased	4	Unknown status	01/06/2010	https://clinicaltrials.gov/study/NCT01115842	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	congestive heart failure	ERGOCALCIFEROL	targetBased	4	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01326650	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Myocardial Ischemia	ERGOCALCIFEROL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	coronary artery disease	ERGOCALCIFEROL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	cardiovascular disease	ERGOCALCIFEROL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	congenital heart disease	LIOTHYRONINE	targetBased	3	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02320669	0.7	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	Abnormal cardiovascular system morphology	LIOTHYRONINE	targetBased	3	Completed	01/04/2001	https://clinicaltrials.gov/study/NCT00027417	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Bradycardia	ATROPINE	targetBased	4	Completed	25/06/2019	https://clinicaltrials.gov/study/NCT03984526	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Bradycardia	ATROPINE	targetBased	4	Completed	25/06/2019	https://clinicaltrials.gov/study/NCT03984526	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Bradycardia	ATROPINE	targetBased	4	Completed	25/06/2019	https://clinicaltrials.gov/study/NCT03984526	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Bradycardia	ATROPINE	targetBased	4	Completed	25/06/2019	https://clinicaltrials.gov/study/NCT03984526	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Bradycardia	ATROPINE	targetBased	4	Completed	25/06/2019	https://clinicaltrials.gov/study/NCT03984526	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Bradycardia	ATROPINE	targetBased	4	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT02186132	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Bradycardia	ATROPINE	targetBased	4	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT02186132	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Bradycardia	ATROPINE	targetBased	4	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT02186132	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Bradycardia	ATROPINE	targetBased	4	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT02186132	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Bradycardia	ATROPINE	targetBased	4	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT02186132	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Bradycardia	ATROPINE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02522858	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Bradycardia	ATROPINE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02522858	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Bradycardia	ATROPINE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02522858	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Bradycardia	ATROPINE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02522858	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Bradycardia	ATROPINE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02522858	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	CILNIDIPINE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=C08CA14	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	CILNIDIPINE	targetBased	3	Completed	17/06/2014	https://clinicaltrials.gov/study/NCT02145104	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cerebral atherosclerosis	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfd129ae-8b0a-f118-b7d0-45d106290b63	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cerebral atherosclerosis	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=461e6444-189e-62ed-6c61-1c36a04459c6	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cerebral atherosclerosis	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87db36f3-c831-4a84-a3c5-e9d6cc7191af	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cerebral atherosclerosis	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14452da8-3b48-497d-9017-bdfb967b7f56	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cerebral atherosclerosis	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13602c1d-d1c9-496b-baa6-8dee92519d67	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cerebral atherosclerosis	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17f205dd-0feb-4c49-a0e1-2d0c362c6bd7	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cerebral atherosclerosis	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e3ea1dbc-47cc-462d-a360-a3944f80b14c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	LACIDIPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08CA09	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	LACIDIPINE	targetBased	4	Completed	01/12/1997	https://clinicaltrials.gov/study/NCT02235402	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	LACIDIPINE	targetBased	3	Completed	01/06/1995	https://clinicaltrials.gov/study/NCT02177331	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	LACIDIPINE	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00460915	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	LACIDIPINE	targetBased	4	Completed	07/11/2005	https://clinicaltrials.gov/study/NCT00338338	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	LACIDIPINE	targetBased	4	Unknown status	01/09/2007	https://clinicaltrials.gov/study/NCT00533858	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	NITRENDIPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08CA08	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NITRENDIPINE	targetBased	4	Recruiting	27/09/2021	https://clinicaltrials.gov/study/NCT04931108	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NITRENDIPINE	targetBased	4	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02217852	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NITRENDIPINE	targetBased	3	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00751829	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	nadolol	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bcae071c-bd67-4fa9-be40-3325ebf04119	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	nadolol	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C07AA12	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	angina pectoris	nadolol	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d208918b-a356-4924-91d9-9593981fe0a6	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	angina pectoris	nadolol	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bcae071c-bd67-4fa9-be40-3325ebf04119	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	nadolol	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d208918b-a356-4924-91d9-9593981fe0a6	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	nadolol	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bcae071c-bd67-4fa9-be40-3325ebf04119	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	nadolol	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f11df27-710b-4903-a985-74ee4674a844	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	nadolol	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d226ea-1624-47ee-82bf-e9660b75029f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	ISRADIPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08CA03	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	ISRADIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac51d3e3-ed76-e033-e1d6-1ffbd14d94c2	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Wolff-Parkinson-White Syndrome	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f0f5fb3-5292-4d04-b590-3c90a663eec8	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	angina pectoris	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35d28979-36b1-4630-b85e-a44e0a443734	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	angina pectoris	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=582fe781-0759-4622-8fa6-b7d90e94e696	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	coronary atherosclerosis	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35d28979-36b1-4630-b85e-a44e0a443734	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	coronary atherosclerosis	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=582fe781-0759-4622-8fa6-b7d90e94e696	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiac arrhythmia	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f0f5fb3-5292-4d04-b590-3c90a663eec8	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90656b7e-c3b6-46f9-9428-421b7d61d0cc	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=582fe781-0759-4622-8fa6-b7d90e94e696	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d15bb34-f5d0-4cd0-8b08-27a0c265d9a5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84050954-e94c-4d90-b3b3-6f47fd14e492	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35d28979-36b1-4630-b85e-a44e0a443734	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac196ff5-9215-402b-bc57-69aa87f8bade	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	NILVADIPINE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=C08CA10	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	coronary artery disease	HYDROXYCHLOROQUINE SULFATE	targetBased	4	Completed	08/10/2017	https://clinicaltrials.gov/study/NCT02874287	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Coronary Vasospasm	DILTIAZEM HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af12246f-890c-4c31-bb77-136f47dda222	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Coronary Vasospasm	DILTIAZEM HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14a67570-6820-46ee-920c-b6d3663609d9	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Coronary Vasospasm	DILTIAZEM HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3e7ecef-f360-4987-a4f5-933214130ab2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Coronary Vasospasm	DILTIAZEM HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1042fa13-e6af-46b9-8008-6c941f0978b1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DILTIAZEM HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DILTIAZEM HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d8e8b1e-f67b-57d2-e053-2991aa0a8d12	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	DILTIAZEM HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=001826f4-f531-454e-a37a-e4e0b147f61b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	DILTIAZEM HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	DILTIAZEM HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9942f1a2-f66d-4d9e-9794-49bee8abf5ab	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	DILTIAZEM HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af12246f-890c-4c31-bb77-136f47dda222	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	DILTIAZEM HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7cf9276-4b4c-10b2-e053-2995a90a3738	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	DILTIAZEM HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c567fe7e-887e-4291-a0d1-2dd3f25cbf25	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	DILTIAZEM HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1042fa13-e6af-46b9-8008-6c941f0978b1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	DILTIAZEM HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e180dc7-c871-4efc-8755-cae882976c8d	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	SOTALOL HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart failure	SOTALOL HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart failure	SOTALOL HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart failure	SOTALOL HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=253da1e1-022a-4175-bd7f-e7673cba0767	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=253da1e1-022a-4175-bd7f-e7673cba0767	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=253da1e1-022a-4175-bd7f-e7673cba0767	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f33f900-0777-4a92-a7f7-00cf3d57d95c	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f33f900-0777-4a92-a7f7-00cf3d57d95c	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f33f900-0777-4a92-a7f7-00cf3d57d95c	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c24cdf0-4648-4e5d-993c-1f428ce56a65	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c24cdf0-4648-4e5d-993c-1f428ce56a65	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c24cdf0-4648-4e5d-993c-1f428ce56a65	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62a71c8c-d92d-4122-848f-9ae35f8bbe2b	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62a71c8c-d92d-4122-848f-9ae35f8bbe2b	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62a71c8c-d92d-4122-848f-9ae35f8bbe2b	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2577dd8d-ab1b-4a55-990a-18c69395edfe	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2577dd8d-ab1b-4a55-990a-18c69395edfe	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2577dd8d-ab1b-4a55-990a-18c69395edfe	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff3061ab-d930-4318-a5be-684e38be229e	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff3061ab-d930-4318-a5be-684e38be229e	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff3061ab-d930-4318-a5be-684e38be229e	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2577dd8d-ab1b-4a55-990a-18c69395edfe	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f33f900-0777-4a92-a7f7-00cf3d57d95c	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=253da1e1-022a-4175-bd7f-e7673cba0767	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62a71c8c-d92d-4122-848f-9ae35f8bbe2b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff3061ab-d930-4318-a5be-684e38be229e	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Ventricular arrhythmia	SOTALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c24cdf0-4648-4e5d-993c-1f428ce56a65	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL HYDROCHLORIDE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00523978	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL HYDROCHLORIDE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00523978	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	SOTALOL HYDROCHLORIDE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00523978	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	SOTALOL HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	SOTALOL HYDROCHLORIDE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00523978	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	ISOPROTERENOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=046f2941-3bc0-4755-861c-71bedb49e706	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	ISOPROTERENOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f570cea-dbf2-41e0-9789-5bf948c2eb7a	1	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	NISOLDIPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08CA07	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NISOLDIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2abc5435-b2ca-4e08-89bc-ab7526781819	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	venous thromboembolism	DABIGATRAN ETEXILATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	venous thromboembolism	DABIGATRAN ETEXILATE	targetBased	3	Completed	25/09/2013	https://clinicaltrials.gov/study/NCT01895777	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	venous thromboembolism	DABIGATRAN ETEXILATE	targetBased	3	Completed	29/09/2014	https://clinicaltrials.gov/study/NCT02197416	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	venous thromboembolism	DABIGATRAN ETEXILATE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00657150	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	venous thromboembolism	DABIGATRAN ETEXILATE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00558259	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial flutter	DABIGATRAN ETEXILATE	targetBased	4	Recruiting	01/04/2023	https://clinicaltrials.gov/study/NCT03129490	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	pulmonary embolism	DABIGATRAN ETEXILATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	pulmonary embolism	DABIGATRAN ETEXILATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5db7f199-8752-4d24-85f7-e34ca8f4d02e	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	pulmonary embolism	DABIGATRAN ETEXILATE	targetBased	4	Unknown status	01/10/2016	https://clinicaltrials.gov/study/NCT02979561	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN ETEXILATE	targetBased	4	Completed	28/04/2015	https://clinicaltrials.gov/study/NCT02348723	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN ETEXILATE	targetBased	4	Recruiting	01/04/2023	https://clinicaltrials.gov/study/NCT03129490	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN ETEXILATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN ETEXILATE	targetBased	3	Completed	22/07/2014	https://clinicaltrials.gov/study/NCT02164864	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN ETEXILATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5db7f199-8752-4d24-85f7-e34ca8f4d02e	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN ETEXILATE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01493557	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN ETEXILATE	targetBased	4	Unknown status	01/03/2016	https://clinicaltrials.gov/study/NCT02646267	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN ETEXILATE	targetBased	4	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT02666157	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN ETEXILATE	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01896297	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN ETEXILATE	targetBased	4	Recruiting	28/12/2017	https://clinicaltrials.gov/study/NCT03975062	1	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	cardiovascular disease	CONIVAPTAN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C03XA02	1	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	heart failure	CONIVAPTAN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5150d9d9-01dc-4a52-9858-214c66d8caea	1	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	heart failure	CONIVAPTAN	targetBased	4	Withdrawn	01/10/2008	https://clinicaltrials.gov/study/NCT00806910	1	LoF	protect	Sponsor support withdrawn
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	heart failure	CONIVAPTAN	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT01752543	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	TERBUTALINE	targetBased	4	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00802230	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	INDACATEROL	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02598505	0.7	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	MANIDIPINE 6300	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=C08CA11	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	MANIDIPINE 6300	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00627952	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart failure	AMIODARONE HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart failure	AMIODARONE HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	heart failure	AMIODARONE HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d4d66f7-fa14-e832-e053-2a95a90a8b62	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d4d66f7-fa14-e832-e053-2a95a90a8b62	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d4d66f7-fa14-e832-e053-2a95a90a8b62	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57df7b65-7829-4364-894f-ae4c2772c733	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57df7b65-7829-4364-894f-ae4c2772c733	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Ventricular arrhythmia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57df7b65-7829-4364-894f-ae4c2772c733	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00784316	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00784316	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00784316	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4	Recruiting	03/02/2022	https://clinicaltrials.gov/study/NCT04594746	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4	Recruiting	03/02/2022	https://clinicaltrials.gov/study/NCT04594746	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4	Recruiting	03/02/2022	https://clinicaltrials.gov/study/NCT04594746	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4	Unknown status	01/04/2011	https://clinicaltrials.gov/study/NCT01341353	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4	Unknown status	01/04/2011	https://clinicaltrials.gov/study/NCT01341353	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4	Unknown status	01/04/2011	https://clinicaltrials.gov/study/NCT01341353	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4	Completed	01/08/2000	https://clinicaltrials.gov/study/NCT00845780	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4	Completed	01/08/2000	https://clinicaltrials.gov/study/NCT00845780	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4	Completed	01/08/2000	https://clinicaltrials.gov/study/NCT00845780	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	3	Recruiting	13/06/2024	https://clinicaltrials.gov/study/NCT05841056	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	3	Recruiting	13/06/2024	https://clinicaltrials.gov/study/NCT05841056	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	3	Recruiting	13/06/2024	https://clinicaltrials.gov/study/NCT05841056	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04efa7dc-7be0-495c-85a4-3d9d6ed5840a	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04efa7dc-7be0-495c-85a4-3d9d6ed5840a	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04efa7dc-7be0-495c-85a4-3d9d6ed5840a	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5d11e6d-d78f-40f0-87bd-6909088141d0	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5d11e6d-d78f-40f0-87bd-6909088141d0	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5d11e6d-d78f-40f0-87bd-6909088141d0	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcc8658c-761a-443f-8c32-1499d86028ec	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcc8658c-761a-443f-8c32-1499d86028ec	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcc8658c-761a-443f-8c32-1499d86028ec	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51772745-9ea9-42cd-97e6-7266f41ae3ca	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51772745-9ea9-42cd-97e6-7266f41ae3ca	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51772745-9ea9-42cd-97e6-7266f41ae3ca	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0915ecd6-1c36-420a-bd59-32d48587e137	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0915ecd6-1c36-420a-bd59-32d48587e137	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0915ecd6-1c36-420a-bd59-32d48587e137	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=304d0be4-0c13-4dbb-8ffb-b2e7caa7fb1e	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=304d0be4-0c13-4dbb-8ffb-b2e7caa7fb1e	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=304d0be4-0c13-4dbb-8ffb-b2e7caa7fb1e	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdd50dc7-f712-4248-b0e3-ba247cf08cee	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdd50dc7-f712-4248-b0e3-ba247cf08cee	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdd50dc7-f712-4248-b0e3-ba247cf08cee	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9108958-b8d7-4fba-87c3-9a32990de551	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9108958-b8d7-4fba-87c3-9a32990de551	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular tachycardia	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9108958-b8d7-4fba-87c3-9a32990de551	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0915ecd6-1c36-420a-bd59-32d48587e137	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0915ecd6-1c36-420a-bd59-32d48587e137	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0915ecd6-1c36-420a-bd59-32d48587e137	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdd50dc7-f712-4248-b0e3-ba247cf08cee	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdd50dc7-f712-4248-b0e3-ba247cf08cee	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdd50dc7-f712-4248-b0e3-ba247cf08cee	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0eb6c22-7553-4e3f-a06d-20a186ced99a	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0eb6c22-7553-4e3f-a06d-20a186ced99a	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0eb6c22-7553-4e3f-a06d-20a186ced99a	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d4d66f7-fa14-e832-e053-2a95a90a8b62	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d4d66f7-fa14-e832-e053-2a95a90a8b62	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d4d66f7-fa14-e832-e053-2a95a90a8b62	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51772745-9ea9-42cd-97e6-7266f41ae3ca	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51772745-9ea9-42cd-97e6-7266f41ae3ca	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51772745-9ea9-42cd-97e6-7266f41ae3ca	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=304d0be4-0c13-4dbb-8ffb-b2e7caa7fb1e	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=304d0be4-0c13-4dbb-8ffb-b2e7caa7fb1e	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=304d0be4-0c13-4dbb-8ffb-b2e7caa7fb1e	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8d04647-8e25-4127-8ecf-360ce1991c2f	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8d04647-8e25-4127-8ecf-360ce1991c2f	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8d04647-8e25-4127-8ecf-360ce1991c2f	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcc8658c-761a-443f-8c32-1499d86028ec	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcc8658c-761a-443f-8c32-1499d86028ec	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcc8658c-761a-443f-8c32-1499d86028ec	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5d11e6d-d78f-40f0-87bd-6909088141d0	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5d11e6d-d78f-40f0-87bd-6909088141d0	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5d11e6d-d78f-40f0-87bd-6909088141d0	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04efa7dc-7be0-495c-85a4-3d9d6ed5840a	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04efa7dc-7be0-495c-85a4-3d9d6ed5840a	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04efa7dc-7be0-495c-85a4-3d9d6ed5840a	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9108958-b8d7-4fba-87c3-9a32990de551	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9108958-b8d7-4fba-87c3-9a32990de551	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	ventricular fibrillation	AMIODARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9108958-b8d7-4fba-87c3-9a32990de551	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	coronary artery disease	METHYLNALTREXONE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02403830	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	coronary artery disease	METHYLNALTREXONE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02403830	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ST Elevation Myocardial Infarction	METHYLNALTREXONE	targetBased	4	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02942550	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ST Elevation Myocardial Infarction	METHYLNALTREXONE	targetBased	4	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02942550	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	LABETALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75d74177-4e71-cef2-e053-2991aa0a9a97	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	LABETALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01735685-40e0-4323-af5a-91db399f6451	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	LABETALOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4195473-51a9-40f1-8678-1478ebca2d84	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be9e2dda-80da-4e0d-a3ee-ab2bd9f3f2ee	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6512740-17e0-4f22-a233-4ac084277879	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72c19612-6dc6-4413-80a2-3f85953e4763	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8ef8420-01d2-11de-a455-0002a5d5c51b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d58f812-37bf-439f-b3f2-c31f8eefe22e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13b13720-f64d-11df-93a0-0002a5d5c51b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e61159ba-ff6b-4696-a642-4f64c79c4708	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b54643f-55b2-404a-b282-39fc6b2d8121	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0eb7d839-63d9-4b51-bf7b-4a8fde6339b5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a7c6372-a22b-4501-a6c6-539457a6cd9d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2f0b90f-9495-48c5-b21f-86e487a04854	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=52e42bf6-34a3-4b95-9907-5e8d19108d47	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT01872039	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c84cda13-e2fb-46d6-a9a2-5a3311387ff8	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2388174b-8983-4be5-a4b5-f2ec45f3e19c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=613c79eb-b34d-4fea-82d0-61b8c4840182	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76fcb7e0-9034-4fcd-be14-ce7e9ccaee2a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18fb1c2b-0c1e-436c-a5b6-d4840b5da228	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	NICARDIPINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7dfde10-01d4-11de-87af-0800200c9a66	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa7e7d95-520a-461c-b1b3-e588aeb6a613	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4be76756-4114-4d50-a36c-fd410f6c773d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=680209f4-ad4c-4f97-8b6b-04f648bfb97c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f48911e0-705f-11dc-afc9-0002a5d5c51b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7545204-1357-4543-aa05-c01fc890bc24	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=003dd1ec-16f8-4f96-b6a8-c4689d35892a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08b1aa59-7892-451a-ad74-0388632e8235	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39e3f327-faab-4f1c-b6a6-f7116bb902b5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd311bf0-c5c8-4f0b-9f8f-e855bb32a71e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=062bf1a0-9a29-4dee-a8cb-f0d051f4c0b1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01139e81-a4fa-4e13-acdf-c75c79a1aa9c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f33bb26-7a40-4cdb-bb50-35efdeeaa810	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc0fa546-063a-434f-b8c0-bfca5b34462c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abee4a34-89cc-d886-192c-32582ab8f024	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5562b3f5-8757-11de-8a39-0800200c9a66	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=322f926c-99ac-49f8-9cc5-584594f2891f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18d7820d-471f-4ee2-9ec6-25d8d27c77de	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c0eb8b2-3fe4-4df4-b21a-09b18a652860	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18686fa-be94-472e-8404-c69e6869ed10	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3bb9dd10-e07c-4433-b6a7-c1c6fc4f05a7	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35086164-bf92-4b3c-9845-f8cd7464c7d6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	myocardial infarction	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2224a34b-b24f-4c23-a1b3-fdb148fc773b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=767c1e67-4cfb-4358-a963-3d58122c8e83	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7cafaf24-3f61-45ac-82db-025616171759	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44e5ad27-e062-461a-bdf4-192d852fbc49	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e04b0eb9-83b5-4b33-a1e7-1c1e84f0c897	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d14c6b5-a70a-477f-b332-fa5b93a6296f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f9c46a7-3833-44c8-9a15-5bed7d2008ba	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dacd31a3-d6df-4b00-b23c-8da4a17eebf0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8157ca93-d926-4264-b606-f73b2b38842a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61837ac5-0a0b-4ea9-b71c-d4c753294ed6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b52e2905-f906-4c46-bb24-2c7754c5d75b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11bde4d6-fb19-4783-8664-c0d116ddd2d1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f7c5855-aa5a-4535-8b37-cf97e09ed883	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24e90827-104e-436c-81ac-78d3758e5723	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01139e81-a4fa-4e13-acdf-c75c79a1aa9c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c1ecc118-b372-40c6-819e-56092cafe595	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37b4cfba-6673-402e-bb5a-82b4ab6ef49b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b00570ff-4081-4514-b45b-eb6f753450f5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5859daf-d6e1-4f8f-a246-5282b81be78d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a542f10-2d9f-44a2-ad71-12032c99e225	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3201369-1c77-4a05-bbd0-0dd333305ace	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06df17aa-6831-498c-9c28-37502a1f3260	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3294d91-4aa9-4a94-be6a-28ccf2d74326	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c32059ed-73cd-4a2c-9690-276e7068041e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9abf41f1-66f9-4be4-a6d7-6c9aa0d5d387	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3357a72-a68f-4ee5-be56-03f1dd8bef83	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7aaf923d-5b82-4a85-bb10-5850087da487	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8373e558-b5a6-4389-b5e1-f8f20ec32651	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c83b8444-0558-44e5-8701-9919848072be	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2275ed71-a964-42b0-b9cb-46ab88da8687	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2829814d-739d-4ff4-9371-bee70bf32248	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=873b5b9a-b198-46f7-abe0-898ad0809b47	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc285a1f-9b43-4bdf-8679-44e25654b84c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48072673-1f7f-4fa8-aebb-00b4dba4a0ae	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e83de08-b0f6-492a-a2db-e8d33a7a28aa	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f573c43b-2dc7-4f0a-a54a-d60a5fe76458	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cec7a02-b7a5-49e1-ab64-3a4dab4149d2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f173ff13-7417-415b-8725-3c2f2dd3e5b5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3d9dd95-d250-4201-8e95-466fd321c37e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=180ee374-24f2-4b9c-9d54-8815f2b1dc9b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abd6a2ca-40c2-485c-bc53-db1c652505ed	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51e87d92-0c8a-46fa-a2d6-a8abf555201f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6f298ba-2d7e-4a3c-9edb-8b60aba716d6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fdb1322-d867-4182-b7d5-30c2a27893f0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=edf9b22c-e37e-4b4e-8a64-20bb036c7d2d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=790129ef-6a1b-45cb-8b02-25fa8a40c2ba	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=638f6fc5-3374-477b-84de-63f93b8e1942	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9d9d64a-3a3c-44ad-b40d-02789f29eb04	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bac4ec4-9542-4927-8121-a7cd1858075b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d8304ba-1f38-428c-afc6-63a132e559ca	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5409b296-3bed-47cd-abba-9fe6f6833af6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a27c8d30-fa25-4927-86fd-fdcfec8fd03a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f699d501-3f23-4261-904a-4877ba200c38	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4ab4f05-1c18-442a-8618-c2c92e589703	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c75cd90-7dac-4876-bfbd-50d842176475	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb2e6030-c1f4-44bb-9279-3c7368785009	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a74239bf-4684-424c-ba4e-6087e363265b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=999aefc6-8842-4a02-a5bb-6601fe8db6e6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47114f60-4151-43d4-ac2d-adc49492a679	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59464d24-16e5-42d3-acd4-6f3b2f4e3bf6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fabb27ef-aba2-c76a-cf6b-beb8826fd381	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb5e7668-0ce4-4276-8416-0c313b59bb73	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=213502a2-f667-4da6-a4b9-462eb303c401	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e062d365-fda8-4c9e-b4b8-3d273153c50c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3911a46c-80fe-4b70-a4ba-416de597481b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e698930-5c05-421f-a408-2a2fbfff0948	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4b30c56-7403-4f69-9a8e-3d82a37e8bc5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f4703c0-0b9e-41a0-8b70-da26683d9ed2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cacb3551-c579-41cb-bed6-4b4d8b0644fc	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ee23c50-1183-414f-bb20-6285b04884e9	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a10fa641-ac6b-466d-bcba-31c678a74be8	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=551c5efd-9e40-4015-92f8-6fbb229b548e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c0ff5b6-de91-4c37-bd8f-a9b1341ebc96	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d233a645-805b-45be-ae20-534367bc15ff	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0141c088-8fc2-4041-880e-a79ce0de6fdd	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42881d5b-7e35-496e-aeeb-8da760d4267c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5402d355-caff-f5e7-4cb4-7e61c57bf39d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=353a319e-2d1b-4bb6-8e3f-fc74d5b78523	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02f30d6b-0eb0-4f01-9539-6645118bc286	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d3d4ee8-5657-4b7c-9478-8b29c13a8c9e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2784f6dd-9115-4def-ad94-7141dbb6f738	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fda0739d-b355-478c-acae-8f773a3ec4b3	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0478c750-ad55-42e6-adf5-a88aad78c055	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4336a551-afff-4d92-b05b-2a8e2000feef	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bef1a169-9186-43e9-b673-64fdb658984f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc73172f-a915-4ac4-a033-0de2a0223dc6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8fcacc3f-80a8-4a2a-bccb-c1edb2e2764d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=759d754e-48eb-4e37-a28a-9b79ac20416b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=efd9eda5-f497-45a3-ae13-dee729add999	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b55da654-3c8e-4670-a503-e98e1d67d204	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff042130-c43a-4281-a731-809a54a1a7f1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=273c6f4d-604f-4797-8961-c5f918542e3a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac0dd8fb-ebe1-4d02-bd0d-4f979c6e3608	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3518853a-4c5b-4161-a178-8da7f656f009	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=003dd1ec-16f8-4f96-b6a8-c4689d35892a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc7d39d7-e006-4ed6-a31c-827452603002	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd6f9f66-148a-4ecc-9fb9-a58e2b6fbc79	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fe3b576-567d-4589-9d4c-620b834b8746	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41ceef84-9aae-4d7c-ba50-06beb85c415d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6b1bbe5-78b0-407f-b953-92a131e3a4aa	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=992fd3c4-ce10-4653-9c32-451209422510	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Prinzmetal's angina	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=090f3e51-8129-4b5d-97f9-ab410e14df2d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE BESYLATE	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01556997	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE BESYLATE	targetBased	3	Completed	14/05/2018	https://clinicaltrials.gov/study/NCT05288400	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE BESYLATE	targetBased	4	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01131546	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	congestive heart failure	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb5e7668-0ce4-4276-8416-0c313b59bb73	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5402d355-caff-f5e7-4cb4-7e61c57bf39d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cacb3551-c579-41cb-bed6-4b4d8b0644fc	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=873b5b9a-b198-46f7-abe0-898ad0809b47	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b00570ff-4081-4514-b45b-eb6f753450f5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fabb27ef-aba2-c76a-cf6b-beb8826fd381	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e698930-5c05-421f-a408-2a2fbfff0948	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41ceef84-9aae-4d7c-ba50-06beb85c415d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=992fd3c4-ce10-4653-9c32-451209422510	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=edf9b22c-e37e-4b4e-8a64-20bb036c7d2d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb2e6030-c1f4-44bb-9279-3c7368785009	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5409b296-3bed-47cd-abba-9fe6f6833af6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02f30d6b-0eb0-4f01-9539-6645118bc286	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37b4cfba-6673-402e-bb5a-82b4ab6ef49b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6b1bbe5-78b0-407f-b953-92a131e3a4aa	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06df17aa-6831-498c-9c28-37502a1f3260	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fda0739d-b355-478c-acae-8f773a3ec4b3	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=efd9eda5-f497-45a3-ae13-dee729add999	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d3d4ee8-5657-4b7c-9478-8b29c13a8c9e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dacd31a3-d6df-4b00-b23c-8da4a17eebf0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=790129ef-6a1b-45cb-8b02-25fa8a40c2ba	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2275ed71-a964-42b0-b9cb-46ab88da8687	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=759d754e-48eb-4e37-a28a-9b79ac20416b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11bde4d6-fb19-4783-8664-c0d116ddd2d1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f173ff13-7417-415b-8725-3c2f2dd3e5b5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc7d39d7-e006-4ed6-a31c-827452603002	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4ab4f05-1c18-442a-8618-c2c92e589703	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c1ecc118-b372-40c6-819e-56092cafe595	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4336a551-afff-4d92-b05b-2a8e2000feef	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01139e81-a4fa-4e13-acdf-c75c79a1aa9c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0478c750-ad55-42e6-adf5-a88aad78c055	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=767c1e67-4cfb-4358-a963-3d58122c8e83	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=999aefc6-8842-4a02-a5bb-6601fe8db6e6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7cafaf24-3f61-45ac-82db-025616171759	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b52e2905-f906-4c46-bb24-2c7754c5d75b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a542f10-2d9f-44a2-ad71-12032c99e225	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42881d5b-7e35-496e-aeeb-8da760d4267c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=353a319e-2d1b-4bb6-8e3f-fc74d5b78523	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c0ff5b6-de91-4c37-bd8f-a9b1341ebc96	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd6f9f66-148a-4ecc-9fb9-a58e2b6fbc79	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9abf41f1-66f9-4be4-a6d7-6c9aa0d5d387	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=180ee374-24f2-4b9c-9d54-8815f2b1dc9b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=003dd1ec-16f8-4f96-b6a8-c4689d35892a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b55da654-3c8e-4670-a503-e98e1d67d204	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e83de08-b0f6-492a-a2db-e8d33a7a28aa	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3357a72-a68f-4ee5-be56-03f1dd8bef83	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24e90827-104e-436c-81ac-78d3758e5723	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abd6a2ca-40c2-485c-bc53-db1c652505ed	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44e5ad27-e062-461a-bdf4-192d852fbc49	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51e87d92-0c8a-46fa-a2d6-a8abf555201f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f7c5855-aa5a-4535-8b37-cf97e09ed883	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f699d501-3f23-4261-904a-4877ba200c38	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f4703c0-0b9e-41a0-8b70-da26683d9ed2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c83b8444-0558-44e5-8701-9919848072be	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f573c43b-2dc7-4f0a-a54a-d60a5fe76458	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8157ca93-d926-4264-b606-f73b2b38842a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abee4a34-89cc-d886-192c-32582ab8f024	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff042130-c43a-4281-a731-809a54a1a7f1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3d9dd95-d250-4201-8e95-466fd321c37e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4b30c56-7403-4f69-9a8e-3d82a37e8bc5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6f298ba-2d7e-4a3c-9edb-8b60aba716d6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=273c6f4d-604f-4797-8961-c5f918542e3a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3518853a-4c5b-4161-a178-8da7f656f009	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8373e558-b5a6-4389-b5e1-f8f20ec32651	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f568859-64e6-454f-801b-c0a0a647dc3d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bac4ec4-9542-4927-8121-a7cd1858075b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cec7a02-b7a5-49e1-ab64-3a4dab4149d2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9d9d64a-3a3c-44ad-b40d-02789f29eb04	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3201369-1c77-4a05-bbd0-0dd333305ace	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=062bf1a0-9a29-4dee-a8cb-f0d051f4c0b1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fe3b576-567d-4589-9d4c-620b834b8746	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f9c46a7-3833-44c8-9a15-5bed7d2008ba	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3294d91-4aa9-4a94-be6a-28ccf2d74326	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ee23c50-1183-414f-bb20-6285b04884e9	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2224a34b-b24f-4c23-a1b3-fdb148fc773b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d233a645-805b-45be-ae20-534367bc15ff	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48072673-1f7f-4fa8-aebb-00b4dba4a0ae	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=551c5efd-9e40-4015-92f8-6fbb229b548e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c75cd90-7dac-4876-bfbd-50d842176475	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2784f6dd-9115-4def-ad94-7141dbb6f738	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7aaf923d-5b82-4a85-bb10-5850087da487	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e062d365-fda8-4c9e-b4b8-3d273153c50c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d14c6b5-a70a-477f-b332-fa5b93a6296f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c32059ed-73cd-4a2c-9690-276e7068041e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a27c8d30-fa25-4927-86fd-fdcfec8fd03a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2829814d-739d-4ff4-9371-bee70bf32248	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5859daf-d6e1-4f8f-a246-5282b81be78d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3911a46c-80fe-4b70-a4ba-416de597481b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59464d24-16e5-42d3-acd4-6f3b2f4e3bf6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4be76756-4114-4d50-a36c-fd410f6c773d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a74239bf-4684-424c-ba4e-6087e363265b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bef1a169-9186-43e9-b673-64fdb658984f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61837ac5-0a0b-4ea9-b71c-d4c753294ed6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fdb1322-d867-4182-b7d5-30c2a27893f0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e04b0eb9-83b5-4b33-a1e7-1c1e84f0c897	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8fcacc3f-80a8-4a2a-bccb-c1edb2e2764d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc285a1f-9b43-4bdf-8679-44e25654b84c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc73172f-a915-4ac4-a033-0de2a0223dc6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=213502a2-f667-4da6-a4b9-462eb303c401	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac0dd8fb-ebe1-4d02-bd0d-4f979c6e3608	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0141c088-8fc2-4041-880e-a79ce0de6fdd	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47114f60-4151-43d4-ac2d-adc49492a679	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=090f3e51-8129-4b5d-97f9-ab410e14df2d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	coronary artery disease	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=638f6fc5-3374-477b-84de-63f93b8e1942	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fda0739d-b355-478c-acae-8f773a3ec4b3	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a27c8d30-fa25-4927-86fd-fdcfec8fd03a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9abf41f1-66f9-4be4-a6d7-6c9aa0d5d387	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cec7a02-b7a5-49e1-ab64-3a4dab4149d2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff042130-c43a-4281-a731-809a54a1a7f1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5859daf-d6e1-4f8f-a246-5282b81be78d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e04b0eb9-83b5-4b33-a1e7-1c1e84f0c897	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d14c6b5-a70a-477f-b332-fa5b93a6296f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2829814d-739d-4ff4-9371-bee70bf32248	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01139e81-a4fa-4e13-acdf-c75c79a1aa9c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2275ed71-a964-42b0-b9cb-46ab88da8687	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5409b296-3bed-47cd-abba-9fe6f6833af6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e698930-5c05-421f-a408-2a2fbfff0948	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc7d39d7-e006-4ed6-a31c-827452603002	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3294d91-4aa9-4a94-be6a-28ccf2d74326	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=873b5b9a-b198-46f7-abe0-898ad0809b47	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=003dd1ec-16f8-4f96-b6a8-c4689d35892a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8373e558-b5a6-4389-b5e1-f8f20ec32651	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8157ca93-d926-4264-b606-f73b2b38842a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d8304ba-1f38-428c-afc6-63a132e559ca	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fe3b576-567d-4589-9d4c-620b834b8746	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7aaf923d-5b82-4a85-bb10-5850087da487	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=759d754e-48eb-4e37-a28a-9b79ac20416b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c32059ed-73cd-4a2c-9690-276e7068041e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41ceef84-9aae-4d7c-ba50-06beb85c415d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dacd31a3-d6df-4b00-b23c-8da4a17eebf0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9d9d64a-3a3c-44ad-b40d-02789f29eb04	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb5e7668-0ce4-4276-8416-0c313b59bb73	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cacb3551-c579-41cb-bed6-4b4d8b0644fc	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06df17aa-6831-498c-9c28-37502a1f3260	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac0dd8fb-ebe1-4d02-bd0d-4f979c6e3608	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3201369-1c77-4a05-bbd0-0dd333305ace	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c83b8444-0558-44e5-8701-9919848072be	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=551c5efd-9e40-4015-92f8-6fbb229b548e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02f30d6b-0eb0-4f01-9539-6645118bc286	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b52e2905-f906-4c46-bb24-2c7754c5d75b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d3d4ee8-5657-4b7c-9478-8b29c13a8c9e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47114f60-4151-43d4-ac2d-adc49492a679	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=999aefc6-8842-4a02-a5bb-6601fe8db6e6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ee23c50-1183-414f-bb20-6285b04884e9	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	angina pectoris	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f4703c0-0b9e-41a0-8b70-da26683d9ed2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f48911e0-705f-11dc-afc9-0002a5d5c51b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5562b3f5-8757-11de-8a39-0800200c9a66	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01139e81-a4fa-4e13-acdf-c75c79a1aa9c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	heart failure	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c83b8444-0558-44e5-8701-9919848072be	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4	Completed	20/02/2017	https://clinicaltrials.gov/study/NCT02774460	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6bb6b9a0-8de1-47cc-8534-7d1852d4243b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b52e2905-f906-4c46-bb24-2c7754c5d75b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4	Terminated	01/12/2016	https://clinicaltrials.gov/study/NCT02940548	1	LoF	protect	The patient recruitment and follow-ups were influenced with the pandemic of COVID-19
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08b1aa59-7892-451a-ad74-0388632e8235	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48072673-1f7f-4fa8-aebb-00b4dba4a0ae	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59464d24-16e5-42d3-acd4-6f3b2f4e3bf6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bd2b07b-0da6-47a2-858b-e18851d566fb	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11bde4d6-fb19-4783-8664-c0d116ddd2d1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=213502a2-f667-4da6-a4b9-462eb303c401	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=627146d8-fa8e-4c8b-b703-29ee080a6d5b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51e87d92-0c8a-46fa-a2d6-a8abf555201f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a97fefa6-99e6-4eb7-9393-ab2252a2c7d8	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe4734a2-6219-8bf5-9c3a-d392910db4dc	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=790129ef-6a1b-45cb-8b02-25fa8a40c2ba	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f173ff13-7417-415b-8725-3c2f2dd3e5b5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c75cd90-7dac-4876-bfbd-50d842176475	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e062d365-fda8-4c9e-b4b8-3d273153c50c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8fcacc3f-80a8-4a2a-bccb-c1edb2e2764d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15416229-d7d3-5bfb-a373-71575c36d5cf	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=224e9b5b-fa1f-452d-8ce7-d630b18f967f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fdb1322-d867-4182-b7d5-30c2a27893f0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3bb9dd10-e07c-4433-b6a7-c1c6fc4f05a7	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4	Withdrawn	12/07/2022	https://clinicaltrials.gov/study/NCT05275907	1	LoF	protect	Screened participants did not meet inclusion criteria prior to study completion date
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c95fe9f4-fb64-41b1-a61f-85b102d09929	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4	Not yet recruiting	30/06/2024	https://clinicaltrials.gov/study/NCT04974151	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=003dd1ec-16f8-4f96-b6a8-c4689d35892a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0141c088-8fc2-4041-880e-a79ce0de6fdd	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fda0739d-b355-478c-acae-8f773a3ec4b3	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43464a6b-a3b8-445b-b020-cf60f0b5e8a4	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=759d754e-48eb-4e37-a28a-9b79ac20416b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=831c406d-1ba2-48f5-84ed-7d96b290cc18	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5409b296-3bed-47cd-abba-9fe6f6833af6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df8e23c8-6c8f-4293-8a37-5ad3d48dba94	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=653623d7-ed10-4505-a32d-6360d3be8b3d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00136851	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a10fa641-ac6b-466d-bcba-31c678a74be8	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=062bf1a0-9a29-4dee-a8cb-f0d051f4c0b1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc0fa546-063a-434f-b8c0-bfca5b34462c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02209439-fe92-42de-81e3-51a8288debc0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8373e558-b5a6-4389-b5e1-f8f20ec32651	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d6d859b-e0c2-46f7-9bf5-f430d28ea12e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44e5ad27-e062-461a-bdf4-192d852fbc49	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=178f8088-43ef-4e2c-a108-d86cd43df1ae	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=680209f4-ad4c-4f97-8b6b-04f648bfb97c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4b30c56-7403-4f69-9a8e-3d82a37e8bc5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6b1bbe5-78b0-407f-b953-92a131e3a4aa	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bef1a169-9186-43e9-b673-64fdb658984f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b55da654-3c8e-4670-a503-e98e1d67d204	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c32059ed-73cd-4a2c-9690-276e7068041e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=353a319e-2d1b-4bb6-8e3f-fc74d5b78523	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78a3bdb0-c945-45cf-b75d-066dbf1d152c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=782bcaf4-0aa4-4527-b36f-d350ceb95637	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=767c1e67-4cfb-4358-a963-3d58122c8e83	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c0eb8b2-3fe4-4df4-b21a-09b18a652860	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5562b3f5-8757-11de-8a39-0800200c9a66	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4336a551-afff-4d92-b05b-2a8e2000feef	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01101009	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b5efcb5-7f6c-4264-8623-8ce100889c2c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=edf9b22c-e37e-4b4e-8a64-20bb036c7d2d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3d9dd95-d250-4201-8e95-466fd321c37e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=563eff16-a16f-470c-94ca-08877e4d42f7	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7545204-1357-4543-aa05-c01fc890bc24	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dacd31a3-d6df-4b00-b23c-8da4a17eebf0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15f7cde7-8dc2-4b07-83a9-9b86d6ec7f43	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=638f6fc5-3374-477b-84de-63f93b8e1942	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37b4cfba-6673-402e-bb5a-82b4ab6ef49b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=273c6f4d-604f-4797-8961-c5f918542e3a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b294ae51-53a3-4a58-9c30-3e8268cc8536	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c20ce12-06d3-4060-9936-ea847a525053	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d3d4ee8-5657-4b7c-9478-8b29c13a8c9e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35bf4392-eb96-4091-b7e9-50c1f2e52467	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00421863	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d8304ba-1f38-428c-afc6-63a132e559ca	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18d7820d-471f-4ee2-9ec6-25d8d27c77de	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=241e7477-ecae-4f84-8410-bbfaa9f57ed0	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=873b5b9a-b198-46f7-abe0-898ad0809b47	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00289406	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6f37813-40bb-4fe8-99e2-ad2339b8e04a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a5c7e83-3b17-4412-89fb-ff2235cbe77c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ee23c50-1183-414f-bb20-6285b04884e9	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c83b8444-0558-44e5-8701-9919848072be	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc73172f-a915-4ac4-a033-0de2a0223dc6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3201369-1c77-4a05-bbd0-0dd333305ace	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=871e47cb-a828-9ba7-e053-2991aa0a96ea	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e4682a6e-9624-48b0-978f-95da00cfb78f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3357a72-a68f-4ee5-be56-03f1dd8bef83	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e04b0eb9-83b5-4b33-a1e7-1c1e84f0c897	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=180506ee-0d90-4399-bc7b-fb1489951551	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fe3b576-567d-4589-9d4c-620b834b8746	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7378a01-f825-4905-9134-6ff13cac10c9	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9d9d64a-3a3c-44ad-b40d-02789f29eb04	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39e3f327-faab-4f1c-b6a6-f7116bb902b5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6f298ba-2d7e-4a3c-9edb-8b60aba716d6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c0ff5b6-de91-4c37-bd8f-a9b1341ebc96	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d0c2df4-e9db-4622-95e8-33aa8a08f593	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cec7a02-b7a5-49e1-ab64-3a4dab4149d2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3911a46c-80fe-4b70-a4ba-416de597481b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abd6a2ca-40c2-485c-bc53-db1c652505ed	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f568859-64e6-454f-801b-c0a0a647dc3d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abee4a34-89cc-d886-192c-32582ab8f024	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98c34c61-4965-427e-8eea-42f8a15dd79d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc285a1f-9b43-4bdf-8679-44e25654b84c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8157ca93-d926-4264-b606-f73b2b38842a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42881d5b-7e35-496e-aeeb-8da760d4267c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d14c6b5-a70a-477f-b332-fa5b93a6296f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f7c5855-aa5a-4535-8b37-cf97e09ed883	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15ba7c1c-dd10-4d09-b6e2-284c1b67f4da	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa7e7d95-520a-461c-b1b3-e588aeb6a613	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc7d39d7-e006-4ed6-a31c-827452603002	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff042130-c43a-4281-a731-809a54a1a7f1	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e11652b8-6ce6-4366-9519-a43a0d36f235	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd6f9f66-148a-4ecc-9fb9-a58e2b6fbc79	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e698930-5c05-421f-a408-2a2fbfff0948	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac0dd8fb-ebe1-4d02-bd0d-4f979c6e3608	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	3	Completed	26/06/2014	https://clinicaltrials.gov/study/NCT02172040	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2224a34b-b24f-4c23-a1b3-fdb148fc773b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7cafaf24-3f61-45ac-82db-025616171759	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41ceef84-9aae-4d7c-ba50-06beb85c415d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=999aefc6-8842-4a02-a5bb-6601fe8db6e6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3817371-3b20-4437-8fdb-8e3dd95863ea	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02353806	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47114f60-4151-43d4-ac2d-adc49492a679	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd3f7aa4-4b0a-464f-920e-7285acebc6ea	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06df17aa-6831-498c-9c28-37502a1f3260	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e59a70d3-d9f2-43ea-92e7-271a2b2d4b1a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb2e6030-c1f4-44bb-9279-3c7368785009	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4	Unknown status	01/09/2017	https://clinicaltrials.gov/study/NCT03294070	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7aaf923d-5b82-4a85-bb10-5850087da487	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17261391-6671-4462-93da-24dd36d4af96	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02f30d6b-0eb0-4f01-9539-6645118bc286	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT01518855	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94ae6054-b7ae-4212-a567-4f803af8f2c7	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c1ecc118-b372-40c6-819e-56092cafe595	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=630a292e-ec00-48f1-8aa8-00fbd176b187	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	3	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01302691	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=776a1619-c3af-65ff-a5ad-2cd807656205	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd311bf0-c5c8-4f0b-9f8f-e855bb32a71e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2829814d-739d-4ff4-9371-bee70bf32248	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2784f6dd-9115-4def-ad94-7141dbb6f738	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb5e7668-0ce4-4276-8416-0c313b59bb73	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=efd9eda5-f497-45a3-ae13-dee729add999	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2275ed71-a964-42b0-b9cb-46ab88da8687	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4da56a43-99aa-46df-aafc-ea193c46e442	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca014f06-982c-6fe1-9948-a3701dd35d34	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3294d91-4aa9-4a94-be6a-28ccf2d74326	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca60a4d5-ace7-4889-94ee-e2265fd63811	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cb15b9d-1c45-4491-bfcc-a902a491b288	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e83de08-b0f6-492a-a2db-e8d33a7a28aa	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=551c5efd-9e40-4015-92f8-6fbb229b548e	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f40161f0-7b9e-4131-92d6-893cb9473e71	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=968c611b-43a7-40f0-9ed3-aa67ee88364b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eaa2bbbc-5fcc-4f15-a51c-c4e1bf320c90	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f4703c0-0b9e-41a0-8b70-da26683d9ed2	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f48911e0-705f-11dc-afc9-0002a5d5c51b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4ab4f05-1c18-442a-8618-c2c92e589703	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01139e81-a4fa-4e13-acdf-c75c79a1aa9c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9abf41f1-66f9-4be4-a6d7-6c9aa0d5d387	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18686fa-be94-472e-8404-c69e6869ed10	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f573c43b-2dc7-4f0a-a54a-d60a5fe76458	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f9c46a7-3833-44c8-9a15-5bed7d2008ba	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b00570ff-4081-4514-b45b-eb6f753450f5	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48622cd3-1e25-4b08-b5bc-f2552e436d1f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d84c3fd-697f-4bc2-aa18-d7a9adcc9ca8	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4653cabc-f249-4b4e-95b6-5fb4ddc0ad5d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99ed4927-9a34-4e8d-8eea-60b63c867d46	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4be76756-4114-4d50-a36c-fd410f6c773d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=254b2202-b14d-9279-8311-cabcb0e75fc8	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98cc3e47-3463-4162-96ac-bf97d77eb041	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56831e08-1445-4798-b661-0a780349085a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fabb27ef-aba2-c76a-cf6b-beb8826fd381	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bac4ec4-9542-4927-8121-a7cd1858075b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02294539	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35086164-bf92-4b3c-9845-f8cd7464c7d6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=090f3e51-8129-4b5d-97f9-ab410e14df2d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f12f18bb-7ddb-e7dc-4edd-32f4ac212bca	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0478c750-ad55-42e6-adf5-a88aad78c055	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4	Not yet recruiting	30/06/2024	https://clinicaltrials.gov/study/NCT04974138	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cacb3551-c579-41cb-bed6-4b4d8b0644fc	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3518853a-4c5b-4161-a178-8da7f656f009	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1dd4f8bf-51cc-468f-a1cb-2427a8c71ad7	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00931710	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f699d501-3f23-4261-904a-4877ba200c38	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5859daf-d6e1-4f8f-a246-5282b81be78d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61837ac5-0a0b-4ea9-b71c-d4c753294ed6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=992fd3c4-ce10-4653-9c32-451209422510	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a542f10-2d9f-44a2-ad71-12032c99e225	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5402d355-caff-f5e7-4cb4-7e61c57bf39d	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24e90827-104e-436c-81ac-78d3758e5723	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d233a645-805b-45be-ae20-534367bc15ff	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=180ee374-24f2-4b9c-9d54-8815f2b1dc9b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a27c8d30-fa25-4927-86fd-fdcfec8fd03a	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a74239bf-4684-424c-ba4e-6087e363265b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f33bb26-7a40-4cdb-bb50-35efdeeaa810	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	congestive heart failure	DOBUTAMINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0dd68b3-20af-464d-b3ba-34eb886df6ae	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	left ventricular hypertrophy	PARICALCITOL	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00497146	0.7	GoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	hypertension	SEVOFLURANE	targetBased	4	Unknown status	01/07/2012	https://clinicaltrials.gov/study/NCT01715584	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	aneurysm	SEVOFLURANE	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00538421	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	myocardial infarction	SEVOFLURANE	targetBased	4	Terminated	01/02/2016	https://clinicaltrials.gov/study/NCT02671084	0.5		protect	interim analysis suggests futility
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	hypertension	SEVOFLURANE	targetBased	4	Unknown status	01/07/2012	https://clinicaltrials.gov/study/NCT01715584	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	coronary artery disease	SEVOFLURANE	targetBased	4	Recruiting	20/11/2019	https://clinicaltrials.gov/study/NCT04039854	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	coronary artery disease	SEVOFLURANE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00477737	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	coronary artery disease	SEVOFLURANE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01120405	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	coronary artery disease	SEVOFLURANE	targetBased	3	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01285271	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	coronary artery disease	SEVOFLURANE	targetBased	3	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01285271	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	coronary artery disease	SEVOFLURANE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00477737	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	coronary artery disease	SEVOFLURANE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01120405	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	coronary artery disease	SEVOFLURANE	targetBased	4	Recruiting	20/11/2019	https://clinicaltrials.gov/study/NCT04039854	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	congenital heart disease	SEVOFLURANE	targetBased	4	Unknown status	20/08/2018	https://clinicaltrials.gov/study/NCT03630796	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	congenital heart disease	SEVOFLURANE	targetBased	4	Completed	01/01/2020	https://clinicaltrials.gov/study/NCT04125550	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	heart disease	SEVOFLURANE	targetBased	4	Terminated	01/05/2012	https://clinicaltrials.gov/study/NCT02664922	1		protect	Poor study design and too many study groups.
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	aneurysm	SEVOFLURANE	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00538421	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	myocardial infarction	SEVOFLURANE	targetBased	4	Terminated	01/02/2016	https://clinicaltrials.gov/study/NCT02671084	0.5		protect	interim analysis suggests futility
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	hypotension	SEVOFLURANE	targetBased	4	Terminated	01/05/2009	https://clinicaltrials.gov/study/NCT00922844	1		protect	too slow recruitment; lack of funding
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	hypotension	SEVOFLURANE	targetBased	4	Unknown status	23/07/2018	https://clinicaltrials.gov/study/NCT03595319	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	congenital heart disease	SEVOFLURANE	targetBased	4	Completed	01/01/2020	https://clinicaltrials.gov/study/NCT04125550	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	congenital heart disease	SEVOFLURANE	targetBased	4	Unknown status	20/08/2018	https://clinicaltrials.gov/study/NCT03630796	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	heart disease	SEVOFLURANE	targetBased	4	Terminated	01/05/2012	https://clinicaltrials.gov/study/NCT02664922	1		protect	Poor study design and too many study groups.
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	sudden cardiac arrest	SEVOFLURANE	targetBased	4	Withdrawn	01/05/2015	https://clinicaltrials.gov/study/NCT04287842	1		protect	technical problem
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	hypotension	SEVOFLURANE	targetBased	4	Terminated	01/05/2009	https://clinicaltrials.gov/study/NCT00922844	1		protect	too slow recruitment; lack of funding
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	hypotension	SEVOFLURANE	targetBased	4	Unknown status	23/07/2018	https://clinicaltrials.gov/study/NCT03595319	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	sudden cardiac arrest	SEVOFLURANE	targetBased	4	Withdrawn	01/05/2015	https://clinicaltrials.gov/study/NCT04287842	1		protect	technical problem
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	aortic stenosis	DESFLURANE	targetBased	4	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT02019797	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	coronary artery disease	DESFLURANE	targetBased	4	Recruiting	20/11/2019	https://clinicaltrials.gov/study/NCT04039854	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	coronary artery disease	DESFLURANE	targetBased	4	Recruiting	20/11/2019	https://clinicaltrials.gov/study/NCT04039854	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	aortic stenosis	DESFLURANE	targetBased	4	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT02019797	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	sudden cardiac arrest	DESFLURANE	targetBased	4	Withdrawn	01/05/2015	https://clinicaltrials.gov/study/NCT04287842	1		protect	technical problem
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	sudden cardiac arrest	DESFLURANE	targetBased	4	Withdrawn	01/05/2015	https://clinicaltrials.gov/study/NCT04287842	1		protect	technical problem
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	AMLODIPINE MALEATE	targetBased	4	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01131546	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	coronary artery disease	GLYCOPYRROLATE	targetBased	4	Completed	01/05/2019	https://clinicaltrials.gov/study/NCT03939923	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	coronary artery disease	GLYCOPYRROLATE	targetBased	4	Completed	01/05/2019	https://clinicaltrials.gov/study/NCT03939923	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	coronary artery disease	GLYCOPYRROLATE	targetBased	4	Completed	01/05/2019	https://clinicaltrials.gov/study/NCT03939923	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	coronary artery disease	GLYCOPYRROLATE	targetBased	4	Completed	01/05/2019	https://clinicaltrials.gov/study/NCT03939923	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	coronary artery disease	GLYCOPYRROLATE	targetBased	4	Completed	01/05/2019	https://clinicaltrials.gov/study/NCT03939923	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	hypotension	GLYCOPYRROLATE	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT04401345	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	hypotension	GLYCOPYRROLATE	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT04401345	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	hypotension	GLYCOPYRROLATE	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT04401345	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	hypotension	GLYCOPYRROLATE	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT04401345	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	hypotension	GLYCOPYRROLATE	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT04401345	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	heart failure	PROPAFENONE HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Ventricular arrhythmia	PROPAFENONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a313c111-e539-47bc-9d57-c3767f74bcca	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	PROPAFENONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e4412a6a-ed4d-410d-8abb-86e1d7b72a3c	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	PROPAFENONE HYDROCHLORIDE	targetBased	3	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00589303	0.7	LoF	protect	Lack of funding
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	PROPAFENONE HYDROCHLORIDE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00523978	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atrial fibrillation	PROPAFENONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bb1bc4a-a019-49c8-af81-be899822428f	1	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	heart failure	CONIVAPTAN HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5150d9d9-01dc-4a52-9858-214c66d8caea	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	ESMOLOL HYDROCHLORIDE	targetBased	4	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02967029	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	ESMOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9a3e69ab-3ffe-33af-e053-2a95a90a6524	1	LoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	congenital heart disease	LIOTHYRONINE SODIUM	targetBased	3	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02320669	0.7	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	Abnormal cardiovascular system morphology	LIOTHYRONINE SODIUM	targetBased	3	Completed	01/04/2001	https://clinicaltrials.gov/study/NCT00027417	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hypotension	REMIFENTANIL HYDROCHLORIDE	targetBased	4	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02967029	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hypotension	REMIFENTANIL HYDROCHLORIDE	targetBased	4	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02967029	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea60885e-a8c3-4120-97dd-a59ae2251b8b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a103502-c809-41ae-93a3-f7485605d0fe	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f997a0b-a4c9-4be8-9add-8d90c1c465e5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL PHOSPHATE	targetBased	4	Completed	17/05/2017	https://clinicaltrials.gov/study/NCT03169426	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06400a4c-42b4-440a-92b4-1f47f98ac7ba	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b2638f5-8975-4259-be52-0da5c263bcc0	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	myocardial infarction	CARVEDILOL PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bbf4dd22-f1e3-4101-89fb-31f5df3bfbc4	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06400a4c-42b4-440a-92b4-1f47f98ac7ba	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f997a0b-a4c9-4be8-9add-8d90c1c465e5	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bbf4dd22-f1e3-4101-89fb-31f5df3bfbc4	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea60885e-a8c3-4120-97dd-a59ae2251b8b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b2638f5-8975-4259-be52-0da5c263bcc0	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a103502-c809-41ae-93a3-f7485605d0fe	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	CARVEDILOL PHOSPHATE	targetBased	3	Completed	05/01/2006	https://clinicaltrials.gov/study/NCT00273052	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	arteriosclerosis disorder	LISDEXAMFETAMINE DIMESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a310fc51-2743-4755-8398-fed5402283f6	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	arteriosclerosis disorder	LISDEXAMFETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a310fc51-2743-4755-8398-fed5402283f6	1		protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	MEPHENTERMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01CA11	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	coronary artery disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/05/2019	https://clinicaltrials.gov/study/NCT03939923	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	coronary artery disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/05/2019	https://clinicaltrials.gov/study/NCT03939923	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	coronary artery disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/05/2019	https://clinicaltrials.gov/study/NCT03939923	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	hypotension	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT04401345	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	hypotension	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT04401345	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	hypotension	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT04401345	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	coronary artery disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/05/2019	https://clinicaltrials.gov/study/NCT03939923	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	coronary artery disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/05/2019	https://clinicaltrials.gov/study/NCT03939923	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	coronary artery disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/05/2019	https://clinicaltrials.gov/study/NCT03939923	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	coronary artery disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/05/2019	https://clinicaltrials.gov/study/NCT03939923	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	coronary artery disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/05/2019	https://clinicaltrials.gov/study/NCT03939923	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	coronary artery disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/05/2019	https://clinicaltrials.gov/study/NCT03939923	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	coronary artery disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/05/2019	https://clinicaltrials.gov/study/NCT03939923	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	coronary artery disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/05/2019	https://clinicaltrials.gov/study/NCT03939923	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	cardiac arrhythmia	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	hypotension	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT04401345	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	hypotension	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT04401345	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	hypotension	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT04401345	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	hypotension	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT04401345	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	hypotension	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT04401345	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	hypotension	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT04401345	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	hypotension	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT04401345	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	hypotension	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT04401345	1	LoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	heart disease	NESIRITIDE	targetBased	4	Terminated	17/05/2004	https://clinicaltrials.gov/study/NCT00083772	1	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	heart failure	NESIRITIDE	targetBased	3	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00475852	0.7	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	heart failure	NESIRITIDE	targetBased	3	Terminated	01/09/2007	https://clinicaltrials.gov/study/NCT00562692	0.7	GoF	protect	Recruitment very difficult. Study drug expired so we have stopped the study.
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	heart failure	NESIRITIDE	targetBased	4	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00842023	1	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	heart failure	NESIRITIDE	targetBased	4	Terminated	17/05/2004	https://clinicaltrials.gov/study/NCT00083772	1	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	heart failure	NESIRITIDE	targetBased	3	Completed	01/01/1997	https://clinicaltrials.gov/study/NCT00271557	0.7	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	diastolic heart failure	NESIRITIDE	targetBased	4	Terminated	17/05/2004	https://clinicaltrials.gov/study/NCT00083772	1	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	acute coronary syndrome	NESIRITIDE	targetBased	3	Completed	01/10/1999	https://clinicaltrials.gov/study/NCT00270374	0.7	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	congestive heart failure	NESIRITIDE	targetBased	3	Completed	01/01/1997	https://clinicaltrials.gov/study/NCT00271557	0.7	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	congestive heart failure	NESIRITIDE	targetBased	4	Terminated	01/03/2007	https://clinicaltrials.gov/study/NCT00453453	1	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	congestive heart failure	NESIRITIDE	targetBased	3	Completed	01/10/1996	https://clinicaltrials.gov/study/NCT00288730	0.7	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	congestive heart failure	NESIRITIDE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00270361	0.7	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	congestive heart failure	NESIRITIDE	targetBased	3	Completed	01/08/1998	https://clinicaltrials.gov/study/NCT00270400	0.7	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	congestive heart failure	NESIRITIDE	targetBased	4	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00652652	1	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	congestive heart failure	NESIRITIDE	targetBased	3	Completed	01/10/1999	https://clinicaltrials.gov/study/NCT00270374	0.7	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	congestive heart failure	NESIRITIDE	targetBased	4	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00270829	1	GoF	protect	Funding not available
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	congestive heart failure	NESIRITIDE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00813202	0.7	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	congestive heart failure	NESIRITIDE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00270387	0.7	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	pulmonary hypertension	NESIRITIDE	targetBased	4	Terminated	31/12/2003	https://clinicaltrials.gov/study/NCT00075179	1	GoF	protect	Low accrual.
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	pulmonary hypertension	NESIRITIDE	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00205426	1	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	cardiovascular disease	NESIRITIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01DX19	1	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	hypertension	NESIRITIDE	targetBased	4	Active, not recruiting	15/11/2018	https://clinicaltrials.gov/study/NCT03738878	1	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	coronary artery disease	NESIRITIDE	targetBased	4	Unknown status	01/07/2005	https://clinicaltrials.gov/study/NCT00262574	1	GoF	protect
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	PLAU	Urokinase-type plasminogen activator	myocardial infarction	UROKINASE	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02131220	1		protect
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	PLAU	Urokinase-type plasminogen activator	coronary artery disease	UROKINASE	targetBased	4	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT01568931	1		protect
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	PLAU	Urokinase-type plasminogen activator	pulmonary embolism	UROKINASE	targetBased	4	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00968929	1		protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	thrombotic disease	DESIRUDIN	targetBased	4	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT00913133	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	intermediate coronary syndrome	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/07/1995	https://clinicaltrials.gov/study/NCT00000601	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	intermediate coronary syndrome	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/07/1995	https://clinicaltrials.gov/study/NCT00000601	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	intermediate coronary syndrome	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/07/1995	https://clinicaltrials.gov/study/NCT00000601	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	heart disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	heart disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	thrombotic disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	heart disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	heart disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	heart disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	heart disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	cardiovascular disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/07/1995	https://clinicaltrials.gov/study/NCT00000601	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	cardiovascular disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/07/1995	https://clinicaltrials.gov/study/NCT00000601	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	cardiovascular disease	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	cardiovascular disease	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	cardiovascular disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	cardiovascular disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	thrombotic disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	thrombotic disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1994	https://clinicaltrials.gov/study/NCT00000549	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/07/1995	https://clinicaltrials.gov/study/NCT00000601	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/07/1992	https://clinicaltrials.gov/study/NCT00319566	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1996	https://clinicaltrials.gov/study/NCT00000555	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Myocardial Ischemia	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Myocardial Ischemia	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Myocardial Ischemia	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Myocardial Ischemia	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Myocardial Ischemia	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1994	https://clinicaltrials.gov/study/NCT00000549	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Myocardial Ischemia	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1994	https://clinicaltrials.gov/study/NCT00000549	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Myocardial Ischemia	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Myocardial Ischemia	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Myocardial Ischemia	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1996	https://clinicaltrials.gov/study/NCT00000555	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Myocardial Ischemia	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1996	https://clinicaltrials.gov/study/NCT00000555	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Myocardial Ischemia	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Myocardial Ischemia	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	cardiovascular disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	cardiovascular disease	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	cardiovascular disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/07/1995	https://clinicaltrials.gov/study/NCT00000601	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypertension	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypertension	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	myocardial infarction	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Myocardial Ischemia	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1996	https://clinicaltrials.gov/study/NCT00000555	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Myocardial Ischemia	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1994	https://clinicaltrials.gov/study/NCT00000549	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Myocardial Ischemia	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Myocardial Ischemia	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Myocardial Ischemia	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Myocardial Ischemia	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	hypertension	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	myocardial infarction	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	myocardial infarction	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/07/1992	https://clinicaltrials.gov/study/NCT00319566	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/07/1992	https://clinicaltrials.gov/study/NCT00319566	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1996	https://clinicaltrials.gov/study/NCT00000555	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1996	https://clinicaltrials.gov/study/NCT00000555	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1994	https://clinicaltrials.gov/study/NCT00000549	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1994	https://clinicaltrials.gov/study/NCT00000549	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/07/1995	https://clinicaltrials.gov/study/NCT00000601	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	coronary artery disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/07/1995	https://clinicaltrials.gov/study/NCT00000601	0.7	GoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	KCNJ2	Inward rectifier potassium channel 2	atrial fibrillation	DRONEDARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=236d4549-f44b-4677-b857-acedd10b9920	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	atrial fibrillation	DRONEDARONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=236d4549-f44b-4677-b857-acedd10b9920	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=673f5ad2-c09b-4a89-9407-efdadd007917	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=895cb85a-5ec8-4070-babf-d1325c028677	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb47560d-9e35-4b0f-b12b-6ea478684a5b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertension	NEBIVOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b8ad213-1dc8-454e-a524-075685c0e1a8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ST Elevation Myocardial Infarction	METHYLNALTREXONE BROMIDE	targetBased	4	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02942550	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ST Elevation Myocardial Infarction	METHYLNALTREXONE BROMIDE	targetBased	4	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02942550	1	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	pericarditis	RILONACEPT	pathwayBased	3	Completed	07/01/2019	https://clinicaltrials.gov/study/NCT03737110	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	pericarditis	RILONACEPT	pathwayBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=282f4099-e848-432a-bac1-e041c192a5ba	1	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	atherosclerosis	CANAKINUMAB	pathwayBased	3	Completed	11/04/2011	https://clinicaltrials.gov/study/NCT01327846	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	CLEVIDIPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08CA16	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	malignant hypertension	CLEVIDIPINE	targetBased	3	Recruiting	27/07/2020	https://clinicaltrials.gov/study/NCT04670809	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	malignant hypertension	CLEVIDIPINE	targetBased	3	Not yet recruiting	01/05/2023	https://clinicaltrials.gov/study/NCT05783557	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	malignant hypertension	CLEVIDIPINE	targetBased	3	Not yet recruiting	11/10/2021	https://clinicaltrials.gov/study/NCT05044364	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	aortic aneurysm	CLEVIDIPINE	targetBased	4	Terminated	01/11/2009	https://clinicaltrials.gov/study/NCT01033370	1	LoF	protect	Project lacked funding.
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	CLEVIDIPINE	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00093262	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	CLEVIDIPINE	targetBased	4	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT06063772	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	CLEVIDIPINE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00093912	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	CLEVIDIPINE	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00093886	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	CLEVIDIPINE	targetBased	4	Withdrawn	01/04/2010	https://clinicaltrials.gov/study/NCT01910532	1	LoF	protect	Sponsor discontinued the research
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	CLEVIDIPINE	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00093249	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	CLEVIDIPINE	targetBased	4	Withdrawn	01/11/2011	https://clinicaltrials.gov/study/NCT01526876	1	LoF	protect	Terminated by Sponsor
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	CLEVIDIPINE	targetBased	3	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00093925	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	CLEVIDIPINE	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00369837	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AZELNIDIPINE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00607035	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	ventricular tachycardia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	ventricular tachycardia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ventricular tachycardia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	cardiac arrhythmia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	cardiac arrhythmia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cardiac arrhythmia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cardiac arrhythmia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cardiac arrhythmia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cardiac arrhythmia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	cardiac arrhythmia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	acute hypotension	NOREPINEPHRINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=256264b1-ddf6-42b7-8a09-194fffea65e2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98531820-a85c-4ee7-9338-2be264219afe	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=25828db2-4942-4f7c-a0d5-dc66f82cfb71	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78c1daef-6e1e-5f2c-e053-2a91aa0a0dba	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1323592-dc57-4c9d-b84d-442648a7b114	1	GoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	venous thromboembolism	DABIGATRAN ETEXILATE MESYLATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	pulmonary embolism	DABIGATRAN ETEXILATE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	pulmonary embolism	DABIGATRAN ETEXILATE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5db7f199-8752-4d24-85f7-e34ca8f4d02e	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN ETEXILATE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN ETEXILATE MESYLATE	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01896297	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN ETEXILATE MESYLATE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01493557	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	atrial fibrillation	DABIGATRAN ETEXILATE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5db7f199-8752-4d24-85f7-e34ca8f4d02e	1	LoF	protect
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	NFE2L2	Nuclear factor erythroid 2-related factor 2	pulmonary hypertension	BARDOXOLONE METHYL	targetBased	3	Terminated	18/04/2017	https://clinicaltrials.gov/study/NCT03068130	0.7	LoF	protect	The company determined that continued exposure of these high-risk PH patients to clinic or in-person visits during the COVID pandemic presented an unacceptable risk.
qHTS of Nrf2 Activators	Nrf2 activators	NFE2L2	NFE2 like bZIP transcription factor 2, Nuclear factor erythroid 2-related factor 2	pulmonary hypertension	BARDOXOLONE METHYL	pathwayBased	3	Terminated	18/04/2017	https://clinicaltrials.gov/study/NCT03068130	0.7	LoF	protect	The company determined that continued exposure of these high-risk PH patients to clinic or in-person visits during the COVID pandemic presented an unacceptable risk.
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	pulmonary hypertension	BARDOXOLONE METHYL	targetBased	3	Terminated	18/04/2017	https://clinicaltrials.gov/study/NCT03068130	0.7	LoF	protect	The company determined that continued exposure of these high-risk PH patients to clinic or in-person visits during the COVID pandemic presented an unacceptable risk.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	pulmonary hypertension	BARDOXOLONE METHYL	targetBased	3	Terminated	18/04/2017	https://clinicaltrials.gov/study/NCT03068130	0.7	LoF	protect	The company determined that continued exposure of these high-risk PH patients to clinic or in-person visits during the COVID pandemic presented an unacceptable risk.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	pulmonary hypertension	BARDOXOLONE METHYL	targetBased	3	Terminated	18/04/2017	https://clinicaltrials.gov/study/NCT03068130	0.7	LoF	protect	The company determined that continued exposure of these high-risk PH patients to clinic or in-person visits during the COVID pandemic presented an unacceptable risk.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	pulmonary hypertension	BARDOXOLONE METHYL	targetBased	3	Terminated	18/04/2017	https://clinicaltrials.gov/study/NCT03068130	0.7	LoF	protect	The company determined that continued exposure of these high-risk PH patients to clinic or in-person visits during the COVID pandemic presented an unacceptable risk.
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	pulmonary hypertension	BARDOXOLONE METHYL	targetBased	3	Terminated	18/04/2017	https://clinicaltrials.gov/study/NCT03068130	0.7	LoF	protect	The company determined that continued exposure of these high-risk PH patients to clinic or in-person visits during the COVID pandemic presented an unacceptable risk.
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	pulmonary hypertension	BARDOXOLONE METHYL	targetBased	3	Terminated	18/04/2017	https://clinicaltrials.gov/study/NCT03068130	0.7	LoF	protect	The company determined that continued exposure of these high-risk PH patients to clinic or in-person visits during the COVID pandemic presented an unacceptable risk.
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	pulmonary hypertension	BARDOXOLONE METHYL	targetBased	3	Terminated	18/04/2017	https://clinicaltrials.gov/study/NCT03068130	0.7	LoF	protect	The company determined that continued exposure of these high-risk PH patients to clinic or in-person visits during the COVID pandemic presented an unacceptable risk.
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	coronary artery disease	LEVOSIMENDAN	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01318460	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	coronary artery disease	LEVOSIMENDAN	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01318460	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	3	Unknown status	01/08/2009	https://clinicaltrials.gov/study/NCT01065194	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	3	Unknown status	01/08/2009	https://clinicaltrials.gov/study/NCT01065194	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT00994825	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT00994825	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	4	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT02261948	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	4	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT02261948	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	4	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00219388	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	4	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00219388	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	4	Recruiting	01/08/2019	https://clinicaltrials.gov/study/NCT03576677	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	4	Recruiting	01/08/2019	https://clinicaltrials.gov/study/NCT03576677	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	4	Recruiting	29/10/2020	https://clinicaltrials.gov/study/NCT04950569	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	4	Recruiting	29/10/2020	https://clinicaltrials.gov/study/NCT04950569	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00348504	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00348504	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00154115	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00154115	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02025621	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02025621	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	3	Terminated	01/02/2011	https://clinicaltrials.gov/study/NCT01290146	0.7	GoF	protect	Due to lack of enrollment
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	3	Terminated	01/02/2011	https://clinicaltrials.gov/study/NCT01290146	0.7	GoF	protect	Due to lack of enrollment
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01536132	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01536132	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	3	Recruiting	24/02/2020	https://clinicaltrials.gov/study/NCT04158674	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	3	Recruiting	24/02/2020	https://clinicaltrials.gov/study/NCT04158674	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	3	Unknown status	08/03/2018	https://clinicaltrials.gov/study/NCT03437226	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	3	Unknown status	08/03/2018	https://clinicaltrials.gov/study/NCT03437226	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	3	Recruiting	11/01/2019	https://clinicaltrials.gov/study/NCT03555123	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	3	Recruiting	11/01/2019	https://clinicaltrials.gov/study/NCT03555123	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00166127	0.7	GoF	protect	Unable to renegotiate an expired contract w/sponsor providing study med
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart failure	LEVOSIMENDAN	targetBased	3	Terminated	01/05/2005	https://clinicaltrials.gov/study/NCT00166127	0.7	GoF	protect	Unable to renegotiate an expired contract w/sponsor providing study med
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	advanced heart failure	LEVOSIMENDAN	targetBased	4	Unknown status	01/11/2009	https://clinicaltrials.gov/study/NCT00988806	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	advanced heart failure	LEVOSIMENDAN	targetBased	4	Unknown status	01/11/2009	https://clinicaltrials.gov/study/NCT00988806	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	mitral valve stenosis	LEVOSIMENDAN	targetBased	4	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT01969071	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	mitral valve stenosis	LEVOSIMENDAN	targetBased	4	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT01969071	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	congestive heart failure	LEVOSIMENDAN	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00048425	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	congestive heart failure	LEVOSIMENDAN	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00048425	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	ST Elevation Myocardial Infarction	LEVOSIMENDAN	targetBased	3	Recruiting	17/11/2018	https://clinicaltrials.gov/study/NCT03699215	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	ST Elevation Myocardial Infarction	LEVOSIMENDAN	targetBased	3	Recruiting	17/11/2018	https://clinicaltrials.gov/study/NCT03699215	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	systolic heart failure	LEVOSIMENDAN	targetBased	4	Recruiting	01/08/2018	https://clinicaltrials.gov/study/NCT03764722	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	systolic heart failure	LEVOSIMENDAN	targetBased	4	Recruiting	01/08/2018	https://clinicaltrials.gov/study/NCT03764722	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	cardiovascular disease	LEVOSIMENDAN	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=C01CX08	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	cardiovascular disease	LEVOSIMENDAN	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=C01CX08	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	cardiovascular disease	LEVOSIMENDAN	targetBased	4	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02012946	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	cardiovascular disease	LEVOSIMENDAN	targetBased	4	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02012946	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart valve disease	LEVOSIMENDAN	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT01210976	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	heart valve disease	LEVOSIMENDAN	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT01210976	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	Aortic Coarctation	LEVOSIMENDAN	targetBased	4	Completed	04/02/2021	https://clinicaltrials.gov/study/NCT04330755	1	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	Aortic Coarctation	LEVOSIMENDAN	targetBased	4	Completed	04/02/2021	https://clinicaltrials.gov/study/NCT04330755	1	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	BENIDIPINE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=C08CA15	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heart disease	MORPHINE SULFATE	targetBased	4	Terminated	11/07/2016	https://clinicaltrials.gov/study/NCT02734940	1	GoF	protect	Unable to find participants who met inclusion/exclusion criteria
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heart disease	MORPHINE SULFATE	targetBased	4	Terminated	11/07/2016	https://clinicaltrials.gov/study/NCT02734940	1	GoF	protect	Unable to find participants who met inclusion/exclusion criteria
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute coronary syndrome	MORPHINE SULFATE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00718406	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute coronary syndrome	MORPHINE SULFATE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00718406	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiovascular disease	DROXIDOPA	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01CA27	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	orthostatic hypotension	DROXIDOPA	targetBased	4	Completed	11/02/2016	https://clinicaltrials.gov/study/NCT02586623	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	orthostatic hypotension	DROXIDOPA	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2179f02c-48d7-48eb-8007-5ae43d8d16bc	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	orthostatic hypotension	DROXIDOPA	targetBased	3	Terminated	01/06/2012	https://clinicaltrials.gov/study/NCT01612078	0.7	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	LERCANIDIPINE HYDROCHLORIDE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01520285	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	VERNAKALANT HYDROCHLORIDE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00125320	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	VERNAKALANT HYDROCHLORIDE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00125320	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	VERNAKALANT HYDROCHLORIDE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00125320	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	VERNAKALANT HYDROCHLORIDE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00115791	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	VERNAKALANT HYDROCHLORIDE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00115791	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	VERNAKALANT HYDROCHLORIDE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00115791	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT HYDROCHLORIDE	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01174160	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT HYDROCHLORIDE	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01174160	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT HYDROCHLORIDE	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01174160	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT HYDROCHLORIDE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00125320	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT HYDROCHLORIDE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00125320	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT HYDROCHLORIDE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00125320	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT HYDROCHLORIDE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00115791	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT HYDROCHLORIDE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00115791	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT HYDROCHLORIDE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00115791	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT HYDROCHLORIDE	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00281554	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT HYDROCHLORIDE	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00281554	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT HYDROCHLORIDE	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00281554	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess	1	LoF	protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	Ischemic stroke	PLASMINOGEN	targetBased	3	Completed	15/12/2016	https://clinicaltrials.gov/study/NCT02814409	0.7		protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	Ischemic stroke	PLASMINOGEN	targetBased	3	Completed	15/12/2016	https://clinicaltrials.gov/study/NCT02814409	0.7		protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	acute coronary syndrome	LIXISENATIDE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01147250	0.7	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	acute coronary syndrome	LIXISENATIDE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01147250	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	acute coronary syndrome	LIXISENATIDE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01147250	0.7	GoF	protect
qHTS Assay for Antagonists of the Relaxin Receptor RXFP1	relaxinInhibitors	RXFP1	Relaxin receptor 1	cardiovascular disease	SERELAXIN	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=C01DX21	0.7	GoF	protect
qHTS Assay for Antagonists of the Relaxin Receptor RXFP1Taking the negative queue for PMs	relaxin PMs	RXFP1	Relaxin receptor 1	cardiovascular disease	SERELAXIN	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=C01DX21	0.7	GoF	protect
qHTS Assay for Agonists of the Relaxin Receptor RXFP1	RXFP1	RXFP1	Relaxin receptor 1	cardiovascular disease	SERELAXIN	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=C01DX21	0.7	GoF	protect
qHTS Assay for Antagonists of the Relaxin Receptor RXFP1	relaxinInhibitors	RXFP1	Relaxin receptor 1	heart failure	SERELAXIN	targetBased	3	Completed	02/10/2013	https://clinicaltrials.gov/study/NCT01870778	0.7	GoF	protect
qHTS Assay for Antagonists of the Relaxin Receptor RXFP1Taking the negative queue for PMs	relaxin PMs	RXFP1	Relaxin receptor 1	heart failure	SERELAXIN	targetBased	3	Completed	02/10/2013	https://clinicaltrials.gov/study/NCT01870778	0.7	GoF	protect
qHTS Assay for Agonists of the Relaxin Receptor RXFP1	RXFP1	RXFP1	Relaxin receptor 1	heart failure	SERELAXIN	targetBased	3	Completed	02/10/2013	https://clinicaltrials.gov/study/NCT01870778	0.7	GoF	protect
qHTS Assay for Antagonists of the Relaxin Receptor RXFP1	relaxinInhibitors	RXFP1	Relaxin receptor 1	heart failure	SERELAXIN	targetBased	3	Terminated	31/01/2014	https://clinicaltrials.gov/study/NCT02064868	0.7	GoF	protect	Study was terminated based on results from pivotal adult AHF study CRLX030A2301
qHTS Assay for Antagonists of the Relaxin Receptor RXFP1Taking the negative queue for PMs	relaxin PMs	RXFP1	Relaxin receptor 1	heart failure	SERELAXIN	targetBased	3	Terminated	31/01/2014	https://clinicaltrials.gov/study/NCT02064868	0.7	GoF	protect	Study was terminated based on results from pivotal adult AHF study CRLX030A2301
qHTS Assay for Agonists of the Relaxin Receptor RXFP1	RXFP1	RXFP1	Relaxin receptor 1	heart failure	SERELAXIN	targetBased	3	Terminated	31/01/2014	https://clinicaltrials.gov/study/NCT02064868	0.7	GoF	protect	Study was terminated based on results from pivotal adult AHF study CRLX030A2301
qHTS Assay for Antagonists of the Relaxin Receptor RXFP1	relaxinInhibitors	RXFP1	Relaxin receptor 1	heart failure	SERELAXIN	targetBased	3	Terminated	12/03/2014	https://clinicaltrials.gov/study/NCT02007720	0.7	GoF	protect	Study was terminated based on results from pivotal adult AHF study CRLX030A2301
qHTS Assay for Antagonists of the Relaxin Receptor RXFP1Taking the negative queue for PMs	relaxin PMs	RXFP1	Relaxin receptor 1	heart failure	SERELAXIN	targetBased	3	Terminated	12/03/2014	https://clinicaltrials.gov/study/NCT02007720	0.7	GoF	protect	Study was terminated based on results from pivotal adult AHF study CRLX030A2301
qHTS Assay for Agonists of the Relaxin Receptor RXFP1	RXFP1	RXFP1	Relaxin receptor 1	heart failure	SERELAXIN	targetBased	3	Terminated	12/03/2014	https://clinicaltrials.gov/study/NCT02007720	0.7	GoF	protect	Study was terminated based on results from pivotal adult AHF study CRLX030A2301
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	cardiovascular disease	SEMAGLUTIDE	targetBased	3	Recruiting	01/03/2023	https://clinicaltrials.gov/study/NCT05669755	0.7	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	cardiovascular disease	SEMAGLUTIDE	targetBased	3	Recruiting	01/03/2023	https://clinicaltrials.gov/study/NCT05669755	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	cardiovascular disease	SEMAGLUTIDE	targetBased	3	Recruiting	01/03/2023	https://clinicaltrials.gov/study/NCT05669755	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	coronary artery disease	SEMAGLUTIDE	targetBased	3	Not yet recruiting	01/11/2021	https://clinicaltrials.gov/study/NCT05071417	0.7	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	coronary artery disease	SEMAGLUTIDE	targetBased	3	Not yet recruiting	01/11/2021	https://clinicaltrials.gov/study/NCT05071417	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	coronary artery disease	SEMAGLUTIDE	targetBased	3	Not yet recruiting	01/11/2021	https://clinicaltrials.gov/study/NCT05071417	0.7	GoF	protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	thrombotic disease	ALFIMEPRASE	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00346424	0.7		protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	thrombotic disease	ALFIMEPRASE	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00346424	0.7		protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	heart disease	FIBRINOGEN, HUMAN	targetBased	3	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01471730	0.7		protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	heart disease	FIBRINOGEN, HUMAN	targetBased	3	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01471730	0.7		protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	thrombotic disease	FIBRINOGEN, HUMAN	targetBased	4	Active, not recruiting	17/06/2019	https://clinicaltrials.gov/study/NCT04405518	1		protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	thrombotic disease	FIBRINOGEN, HUMAN	targetBased	4	Active, not recruiting	17/06/2019	https://clinicaltrials.gov/study/NCT04405518	1		protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	congenital heart disease	FIBRINOGEN, HUMAN	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT03014700	1		protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	congenital heart disease	FIBRINOGEN, HUMAN	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT03014700	1		protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	essential hypertension	LEVAMLODIPINE	targetBased	4	Unknown status	02/12/2015	https://clinicaltrials.gov/study/NCT03226340	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cardiovascular disease	LEVAMLODIPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C08CA17	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	LEVAMLODIPINE	targetBased	3	Withdrawn	01/04/2022	https://clinicaltrials.gov/study/NCT03814109	0.7	LoF	protect	Sponsor decision
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	LEVAMLODIPINE	targetBased	3	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01634295	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	LEVAMLODIPINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212895s000lbl.pdf	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	LEVAMLODIPINE	targetBased	3	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT01983735	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	LEVAMLODIPINE	targetBased	3	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01501253	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126061	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126061	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00126022	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00126022	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126074	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126074	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126074	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126074	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126074	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00126022	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00126022	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00126022	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126061	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126061	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126061	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126061	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126061	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126074	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126074	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00126022	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00126022	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126061	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126061	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00126022	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00126022	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126074	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	atrial flutter	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126074	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00126022	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00126022	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00126022	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126061	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126061	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126061	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126074	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126074	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126074	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126074	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126074	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126061	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00126061	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00126022	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	atrial fibrillation	TEDISAMIL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00126022	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	VERNAKALANT	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01BG11	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	VERNAKALANT	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01BG11	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiac arrhythmia	VERNAKALANT	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C01BG11	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	VERNAKALANT	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00125320	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	VERNAKALANT	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00125320	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	VERNAKALANT	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00125320	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	VERNAKALANT	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00115791	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	VERNAKALANT	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00115791	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial flutter	VERNAKALANT	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00115791	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	4	Withdrawn	01/09/2012	https://clinicaltrials.gov/study/NCT01627106	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	4	Withdrawn	01/09/2012	https://clinicaltrials.gov/study/NCT01627106	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	4	Withdrawn	01/09/2012	https://clinicaltrials.gov/study/NCT01627106	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	4	Recruiting	17/06/2021	https://clinicaltrials.gov/study/NCT04485195	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	4	Recruiting	17/06/2021	https://clinicaltrials.gov/study/NCT04485195	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	4	Recruiting	17/06/2021	https://clinicaltrials.gov/study/NCT04485195	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00468767	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00468767	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00468767	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00668759	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00668759	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00668759	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Terminated	01/10/2009	https://clinicaltrials.gov/study/NCT00989001	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Terminated	01/10/2009	https://clinicaltrials.gov/study/NCT00989001	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Terminated	01/10/2009	https://clinicaltrials.gov/study/NCT00989001	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT04748991	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT04748991	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT04748991	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00125320	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00125320	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00125320	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01174160	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01174160	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01174160	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01447862	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01447862	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01447862	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	4	Completed	01/01/2017	https://clinicaltrials.gov/study/NCT03005366	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	4	Completed	01/01/2017	https://clinicaltrials.gov/study/NCT03005366	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	4	Completed	01/01/2017	https://clinicaltrials.gov/study/NCT03005366	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00281554	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00281554	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00281554	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00115791	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00115791	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	atrial fibrillation	VERNAKALANT	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00115791	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE HYDROCHLORIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213536s000lbl.pdf	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypotension	EPHEDRINE HYDROCHLORIDE	targetBased	4	Not yet recruiting	15/02/2024	https://clinicaltrials.gov/study/NCT06257316	1	GoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID MESYLATES	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE01	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cardiovascular disease	ERGOLOID	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=C04AE51	1	GoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Brugada syndrome	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Terminated	12/09/2008	https://clinicaltrials.gov/study/NCT00701077	0.7	LoF	protect	recruitments issues
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Brugada syndrome	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Terminated	12/09/2008	https://clinicaltrials.gov/study/NCT00701077	0.7	LoF	protect	recruitments issues
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Brugada syndrome	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Terminated	12/09/2008	https://clinicaltrials.gov/study/NCT00701077	0.7	LoF	protect	recruitments issues
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Brugada syndrome	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Terminated	12/09/2008	https://clinicaltrials.gov/study/NCT00701077	0.7	LoF	protect	recruitments issues
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Brugada syndrome	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Terminated	12/09/2008	https://clinicaltrials.gov/study/NCT00701077	0.7	LoF	protect	recruitments issues
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Brugada syndrome	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Terminated	12/09/2008	https://clinicaltrials.gov/study/NCT00701077	0.7	LoF	protect	recruitments issues
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Brugada syndrome	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Terminated	12/09/2008	https://clinicaltrials.gov/study/NCT00701077	0.7	LoF	protect	recruitments issues
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Lambert-Eaton myasthenic syndrome	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02970162	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Lambert-Eaton myasthenic syndrome	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02970162	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Lambert-Eaton myasthenic syndrome	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02970162	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Lambert-Eaton myasthenic syndrome	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02970162	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Lambert-Eaton myasthenic syndrome	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02970162	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Lambert-Eaton myasthenic syndrome	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02970162	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Lambert-Eaton myasthenic syndrome	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02970162	0.7	LoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	coronary artery disease	DEXTROTHYROXINE SODIUM	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	heart disease	DEXTROTHYROXINE SODIUM	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	myocardial infarction	DEXTROTHYROXINE SODIUM	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	Myocardial Ischemia	DEXTROTHYROXINE SODIUM	targetBased	3	Completed	01/04/1965	https://clinicaltrials.gov/study/NCT00000482	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	cardiac arrhythmia	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	hemorrhoid	IFERANSERIN	targetBased	3	Terminated	01/07/2011	https://clinicaltrials.gov/study/NCT01355874	0.35	LoF	protect	The primary endpoint was not met on the double blind data
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	atrial fibrillation	LIRAGLUTIDE	targetBased	4	Active, not recruiting	18/03/2019	https://clinicaltrials.gov/study/NCT03856632	1	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	atrial fibrillation	LIRAGLUTIDE	targetBased	4	Active, not recruiting	18/03/2019	https://clinicaltrials.gov/study/NCT03856632	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	atrial fibrillation	LIRAGLUTIDE	targetBased	4	Active, not recruiting	18/03/2019	https://clinicaltrials.gov/study/NCT03856632	1	GoF	protect
Factor XIa 1536 HTS	F11_modulation	F11	Coagulation factor XI	acute coronary syndrome	MILVEXIAN	targetBased	3	Recruiting	07/04/2023	https://clinicaltrials.gov/study/NCT05754957	0.7	LoF	protect
Factor XIa 1536 HTS	F11_modulation	F11	Coagulation factor XI	atrial fibrillation	MILVEXIAN	targetBased	3	Recruiting	11/04/2023	https://clinicaltrials.gov/study/NCT05757869	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	AMLODIPINE BENZOATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211340s000lbl.pdf	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertension	LEVAMLODIPINE MALEATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212895s000lbl.pdf	1	LoF	protect
Factor XIa 1536 HTS	F11_modulation	F11	Coagulation factor XI	atrial fibrillation	ABELACIMAB	targetBased	3	Recruiting	27/12/2022	https://clinicaltrials.gov/study/NCT05712200	0.7	LoF	protect
Factor XIa 1536 HTS	F11_modulation	F11	Coagulation factor XI	venous thromboembolism	ABELACIMAB	targetBased	3	Recruiting	05/05/2022	https://clinicaltrials.gov/study/NCT05171049	0.7	LoF	protect
Factor XIa 1536 HTS	F11_modulation	F11	Coagulation factor XI	venous thromboembolism	ABELACIMAB	targetBased	3	Recruiting	27/09/2022	https://clinicaltrials.gov/study/NCT05171075	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	intermediate coronary syndrome		targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=911cd48f-01ea-4dec-b30c-95e7e0ea9d2a	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	intermediate coronary syndrome		targetBased	3	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00093158	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	acute coronary syndrome		targetBased	3	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01087723	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	acute coronary syndrome		targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01642238	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	acute coronary syndrome		targetBased	4	Completed	01/10/2019	https://clinicaltrials.gov/study/NCT03588611	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	acute coronary syndrome		targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00464087	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	acute coronary syndrome		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/angiox	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	ST Elevation Myocardial Infarction		targetBased	4	Completed	11/01/2019	https://clinicaltrials.gov/study/NCT03664180	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	ST Elevation Myocardial Infarction		targetBased	4	Unknown status	01/08/2010	https://clinicaltrials.gov/study/NCT01158846	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	ST Elevation Myocardial Infarction		targetBased	4	Not yet recruiting	30/11/2019	https://clinicaltrials.gov/study/NCT04185077	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	ST Elevation Myocardial Infarction		targetBased	4	Unknown status	16/01/2019	https://clinicaltrials.gov/study/NCT03882775	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	ST Elevation Myocardial Infarction		targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01519518	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	aortic stenosis		targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01651780	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	thrombotic disease		targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50975be1-6d1f-497c-b989-1825a0fae1a7	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	thrombotic disease		targetBased	3	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00073580	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	thrombotic disease		targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f133813-f74e-4508-bc64-debbf104ff1e	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	thrombotic disease		targetBased	3	Completed	01/04/1999	https://clinicaltrials.gov/study/NCT00043940	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	myocardial infarction		targetBased	3	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00433966	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	myocardial infarction		targetBased	3	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00093158	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	myocardial infarction		targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00093184	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	myocardial infarction		targetBased	4	Unknown status	01/09/2009	https://clinicaltrials.gov/study/NCT00976092	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	myocardial infarction		targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02311231	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	acute myocardial infarction		targetBased	4	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01696110	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	acute myocardial infarction		targetBased	3	Terminated	19/12/2014	https://clinicaltrials.gov/study/NCT02565147	0.35	LoF	protect	Futility at the interim analysis.
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	acute myocardial infarction		targetBased	3	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT02897037	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	coronary artery disease		targetBased	4	Unknown status	01/03/2006	https://clinicaltrials.gov/study/NCT00370045	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	coronary artery disease		targetBased	4	Unknown status	01/03/2010	https://clinicaltrials.gov/study/NCT01084993	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	coronary artery disease		targetBased	4	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01464671	0.5	LoF	protect	DSMB halted the study early due to futility. There were no safety concerns.
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	coronary artery disease		targetBased	4	Unknown status	01/05/2016	https://clinicaltrials.gov/study/NCT02787317	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	coronary artery disease		targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01848899	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	coronary artery disease		targetBased	3	Terminated	01/09/2013	https://clinicaltrials.gov/study/NCT01848106	0.7	LoF	protect	Clinical Hold
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	coronary artery disease		targetBased	4	Unknown status	01/05/2010	https://clinicaltrials.gov/study/NCT01157455	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	coronary artery disease		targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00448461	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	coronary artery disease		targetBased	3	Unknown status	01/04/2012	https://clinicaltrials.gov/study/NCT01555658	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	coronary artery disease		targetBased	4	Terminated	01/06/2008	https://clinicaltrials.gov/study/NCT00669149	1	LoF	protect	recruitment difficulties
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	heart disease		targetBased	3	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00073580	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	cardiovascular disease		targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00079508	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	cardiovascular disease		targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00079586	0.7	LoF	protect

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.

drTarget portfolio target-disease associations for cardiovascular diseases

DrTarget’s AI-Driven Insights into Cardiovascular Diseases

Our AI-powered approach enables:

✔ Identification of novel drug targets for cardiovascular diseases✔ Drug repurposing strategies to accelerate treatment discovery✔ Pathway and biomarker analysis for precision cardiology

By integrating AI-driven virtual screening and multi-source validation, DrTarget supports the discovery of next-gen cardiovascular therapies aimed at improving heart health and vascular function.

Check best scored target-disease associations in table:

Some of these associations have also gone through clinical trials, as those in the graph below.

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.

✔ Identification of novel drug targets for cardiovascular diseases
✔ Drug repurposing strategies to accelerate treatment discovery
✔ Pathway and biomarker analysis for precision cardiology